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ABSTRACT 
 
The metastasis suppressor CD82/KAI1, a member of the tetraspanin family of 
transmembrane proteins has previously been shown to associate with ErbB2 
(Odintsova et al. 2003). We hypothesised that CD82 could potentiate the 
efficacy of Herceptin by either regulating the distribution and dynamics of the 
ErbB2/Herceptin complex or by modifying the recruitment of signalling 
molecules to the plasma membrane. The role of CD82 in Herceptin-mediated 
cellular responses was investigated using ErbB2-positive breast cancer cell 
lines expressing varying levels of CD82. We found that ectopic expression of 
CD82 resulted in a poor cellular response to Herceptin treatment, redistribution 
of ErbB2 and an increase in phosphorylation of ErbB2, Src and proteins of the 
mitogen-activated protein kinase (MAPK) signalling cascade in a manner that 
was independent of the Ras proteins. The CD82-mediated effect on ErbB 
signalling was found to be specific to the MAPK pathways, as the 
phosphoinositide 3-kinase (PI3K) pathway was unaffected by ectopic 
expression of CD82. Taken together, our results demonstrate that CD82 
negatively modulates the cellular response of ErbB2-positive breast cancer cells 
to Herceptin treatment by not only regulating the distribution of the ErbB2 
receptor, but also its phosphorylation and activation of downstream signalling 
pathways, particularly the MAPK pathway.  
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1 INTRODUCTION 
 
1.1 Introduction to cancer 
 
Cancer is a generic name used to denote a variety of malignant neoplastic 
diseases that stem from different cell types. It is a progressive disease that 
involves numerous alterations in the genetic material of normal cells, that 
ultimately leads to transformed cancer cells with a growth advantage over their 
neighbouring non-transformed cells (Hanahan and Weinberg 2000;Hanahan 
and Weinberg 2011).  
 
1.1.1 Breast cancer 
 
Breast cancer is the most common cancer in the United Kingdom (UK), 
preceding prostate, lung and colorectal cancers, which all together account for 
more than half (59%) of all new cases of cancer (Office of National Statistics) 
(http://www.ons.gov.uk/ons/publications/re-reference-
tables.html?edition=tcm%3A77-251462). In 2007-2009, there were 47,809 
(30.6%) registered cases of breast cancer in the UK out of a total of 156,254 
cases of all malignancies registered in women. Of all the cancers registered in 
the UK during the same period, breast cancer had the highest incidence rate of 
124 cases per 100,000 women preceding lung cancer which is the second 
highest registered type of cancer in women for which only 39 cases were 
registered per 100,000 women (Office of National Statistics) 
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(http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-incidence-and-mortality/2007-
2009/stb-cancer-incidence-and-mortality.html). Breast cancer is a 
heterogeneous disease which encompasses several pathological entities with 
distinct clinical behaviour. Based on gene expression profile analysis using 
microarrays, breast cancer can be classified into five groups according to their 
expression pattern, namely: luminal A, luminal B, normal breast-like, ErbB2-
positive and basal-like. Of the five types of breast cancer, luminal A carcinomas 
are considered to have a better prognosis compared to basal-like, which is the 
most aggressive subtype (Geyer et al. 2009;Tavassoli 2010). The human 
mammary gland consists of two distinct types of epithelial cells; basal and 
luminal epithelial cells. The former can be immunohistochemically distinguished 
from luminal, by staining with antibodies against the basal cytokeratins 5/6, 
whilst the latter cells stain positive for the luminal cytokeratins 8/18. 
Cytokeratins are widely used as biomarkers due to their tissue specific 
expression (Perou et al. 2000). 
 
1.1.1.1 Luminal subtypes 
 
The luminal subtypes are hormone receptor-expressing breast carcinomas. 
Luminal A cancers are positive for the hormone receptors; oestrogen receptor 
(ER+) and progesterone receptor (PR+), but do not overexpress ErbB2, 
therefore are considered to be ErbB2 negative (ErbB2-). In contrast, luminal B 
cancers are ER+, PR+ and ErbB2+ (Brenton et al. 2005;Carey et al. 2006;Carey 
2010;Millikan et al. 2008). These types of breast cancers are treated with 
endocrine therapy such as Tamoxifen and generally have a good prognosis 
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compared to other breast cancer subtypes. However, there are variations 
between the two luminal groups in their response to treatment, whereby luminal 
B tumours generally have a worse prognosis, with high proliferative rates than 
luminal A (Brenton et al. 2005). 
 
1.1.1.2 Triple-negative breast cancer 
 
Triple-negative breast cancer is a subtype that is negative of the three main 
breast cancer markers; ER-, PR- and ErbB2-. It can be classified into two sub-
groups, basal-like and non-basal-like, according to the expression of 
cytokeratins 5/6 and the epidermal growth factor receptor (EGFR) (Yamamoto 
et al. 2009). The basal-like subtype shows gene expression patterns 
reminiscent for normal basal epithelial cells of the breast. These include, 
positive immunohistochemistry staining for the breast basal cytokeratins 5/6, ER 
negative, low expression levels of ErbB2 (thus considered ErbB2-), and 
overexpression of EGFR. Conversely, the non-basal-like subgroup of triple-
negative breast cancer is cytokeratins 5/6-negative and also EGFR-negative 
(Brenton et al. 2005;Geyer et al. 2009;Yamamoto et al. 2009). Triple-negative 
breast cancers display an aggressive clinical behaviour, with high recurrence 
rates within the first five years post diagnosis and a worse outcome compared 
to tumours of other subgroups. This could be due to the fact that no therapeutic 
target has been confirmed yet for this subtype as compared to the targeted 
therapy available for the hormone receptor-positive and ErbB2-positive breast 
cancer subtypes; endocrine therapy and Herceptin, respectively (Geyer et al. 
2009). 
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1.1.1.3 The ErbB2-enriched subtype 
 
ErbB2 positive breast cancers are characterised by overexpression of the 
ErbB2 receptor and whether they harbour amplification of the ErbB2 gene. 
These tumours are also often ER and PR negative (Carey 2010;Geyer et al. 
2009;Schnitt 2010). However, not all ErbB2-enriched breast cancers are 
classified into the ErbB2-enriched category; ErbB2-driven breast cancers that 
express both the luminal and ErbB2 gene clusters are categorised into the 
luminal subtypes rather than in the ErbB2-enriched subtype (Carey 2010). The 
ErbB2-enriched subtype of breast cancer carries a poor prognosis. However, 
the incorporation of Herceptin, a monoclonal antibody against ErbB2 into 
adjuvant chemotherapy improved disease-free survival in some cases of this 
subgroup, thus demonstrating the effectiveness of targeted therapy at improving 
outcome (Brenton et al. 2005;Carey 2010;Hudis 2007;Olopade et al. 2008). 
Both ErbB2 and Herceptin will be discussed further in the next sections. 
 
1.2 The ErbB receptor tyrosine kinase family 
 
The epidermal growth factor (EGF) family of receptor tyrosine kinases (RTKs) 
comprises of four members, namely, EGFR/ErbB1/HER1, ErbB2/Neu/HER2, 
ErbB3/HER3 and ErbB4/HER4, located on chromosomes 7p12; 17q11.2-q12; 
12q13; and 2q33.3-q34, respectively (Figure 1.1) (Robinson et al. 2000). From 
henceforth, they will be referred to as EGFR and ErbB receptors accordingly. 
This receptor family was originally named the ErbB family due to their homology 
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to the v-erbB oncogene of the avian erythroblastosis virus (Citri and Yarden 
2006;Roskoski, Jr. 2004). Receptor tyrosine kinases are single-pass 
transmembrane receptors with an extracellular ligand binding domain, a single 
transmembrane domain and an intracellular tyrosine kinase domain, flanked by 
a juxtamembrane and a C-terminal regulatory region (Figure 1.2) (Burgess et al. 
2003;Li and Hristova 2010). 
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 Figure 1.1: The ErbB family of receptor tyrosine kinases.  
 
The four family members of the epidermal growth factor (EGF) family of 
receptor tyrosine kinases and the binding specificity of the EGF-related growth 
factor ligands. There is currently no EGF-related growth factor ligand known to 
bind to ErbB2. The extracellular domain of all family members consists of four 
subdomains I-IV; of which, domains I and III are important for ligand binding, 
domain II also known as the dimerisation arm, is important for receptor-receptor 
interactions and domain IV is involved in receptor auto-inhibition. In the absence 
of a ligand, the receptors exist in a tethered auto-inhibitory conformational state 
whereby subdomains II and IV interact, thus burying and inhibiting the 
dimerisation arm from interacting with neighbouring ligand-bound ErbB 
receptors. ErbB2 however, exists in a fixed conformation resembling the ligand-
bound state with the dimerisation arm exposed and thus permanently poised for 
receptor-receptor interactions. Abbreviations of ligands: EGF - epidermal growth 
factor; AR - amphiregulin; TGF-α - transforming growth factor-alpha; BTC - 
betacellulin; HB-EGF - heparin-binding EGF-like growth factor; EPR - 
epiregulin; and NRGs - neuregulins 1, 2, 3 and 4 (also known as heregulins 
(HrG) 1-4. This figure was adapted from Burgess et al. and Hynes et al. 
(Burgess et al. 2003;Hynes and Lane 2005). 
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1.2.1 Structural features of the ErbB extracellular domain  
 
The ErbB proteins belong to subclass I of the RTK superfamily and are 
characterised by four main structural features namely, the extracellular domain, 
a transmembrane region, a tyrosine kinase domain, and the C-terminal region 
(Barros et al. 2010;Blume-Jensen and Hunter 2001;Bublil and Yarden 2007) 
(Figure 1.2). The extracellular region of the ErbB proteins comprises four 
subdomains of two different types: the leucine-rich (L) domains (L1 and L2); and 
the cysteine-rich (CR) domains (CR1 and CR2), which are organised in the 
order of L1-CR1-L2-CR2 (Burgess et al. 2003;Jorissen et al. 2003). The 
alternative nomenclature of these domains is I-II-III-IV, which is what will be 
used from henceforth in this thesis, respectively (Figures 1.1 and 1.2). The 
structural characteristics of each domain type include the six-turn β-helical 
configuration capped at each end by an α helix, specific for the L domains 
(domains I and III). The CR domains consist of multiple disulphide-bonded 
modules, with domain II containing 8 whilst domain IV contains 7 of these 
disulphide-bonded modules. Domain II is important for receptor dimerisation 
and is often referred to as the dimerisation arm since one of its disulphide-
bonded modules (module 5) protrudes out as a point of contact with an active 
dimerisation partner. Domains I and III are required for ligand binding, whereas 
subdomains II and IV are involved in receptor auto-inhibition (Burgess et al. 
2003).  
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When the receptor is non-activated (i.e. not ligand-bound), it takes on a tethered 
conformational state whereby autoinhibitory intramolecular interactions occur 
between subdomains II and IV that result in burying and thus occlusion of the 
dimerisation arm, which impedes it from interacting with the dimerisation arm of 
an active (ligand-bound) neighbouring binding partner (Ferguson et al. 2003). 
Ligand binding involves domains I and III, whereby a single growth factor 
molecule simultaneously interacts with domains I and III of the same receptor. 
Upon binding, it causes rearrangement of the domains to give rise to an 
extended conformation resulting in the exposure of the dimerisation arm, thus 
facilitating homo- or heterodimerisation (Ferguson et al. 2003;Linggi and 
Carpenter 2006;Roskoski, Jr. 2004).  
 
Structural studies of the extracellular region of ErbB2 revealed specific features 
that differed from structures of other family members. Firstly, it was revealed 
that the auto-inhibitory tethering interaction between subdomains II and IV that 
is observed with the other inactive family members, is absent in the ErbB2 
extracellular structure. The ErbB2 receptor is thus locked in a fixed 
conformation resembling the ligand-bound state seen with other family 
members, whereby the dimerisation arm is exposed (Figure 1.1) (Cho et al. 
2003;Garrett et al. 2003). This indicates that ErbB2 is permanently poised to 
interact with other ErbB ligand-bound receptors, thus rendering it as the 
preferred partner for heterodimerisation with other ErbB receptors (Burgess et 
al. 2003;Cho et al. 2003;Ferguson et al. 2003;Garrett et al. 2003). Secondly, 
these studies also revealed that domains I and III are in close proximity to one 
another in the ErbB2 structure, even closer than what was observed with the 
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ligand-bound structure of EGFR. In the ErbB2 conformation, the ligand-binding 
sites on domains I and III are in direct contact with one another thereby 
hindering any possible interaction of a ligand. Thirdly, key residues in domain IV 
of the ErbB2 extracellular region were found to be different from those of other 
family members. For example, Gly563 that is conserved in EGFR, ErbB3 and 
ErbB4 was found to be replaced by Pro572 in the extracellular region of ErbB2. 
This is thought to account for the lack of the auto-inhibitory tether between 
domains II and IV (Cho et al. 2003;Garrett et al. 2003). 
 
On the other hand, a recent study by Alvarado and colleagues argued against 
the notion that ErbB2 lacks auto-inhibition. The authors revealed evidence to 
suggest that the direct interaction between domains I and III of the extracellular 
region of ErbB2 is autoinhibitory as it occludes the ligand binding site (Alvarado 
et al. 2009). 
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Figure 1.2: Structural features of ErbB proteins. 
 
ErbB proteins share four main structural features: the N-terminal extracellular 
domain for ligand binding, which also comprises the four subdomains (I-IV) that 
are important for ligand binding and structural conformation; a transmembrane 
domain; an intracellular tyrosine kinase domain; and a C-terminal tail for 
tyrosine phosphorylation, which also serve as docking sites for 
phosphotyrosine-binding effector molecules. The example shown here is of an 
unliganded receptor in a tethered auto-inhibitory conformational state. This 
figure was adapted from Burgess et al. (Burgess et al. 2003). 
 
  Introduction 
 
11 
 
 
1.2.2 ErbB Ligands 
 
The characteristics of RTK proteins include ligand binding and the subsequent 
tyrosine kinase activation, which couples the receptors to downstream 
intracellular signalling cascades thereby facilitating the relay of signals from the 
extracellular space to the intracellular space, through phosphorylation of 
downstream effectors. There are at least 13 ligands known to bind to ErbB 
receptors, with various specificities (Figure 1.1). These include EGF, 
transforming growth factor-alpha (TGF-α) and amphiregulin (AR), which 
specifically bind to EGFR with high affinity and no other ErbB family members. 
Other ligands include betacellulin (BTC), epiregulin (EPR) and heparin-binding 
EGF-like growth factor (HB-EGF), which are known to bind both EGFR and 
ErbB4. The neuregulins (also known as heregulins) make up the other group of 
ErbB ligands, whereby neuregulins (NRG) 1 and NRG2 bind both ErbB3 and 
ErbB4, whilst NRG3 and NRG4 specifically bind ErbB4 exclusively (Barros et al. 
2010;Linggi and Carpenter 2006).  
 
1.2.3 ErbB receptor dimerisation and downstream signalling 
 
A study by de Vos and colleagues into the mechanisms of ligand-induced 
dimerisation of the human growth hormone (hGH) receptor led to a paradigm 
that a single ligand binds simultaneously to two receptor molecules to form a 
1:2 (ligand:receptor) complex, thereby mediating dimerisation (de Vos et al. 
1992). Conversely however, later studies analysing the binding of EGF to the 
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epidermal growth factor receptor revealed that one EGF molecule binds to the 
extracellular region of one receptor molecule to form a 2:2 (ligand:receptor) 
dimer complex (Ferguson et al. 2003;Lemmon et al. 1997). Ligand binding to 
the extracellular region of the receptor via domains I and III induces a structural 
conformational change that results in the exposure of the dimerisation arm 
(domain II), which is the first point of contact between two receptors in a dimer 
(Figure 1.3). It is proposed that further contact occurs between the kinase 
domains of the two receptors within a dimer complex thereby inducing activation 
of their kinase activity and the subsequent transphosphorylation of the receptors 
at multiple tyrosine phosphorylation sites located within the C-terminal tail 
(Barros et al. 2010;Hynes and Lane 2005). Recent structural studies of EGFR 
suggest that the kinase domain of EGFR can dimerise to form two types of 
kinase-domain conformation states, inactive symmetric and active asymmetric 
dimmers (Bessman and Lemmon 2012;Mi et al. 2011;Zhang et al. 2006). In the 
asymmetric dimer, the C-terminal lobe of one monomer kinase domain interacts 
with the N-terminal lobe of the other monomer kinase domain (Mi et al. 
2011;Zhang et al. 2006). 
 
ErbB receptors function as homodimers through association between two 
identical receptors, or heterodimers through association with their cognate 
family members. Thus the four family members can interact to form 10 distinct 
states comprising four homodimers (EGFR/EGFR, ErbB2/ErbB2, ErbB3/ErbB3 
and ErbB4/ErbB4) and six heterodimers (EGFR/ErbB2, EGFR/ErbB3, 
EGFR/ErbB4, ErbB2/ErbB3, ErbB2/ErbB4 and ErbB3/ErbB4) (Roskoski, Jr. 
2004;Yarden and Sliwkowski 2001). The phosphorylated tyrosine residues then 
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serve as docking sites for numerous adaptor proteins that contain Src homology 
2 (SH2) domains or phosphotyrosine-binding (PTB) domains. Examples of such 
adaptor molecules include the Src homology 2 domain-containing (Shc) protein, 
p85 and the growth factor receptor-bound protein 2 (Grb2). Recruitment of 
adaptor proteins to these phosphorylated sites couples activated receptors to 
various downstream signalling pathways. The two main signalling pathways 
associated with the ErbB receptors are the mitogen-activated protein kinase 
(MAPK) and the phosphoinositide 3-kinase (PI3K) pathways, which promote 
proliferation and survival. Coupling to the MAPK pathway is through adaptor 
proteins Shc and Grb2, whilst the PI3K pathway can be activated via docking of 
p85, the regulatory subunit of PI3K onto activated receptors (Hynes and Lane 
2005;Olayioye et al. 2000). There is an overlap in the adaptor molecules 
recruited to the receptors; however individual ErbB receptors have the ability to 
preferentially associate with some effector proteins than others, thus ensuring 
specificity in the signalling potential of these receptors (Hynes and MacDonald 
2009). For example, out of the four ErbB family members, ErbB3 is the most 
efficient activator of the PI3K pathway due to the presence of six docking sites 
for the p85 subunit of PI3K (Hynes and MacDonald 2009;Olayioye et al. 
2000;Stern 2008). The C-terminus domain of ErbB3 contains six YXXM motifs 
(Y – tyrosine; X – any amino acid; M – methionine), which when phosphorylated 
serve as a docking site for the SH2 domain of p85 (Olayioye et al. 
2000;Smirnova et al. 2012). 
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Figure 1.3: Ligand-induced heterodimerisation of ErbB2 and ErbB3. 
 
In the absence of a ligand, ErbB3 monomers are inactive due to the tethered 
autoinhibitory intramolecular interactions involving domains II/IV. However, 
ligand binding to domains I/III induces domain rearrangement leading to the 
exposure and extension of the dimerisation arm of domain II. The extended 
configuration of the resulting ligand-bound monomer makes it suitably poised 
for intermolecular interactions, but it remains inactive until dimerisation. In the 
example shown above, ErbB3 dimerises with ErbB2 thereby forming an active 
heterodimer. Such an association induces receptor autophosphorylation. This 
figure was adapted from Burgess et al. (Burgess et al. 2003). 
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1.2.3.1 The PI3K pathway and breast cancer progression  
 
The presence of six docking sites for the p85 regulatory subunit of PI3K in the 
C-terminal tail of ErbB3 is not enough to activate the PI3K pathway, since 
ErbB3 is deemed kinase-dead due to a non-functional kinase domain. 
Therefore, signalling via the PI3K pathway requires the formation of ErbB3 
heterodimers with other ErbB receptors such as ErbB2. Once ErbB2/ErbB3 
heterodimers are formed, the PI3K signalling cascade can be activated via 
docking of p85 to active ErbB3 receptors (Figure 1.4). Upon recruitment of p85, 
p110 which is the catalytic subunit of the PI3K protein, phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
trisphosphate (PIP3). The latter is a crucial second messenger that recruits Akt 
to the plasma membrane for activation (Dillon et al. 2007;Manning and Cantley 
2007;Yuan and Cantley 2008). This reaction is antagonised by PTEN 
(phosphatase and tensin homolog deleted on chromosome 10), which 
negatively regulates the intracellular levels of PIP3 and thus Akt activity. Once 
generated, PIP3 binds phosphoinositide-dependent kinase-1 (PDK1) at the 
plasma membrane, which then phosphorylates the kinase domain of Akt at 
Threonine (T) 308. Full activation of Akt is achieved following phosphorylation at 
a second residue, serine (S) 473 by PDK2. Activated Akt can then translocate 
to the cytoplasm and nucleus where it phosphorylates downstream effector 
proteins such as the murine double minute 2 (MDM2), or the cell cycle inhibitors 
p27Kip1 and p21WAF1, ultimately leading to promotion of cell growth and survival 
(Figure 1.4) (Dillon et al. 2007;Manning and Cantley 2007).  
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The PI3K pathway is deregulated in many human cancers through mutations 
such as activating mutations of the PIK3CA gene encoding the p110 catalytic 
subunit, which are observed in 20-25% of primary breast tumours (Hynes and 
MacDonald 2009). The pathway is also affected by loss-of-function mutations in 
the tumour suppressor gene PTEN. Both types of mutations result in elevated 
levels of PIP3 and Akt activation, ultimately leading to cellular transformation 
(Blume-Jensen and Hunter 2001;Hynes and MacDonald 2009;Stern 2008). In 
most human cancers including breast cancer, PTEN is one of the most 
frequently mutated genes (Chow and Baker 2006). ErbB2 overexpressing 
breast cancers are reported to maintain elevated PI3K activity, particularly 
through the oncogenic ErbB2/ErbB3 heterodimer signalling unit (Hynes and 
MacDonald 2009). 
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Figure 1.4: The PI3K/Akt signalling pathway. 
 
Schematic representation of the PI3K/Akt signalling pathway from activated 
receptor tyrosine kinases (RTKs). Lines represent either activation (arrow head) 
or inactivation/inhibition (blunt end). Abbreviations: Bad - Bcl-2-associated 
death promoter; Bim - Bcl-2 interacting mediator of cell death; FOXO - 
Forkhead Homeobox type O; GDP/GTP - guanosine-di-(tri)-phosphate; Grb2 - 
growth factor receptor-bound 2; KIP1 – kinase inhibitor protein 1; MDM2 - 
murine double minute 2; PDK1 - phosphoinositide-dependent protein kinase 1; 
PI3K - phosphoinositide-3 kinase; PIP2/PIP3 - phosphatidylinositol-di-(tris)-
phosphate; PTEN - phosphatase and tensin homolog deleted on chromosome 
ten; Shc - Src homology 2 domain containing; SOS - son of sevenless; WAF1 – 
wild-type p53 activated-fragment 1. This figure was adapted from Baselga 
(Baselga 2011). 
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1.2.3.2 MAPK signalling 
 
The mitogen-activated protein kinase (MAPK) pathways function downstream of 
cell surface receptors thereby enabling cells to mediate signal transduction from 
extracellular environmental stimuli such as growth factors or cellular stress into 
intracellular signalling cascades thus regulating key functions such as cell 
proliferation, survival and differentiation (Gehart et al. 2010;Mebratu and 
Tesfaigzi 2009;Roberts and Der 2007). There are at least six distinct groups of 
MAPK proteins that have been characterised in mammals and these include 
extracellular signal-regulated kinases (Erk1/2); Erk3/4; Erk5; Erk7/8, Jun N-
Terminal kinase (JNK1/2/3) and the p38 kinase isoforms α/β/γ/δ (Dhillon et al. 
2007). The MAPK signalling network comprises of a three-tier protein kinase 
module that involves a series of protein phosphorylation. An external stimulus 
causes activation of a MAPK kinase kinase (MAPKKK), which in turn 
phosphorylates a MAPK kinase (MAPKK) that subsequently phosphorylates 
and thus activate a terminal MAPK with effects on downstream targets such as 
transcription factors (Figure 1.5) (Dhillon et al. 2007;Roberts and Der 2007).  
 
Upstream of the MAPK pathway is Ras, a small GTPase. Ras proteins act as 
molecular switches, that turn signalling pathways on or off by cycling between 
inactive guanosine diphosphate (GDP)-bound and active guanosine 
triphosphate (GTP)-bound states. Guanosine nucleotide exchange factors 
(GEFs) such as son of sevenless (SOS) mediate the signal-induced conversion 
of the inactive to active state by stimulating the exchange of GDP to the more 
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abundant GTP (Mor and Philips 2006). Upon receptor activation, SOS is 
recruited to the receptor via the adaptor protein Grb2 thereby inducing the 
conversion of GDP bound to Ras for GTP and thus Ras activation (Figure 1.6). 
Additionally, the activation state of Ras is also partly self-limited by its intrinsic 
GTPase activity through the action of GTPase activating proteins (GAPs), which 
increase the catalytic activity of Ras to revert from the GTP-bound active state 
to the inactive GDP-bound state. The actions of both GEFs and GAPs therefore 
regulate the duration of Ras signalling by allowing the signal to be switched on 
and off, thereby controlling the duration of the signal (Fehrenbacher et al. 
2009;Mor and Philips 2006;Omerovic and Prior 2009).  
 
Once activated, GTP-bound Ras can then affect many downstream effector 
proteins including Raf, a serine/threonine MAPKKK. Activation of Raf leads to 
phosphorylation of MEK1/2, a dual-specificity MAPKK which then in turn, 
phosphorylates and activates Erk1/2 MAPK on threonine and tyrosine residues. 
Erk1/2 are serine/threonine kinases, which when activated can phosphorylate a 
wide range of substrates, both nuclear and cytoplasmic (Figures 1.5 and 1.6) 
(Fehrenbacher et al. 2009;Roberts and Der 2007). The MAPK signalling 
cascades emanate from multiple receptors including the ErbB receptors, insulin-
like growth factor-1 receptor (IGF-1R) and G-protein coupled receptors (GPCR); 
and can therefore be activated by various stimuli. MAPK signalling can thus 
induce a range of biological responses, depending on the type of activated 
receptor and stimuli. Indeed, it has previously been reported that stimulation of 
neuronal PC12 cells with nerve growth factor (NGF) induced cellular 
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differentiation; whilst stimulation of the same cells with EGF resulted in cell 
proliferation (Marshall 1995;Sacks 2006).  
 
Scaffold proteins play a critical role in regulating MAPK signalling by assembling 
these signalling molecules into a complex, which not only enables rapid relay of 
signals, but also ensures a degree of specificity through isolation of these 
signalling modules from each other and thus limiting crosstalk between different 
pathways (Dhanasekaran et al. 2007;Sacks 2006). Kinase suppressor of Ras 1 
(KSR1) is one of the scaffold proteins involved in the Erk signalling pathway. It 
is a multidomain protein that binds all three-tier kinases (Raf/MEK/Erk) of the 
Erk pathway (Figure 1.6). In resting cells, KSR1 is retained in the cytoplasm via 
its constitutive association with MEK1/2, the core domain of protein 
phosphatase-2A (PP2A), 14-3-3 and the Ras-responsive E3-ubiquitin ligase, 
IMP (impedes mitogenic signal propagation). Ras activation induces IMP auto-
polyubiquitination, which is subsequently degraded. This leads to 
dephosphorylation of KSR1 at serine 392 by PP2A, thereby reducing its 
interaction with 14-3-3 (Matheny et al. 2004). Consequently, the KSR1-MEK1/2 
complex is released to translocate to the plasma membrane where it interacts 
with Raf and Erk thus facilitating their activation (Dhanasekaran et al. 
2007;Kolch 2005).  
 
Besides regulation of Erk signalling via KSR sequestration, the ERK pathway 
can also be regulated by specific proteins that inhibit protein interactions 
between members of this pathway. These endogenous inhibitors include Raf 
kinase inhibitor protein (RKIP), which inhibits MEK phosphorylation by binding 
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to both Raf and MEK, thereby hindering their interaction. Other inhibitor proteins 
include Sprouty and SPRED (Sprouty-related proteins with an EVH1 
(Enabled/VASP homology domain-1) domain), which when phosphorylated, 
bind and sequester Grb2 thereby impairing the recruitment of SOS to the active 
receptors, ultimately inhibiting Ras activation (Kim and Bar-Sagi 2004;Kolch 
2005). Furthermore the duration of MAPK signalling activation is determined by 
a balance between phosphorylation and dephosphorylation of the kinases. 
Serine/threonine phosphatases such as PP2A and the dual-specificity protein 
phosphatases such as the MAPK phosphatase (MKP)-1, inhibit the activity of 
the MAPK kinases such as MEK1/2 and Erk1/2 by removing their activating 
phosphates thereby reversing their activation (Westermarck et al. 2001).  
 
Aberrant regulation of MAPK signalling is correlated with cancer. For example, it 
is estimated that mutations in the Erk signalling pathway are found in at least 
30% of human breast cancers (Roberts and Der 2007;Whyte et al. 2009). 
Constitutive activation of the Erk pathway can occur due to mutations in the b-
raf gene that results in constitutive activation of the catalytic activity of B-Raf. 
Mutations in the RAS genes that lock the protein in the active GTP-bound state 
are found in 30% of human cancers. Furthermore, overexpression of growth 
factors and their cognate receptors can also lead to hyperstimulation of these 
signalling pathways (Dhillon et al. 2007;Fehrenbacher et al. 2009;McCubrey et 
al. 2007;Roberts and Der 2007). 
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Figure 1.5: The MAPK signalling cascades. 
 
Schematic overview of the MAPK signalling network, represented as a three-tier 
(MAPKKK-MAPKK-MAPK) protein kinase module. Shown are the Erk1/2, p38, 
JNK and Erk5 signalling pathways. This figure was obtained from Roberts et al. 
(Roberts and Der 2007). 
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 Figure 1.6: Erk signalling and KSR1 regulation. 
 
Schematic representation of the Erk signalling pathway from activated receptor 
tyrosine kinases (RTKs). Mitogenic signals are propagated from the 
extracellular space to the intracellular compartments via a series of protein 
phosphorylation. In resting cells, kinase suppressor of Ras 1 (KSR1) is retained 
in the cytoplasm via its association with 14-3-3 and the E3-ubiquitin ligase IMP 
(impedes mitogenic signal propagation). Ras activation induces 
dephosphorylation of KSR1 and degradation of IMP, thus facilitating membrane 
translocation of KSR1 followed by the subsequent assembly and activation of 
the Raf-MEK-Erk signalling module. Phosphorylated Erk can affect numerous 
cytoplasmic and nuclear targets, ultimately leading to a wide range of biological 
responses. This figure was adapted from Kolch (Kolch 2005).  
 
 
  Introduction 
 
24 
 
 
1.2.4 ErbB2 and breast cancer 
 
The ErbB2 gene is located on chromosome 17q and encodes a protein of 
185kDa belonging to the EGFR family of RTKs as described in section 1.2. 
Overexpression and/or gene amplification of ErbB2 is observed in at least 20-
25% of invasive breast cancers and this is associated with a poor prognosis and 
a reduced disease-free survival period (Chang 2010;Freudenberg et al. 
2009;Schmitt 2009). ErbB2 overexpression is correlated with breast cancer 
progression, since ErbB2 is generally either absent or expressed at low levels in 
benign breast lesions. Its expression is reported to be an important event in the 
early stages of malignant transformation (Freudenberg et al. 2009). Benign 
breast lesions are relatively common, with only a very small proportion of these 
cases progress to invasive breast carcinoma (IBC). It is therefore important to 
identify and begin treatment of such lesions at an early stage in order to prevent 
the development of lethal IBC. ErbB2 expression status is one of the ways of 
determining disease stage; and this is also seen as a very important prognosis 
factor that can predict response to different therapeutic targets. Patients with 
benign breast lesions that have ErbB2 gene amplification have an increased 
risk of developing IBC (Freudenberg et al. 2009;Schmitt 2009). All these factors 
highlight ErbB2 as an important therapeutic target. 
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1.2.4.1 ErbB2-targeted therapies 
 
The importance of ErbB2 in particular to the progression of a subset of breast 
cancers generated great interest in the development of ErbB2-targeted cancer 
therapeutics over the years. These include the monoclonal antibody 
Trastuzumab which binds the extracellular portion of ErbB2; and small molecule 
tyrosine kinase inhibitors (TKIs) such as Lapatinib, which inhibit the intracellular 
kinase activity (Hynes and MacDonald 2009;Ignatiadis et al. 2009).  
 
1.2.4.1.1 Lapatinib 
 
Lapatinib is a reversible TKI targeting the kinase domain of both EGFR and 
ErbB2, thus inhibiting receptor activation and consequently downstream 
signalling via the MAPK and PI3K/Akt pathways (Freudenberg et al. 2009). 
Currently, Lapatinib is approved for patients with advanced ErbB2-positive 
breast cancer who have been previously treated with other anticancer drugs. As 
a small molecule, Lapatinib is capable of crossing the blood-brain barrier and 
could therefore have activity against breast cancer metastases to the brain 
(Kroep et al. 2010). 
 
1.2.4.1.2 Trastuzumab 
 
Trastuzumab (Herceptin) is the first of its kind; a recombinant humanised IgG1 
monoclonal antibody directed at the extracellular domain of ErbB2. From 
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henceforth, Trastuzumab will be referred to by its trade name, Herceptin. 
Initially, Herceptin was identified through screening of various monoclonal 
antibodies against ErbB2 including the murine antibody 4D5, of which a 
humanised version, Herceptin was subsequently developed (Fendly et al. 
1990;Ignatiadis et al. 2009;Spector and Blackwell 2009).  
 
In vivo studies using xenografts of ErbB2-overexpressing breast cancer cell 
lines in mice and clinical trials involving patients with ErbB2-overexpressing 
metastatic breast cancer demonstrated activity of Herceptin as a single agent 
and in combination with a range of chemotherapeutic agents (Pegram et al. 
1999;Pegram et al. 1998;Pegram et al. 2004;Yeon and Pegram 2005). Further 
trials comparing treatment regimens of chemotherapy alone against Herceptin-
chemotherapy combinations as first line therapy for women with ErbB2-
overexpressing metastatic breast cancer revealed that Herceptin enhanced the 
activity of first-line chemotherapy and provided a survival advantage for patients 
of up to eight months (Routledge et al. 2006).  
 
In 1998, Herceptin was approved by the United States Food and Drug 
Administration (FDA) for use in patients with ErbB2-overexpressing metastatic 
breast cancer as monotherapy (second-line treatment) or in combination with 
paclitaxel (as first-line treatment) (Yeon and Pegram 2005).  
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1.2.4.1.2.1 Mechanisms of action 
 
Although the exact mechanisms of action of how Herceptin exerts its 
therapeutic effects are not fully elucidated, several mechanisms have been 
proposed to account for its anti-tumour activity, based on preclinical and clinical 
studies (Spector and Blackwell 2009;Valabrega et al. 2007). 
 
1.2.4.1.2.1.1 Attenuation of cell signalling 
 
It has been proposed that Herceptin could act by reducing receptor signalling 
via the PI3K/Akt signalling pathway (Valabrega et al. 2007). As discussed in 
previous sections, the PI3K/Akt pathway is an important target in breast cancer 
management as it regulates numerous cellular functions including proliferation, 
cell cycle progression and survival (Figure 1.4). Several studies have 
demonstrated that Herceptin inhibits cellular signalling via the PI3K pathway by 
inhibiting Akt phosphorylation (Le et al. 2005a;Nagata et al. 2004). This in turn 
leads to G1 cell cycle arrest due to the induction of p27Kip1, a cyclin-dependent 
kinase inhibitor that controls cell cycle progression by inhibiting the activity of 
cyclin-CDK complexes (Lane et al. 2000;Le et al. 2003;Le et al. 2005b). 
 
1.2.4.1.2.1.2 Immune-mediated response 
 
The mechanism of action by which Herceptin induces its anti-tumour cytostatic 
and possibly cytotoxic effects in vivo could be due to the activation of antibody-
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dependent cellular cytotoxicity (ADCC). This immune-mediated response of 
ADCC occurs when Herceptin bound to the extracellular domain of ErbB2 on 
tumour cells recruits immune effector cells such as natural killer cells to the 
tumour microenvironment through its Fc domain. Immune effector cells such as 
monocytes and macrophages express both activation (FcγRIII) and inhibitory 
(FcγRIIB) Fcγ receptors. Natural killer cells, which are the main cell type 
involved in ADCC, express only the FcγRIII activation receptors on their cell 
surface and not the inhibitory FcγRIIB counterpart (Clynes et al. 2000;Hudis 
2007). It has been proposed that activation of immune effector cells through the 
engagement of Herceptin to Fcγ receptors via its Fc domain is important for the 
anti-tumour activity of Herceptin. The recruited and activated natural killer cells 
can induce apoptosis of the Herceptin-bound tumour cells through secretion of 
cytoplasmic granule toxins such as perforin and granzymes (Smyth et al. 
2005;Valabrega et al. 2007). In agreement with this proposed mechanism, a 
preclinical study by Clynes and colleagues demonstrated that treatment with 
Herceptin of mice bearing ErbB2-overexpressing xenografts, in which the Fc 
receptor was deleted, resulted in a marginal effect on tumour volume when 
compared to the Herceptin effect in the control group (Clynes et al. 2000). 
Additionally, a pilot clinical study by Gennari and colleagues demonstrated the 
importance of a functional immune system for the efficacy of Herceptin (Gennari 
et al. 2004). 
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1.2.4.1.2.1.3 Inhibition of ErbB2 ectodomain cleavage  
 
As previously mentioned, the molecular weight of full length ErbB2 is 185kDa. 
In ErbB2 overexpressing breast cancer, the ErbB2 receptor can undergo 
proteolytic cleavage of its extracellular domain thus resulting in a truncated 
membrane-bound fragment termed p95ErbB2. This truncated fragment of ErbB2 
has a functional kinase domain, is phosphorylated and is therefore capable of 
signalling (Scaltriti et al. 2007). A study by Molina and colleagues demonstrated 
that Herceptin can inhibit both basal and chemically-induced ErbB2 ectodomain 
cleavage thereby inhibiting formation of phosphorylated p95ErbB2 (Molina et al. 
2001). 
 
1.2.4.1.2.1.4 Inhibition of angiogenesis  
 
During the early stages of tumour development, tumour cells can proliferate up 
to a size of 1-2mm in the absence of their own vascularisation. However, once a 
tumour reaches a certain mass, it can induce the formation of new blood 
vessels from pre-existing ones, a process called neovascularisation. These new 
blood vessels can therefore supply tumour cells with more nutrients to facilitate 
further growth (Leber and Efferth 2009). Tumour cells can induce angiogenesis 
through activation and thus stimulation of endothelial cells to secrete pro-
angiogenic factors (Cook and Figg 2010). A study by Izumi and colleagues 
demonstrated that Herceptin treatment induced vasculature regression and 
normalisation in a murine xenograft tumour model of overexpressing ErbB2. 
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These authors found that Herceptin markedly reduced vessel diameter and 
tumour volume when compared to a control antibody (Izumi et al. 2002). 
Furthermore, gene expression analysis of angiogenesis-related genes revealed 
that Herceptin treatment resulted in reduced expression of pro-angiogenic 
factors including vascular endothelial growth factor (VEGF) and increased 
expression of the anti-angiogenic factor, thrombospondin-1 (TSP-1) (Izumi et al. 
2002). 
 
1.2.4.1.2.2 Mechanism of resistance 
 
The response rates to Herceptin monotherapy range from 11-26% in patients 
with ErbB2-positive metastatic breast cancer, thus indicating that a vast majority 
of patients do not respond to Herceptin as a single agent (Kruser and Wheeler 
2010;Valabrega et al. 2007). However, combinations of Herceptin with taxanes 
such as paclitaxel or docetaxel increase the response rates ranging from 50-
80% (Valabrega et al. 2007). The underlying issue with Herceptin therapy is that 
the majority of patients who initially respond to Herceptin-based regimens 
develop resistance within the first year of treatment initiation. There is thus a 
need to elucidate the molecular mechanisms underlying Herceptin-induced 
resistance in order to improve patient survival and also to identify groups of 
patients that are likely to develop resistance to such regimens. This would save 
treatment costs and the unnecessary exposure to side effects such as 
cardiotoxicity. Several potential mechanisms to Herceptin resistance have been 
proposed as discussed below (Mukohara 2011;Valabrega et al. 2007). 
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1.2.4.1.2.2.1 Impaired access of Herceptin to the ErbB2 epitope 
 
There is evidence in the literature to suggest that tumour cells acquire 
resistance to Herceptin by limiting access of the antibody to its epitope. 
Although Herceptin has been shown to inhibit cleavage of the ErbB2 
extracellular domain (Molina et al. 2001), resistance to Herceptin is reported in 
p95ErbB2-positive breast cancer patients. Specifically, Scaltriti and colleagues 
investigated response to Herceptin in breast cancer patients, xenografts and 
cell lines expressing either p95ErbB2 or full length ErbB2. From these studies, the 
authors collectively found that p95ErbB2-expression correlated with resistance to 
Herceptin (Scaltriti et al. 2007). In a separate study, Nagy and colleagues 
observed that a Herceptin-resistant breast cancer cell line expressed high levels 
of MUC4, a membrane-associated mucin, the levels of which, inversely 
correlated with the Herceptin binding capacity (Nagy et al. 2005).  
 
These studies demonstrate that Herceptin is not effective in a subset of breast 
cancer that either lacks the ErbB2 epitope for Herceptin through ectodomain 
shedding or in which the epitope is hindered. For such patients, alternative 
treatment regimens such as tyrosine kinase inhibitors like Lapatinib would be 
more appropriate than Herceptin.  
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1.2.4.1.2.2.2 Loss of PTEN 
 
PTEN is a phosphatase that antagonises PI3K function by de-phosphorylating 
phosphatidylinositol-3,4,5 trisphosphate (PIP3) at the site that recruits Akt to the 
plasma membrane; thereby it negatively regulates Akt activity (Figure 1.4). 
Nagata and colleagues previously reported that PTEN activation contributes to 
the anti-tumour activity of Herceptin. These authors demonstrated that 
treatment of ErbB2-overexpressing breast cancer cells with Herceptin enhanced 
the membrane localisation of PTEN and thus its activation. This correlated with 
a reduction in the inhibitory tyrosine phosphorylation of PTEN, following 
Herceptin treatment (Nagata et al. 2004).   
 
In a separate study by Esteva and colleagues whereby PTEN expression status 
was evaluated in a cohort of patients with ErbB2-positive metastatic breast 
cancer, loss of PTEN expression was observed in 52% tumours of 137 patients. 
Furthermore, these authors found that loss of PTEN significantly correlated with 
resistance to Herceptin (P=0.028) and shorter survival time (P=0.008), 
particularly in patients receiving Herceptin as first-line therapy (Esteva et al. 
2010).  
 
1.2.4.1.2.2.3 Alternative signalling 
 
The insulin-like growth factor-1 receptor (IGF-1R) is a member of the type II 
family of growth factor receptors. Ligand binding to the receptor can lead to 
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activation of PI3K and MAPK signalling pathways, thereby promoting cell 
proliferation and survival (Lu et al. 2004). Data from in vitro studies in the 
literature suggest that cross talk occurs between IGF-1R and ErbB2 receptors 
and that this is associated with resistance to Herceptin (Huang et al. 2010;Jin 
and Esteva 2008;Lu et al. 2001;Lu et al. 2004;Nahta et al. 2005). Specifically, a 
study by Nahta and colleagues demonstrated that stimulation of Herceptin-
sensitive and resistant breast cancer cells with IGF-1 resulted in a rapid 
increase in phosphorylation of ErbB2 and downstream pathways. This was 
particularly observed in the Herceptin-resistant cells than in the sensitive cells. 
Furthermore, these authors demonstrated that chemically-induced inhibition of 
IGF-1R tyrosine kinase activity restored sensitivity of resistant cells to Herceptin 
(Nahta et al. 2005). 
 
A study by Shattuck and colleagues implicated the Met receptor in resistance to 
Herceptin. In this study, the authors demonstrated co-expression of the Met 
receptor with ErbB2 in breast cancer, and also that depletion or inhibition of Met 
enhanced Herceptin-mediated growth inhibition (Shattuck et al. 2008). 
 
Collectively, the above described mechanisms of resistance to Herceptin and 
the associated studies clearly demonstrate that the use of Herceptin as a single 
agent is not sufficient in the management of breast cancer. These mechanisms 
highlight the requirement of alternative treatment regimens involving a range of 
combinations with multiple targets, in order to combat resistance. 
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1.3 Tetraspanins 
 
1.3.1 The Tetraspanin superfamily 
 
Tetraspanins belong to a superfamily of small four transmembrane proteins, 
comprising 33 members in mammals (Table 1.1) (Hemler 2008;Romanska and 
Berditchevski 2011). These membrane proteins are ubiquitously expressed 
across a range of species, including fungi, Drosophila, Caenorhabditis elegans 
and mammals (Hemler 2001;Levy and Shoham 2005b). Furthermore, all 
nucleated cells express tetraspanins on their cell membranes (Levy and 
Shoham 2005a;Wright et al. 2004b). Some tetraspanins such as CD9, CD81 
and CD151 have an extensive, though not ubiquitous cell and tissue 
distribution, whilst other tetraspanins belonging to specialised structures have a 
restricted pattern of expression. These include the uroplakins UP1a and UP1b, 
found on the membrane of the urothelium and the proteins encoded by the 
retinal dystrophy syndrome (RDS) genes, RDS/peripherin and Rom-1, which 
are localised on the outer segment of the photoreceptor structure (Charrin et al. 
2009). 
 
  Introduction 
 
35 
 
 
 
Table 1.1: The nomenclature and chromosomal locations of human 
tetraspanins.  
 
This table was obtained from Romanska et al. (Romanska and Berditchevski 
2011). 
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1.3.1.1 Characteristics of tetraspanins 
 
Not all four transmembrane spanning proteins belong to the tetraspanin 
superfamily. All tetraspanin family members share key structural features that 
distinguish them from other four transmembrane proteins, such as stargazin 
and sarcospan (Min et al. 2006). 
 
1.3.1.1.1 Topology 
 
Tetraspanins are small proteins ranging between 204-355 amino acids in length 
and comprise of four transmembrane (TM) domains (TM1-4). The key structural 
features of tetraspanins include short intracellular N- and C-terminal tails of less 
than 20 amino acid residues; an intracellular loop; a short extracellular loop 
(EC1) of 13-31 amino acids located between TM1 and TM2; and a large 
extracellular loop (EC2) of 76-131 amino acids found between TM3 and TM4 
(Figure 1.7) (Charrin et al. 2009;Hemler 2005).  
 
In 2001, Kitadokoro et al. described the crystallographic structure of the 
extracellular domain of tetraspanin CD81 (Kitadokoro et al. 2001). This work 
revealed a unique structure of the extracellular domain to consist of 5 α-helices 
(A-E) organised into two subdomains, namely the stalk, comprising of two anti-
parallel α-helices, A & E; and the head subdomain comprising α-helices B, C & 
D. The C and D region of the EC2 domain of CD81 is not structurally conserved 
amongst all tetraspanins and is thus termed the variable region. In contrast, the 
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A and B helices are connected by a short loop, and together with the E helix, 
they form what is known as the constant region of the EC2 domain. This region 
is conserved within the tetraspanin family and thus serves as the basic 
structural feature for which the extracellular domains of other tetraspanins are 
modelled against (Figure 1.7) (Kitadokoro et al. 2001;Miranti 2009).  
 
The EC2 variable region is stabilised by structural motifs including the two 
disulphide bridges formed between the highly conserved signature motif of 
tetraspanins, the cysteine-cysteine-glycine (CCG) motif and with two other 
conserved cysteines (Charrin et al. 2009;Kitadokoro et al. 2001;Zoller 2009). 
The number of cysteine residues within the EC2 domain varies amongst the 
tetraspanin family with 4 cysteines being reported for CD81 and another 
example including CD9. The EC2 domains of most tetraspanins are reported to 
have 6 cysteines and this includes tetraspanins CD151 and CD82 (Figure 1.7). 
However, some tetraspanins are reported to contain 7 or 8 cysteine residues 
resulting in up to 4 disulphide bridges (Charrin et al. 2009;Hemler 2005;Levy 
and Shoham 2005b). Further to the cysteine residues found in the extracellular 
loop, tetraspanins contain juxtamembrane cysteine residues which are potential 
sites for palmitoylation, a post-translational modification involving the covalent 
linkage of palmitate to cysteine residues. Palmitoylation plays an important role 
in the organisation of tetraspanins into tetraspanin-enriched microdomains and 
will be discussed further in the next section (Charrin et al. 2009;Hemler 
2005;Levy and Shoham 2005b).  
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The EC2 domain is important for protein-protein interactions as demonstrated 
for the interaction between tetraspanin CD151 with α3β1. A study by 
Berditchevski and colleagues, using a panel of CD151/CD9 chimeras and 
CD151 mutants demonstrated the importance of the EC2 domain of CD151 in 
particular the variable region constituting the CCG motif, for the association of 
CD151 with integrin α3β1. It was also shown in that study that the EC2 domain 
was not required for tetraspanin-tetraspanin interactions, since its deletion did 
not abolish the interaction of CD151 with other tetraspanins such as CD9, 
thereby highlighting the requirement of other structural domains in facilitating 
tetraspanin-tetraspanin interactions (Berditchevski et al. 2001). 
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Figure 1.7: Structural features of tetraspanins. 
 
The main characteristic features of tetraspanins include the four 
transmembrane domains (TM1-4), a small extracellular loop (EC1), an 
intracellular loop, a large extracellular loop (EC2) and short amino- and 
carboxyl-terminal tails. The large extracellular loop is subdivided into a constant 
region (peach) comprising 3 α-helices A, B and E; and a variable region (blue) 
important for protein-protein interactions. The EC2 variable region comprises 
several highly conserved amino-acid residues such as the cysteine-cysteine-
glycine (CCG) motif found in all tetraspanins. These residues form two to four 
disulphide bridges (red) with other conserved cysteines, which account for the 
variations in the EC2 structures of family members. Furthermore, tetraspanins 
contain polar residues within TM1, 3 and 4 (red balls) for structural stability; 
potential N-glycosylation sites within the EC2 domain; and intracellular 
juxtamembrane cysteines which are sites for palmitoylation. This figure was 
obtained from Hemler (Hemler 2005).  
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1.3.1.2 Tetraspanin-enriched microdomains 
 
Studies in the 1990s demonstrated the ability of tetraspanins to associate with 
each other and with other transmembrane proteins. These studies utilised 
biochemical techniques including immunoprecipitation under a range of 
detergent conditions, whereby tetraspanins were co-immunoprecipitated with 
various binding partners (Berditchevski et al. 1996;Rubinstein et al. 1996). Such 
advances led to the emergence of the concept that tetraspanins organise the 
plasma membrane to form membrane domains termed, tetraspanin-enriched 
microdomains (TERMs), also referred to as the tetraspanin web or TEMs. 
Herein, they will be referred to as TERMs (Figure 1.8) (Charrin et al. 
2009;Hemler 2005;Yanez-Mo et al. 2009). Besides tetraspanins, other 
components of TERMs can be classified into several groups including integrins 
(such as α3β1) and other adhesion molecules including intracellular and 
vascular cell adhesion molecules, ICAM-1 and VCAM-1, respectively; members 
of the immunoglobulin superfamily (such as EWI-2); enzymes (such as 
metalloproteinases); and signalling molecules (such as EGFR) (Figure 1.8) 
(Charrin et al. 2009;Yanez-Mo et al. 2009).  
 
Tetraspanins bind to their partner proteins with different levels of interactions 
which can be classified as primary, secondary or tertiary interactions based on 
the detergent conditions that are required to disrupt the association (Hemler 
2003;Zoller 2009). Partner proteins are defined as those that retain their 
association with a given tetraspanin even after use of detergent conditions that 
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disrupt tetraspanin-tetraspanin interactions (Charrin et al. 2009). Primary 
interactions are direct protein-protein interactions revealed by chemical 
crosslinking techniques (Kovalenko et al. 2004). Such interactions occur early in 
biosynthesis presumably within the endoplasmic reticulum. They are often 
retained in stringent detergent conditions (1% NP-40); and include tetraspanin 
homodimers, homotrimers, homotetramers as well as heterointeractions with 
non-tetraspanin proteins. Examples of primary interactions between 
tetraspanins and non-tetraspanin proteins include CD151 with integrin α3β1; 
and CD9 or CD81 with EWI-2 (Charrin et al. 2009;Hemler 2003;Hemler 
2005;Kovalenko et al. 2004;Zoller 2009).  
 
Primary protein complexes act as building blocks that assemble together 
forming a network of secondary interactions. These secondary interactions can 
be distinguished from primary interactions in that they occur late in biosynthesis 
(Golgi apparatus). They are independent of the EC2 domain, can be stabilised 
by palmitoylation and furthermore, secondary interactions are disrupted by 
detergents such 1% Triton X-100 and digitonin, but are maintained under milder 
detergent conditions such as 1% Brij 96/97. In the literature, it is reported that 
the majority of tetraspanin interactions are secondary interactions (Hemler 
2003;Hemler 2005;Hemler 2008;Kovalenko et al. 2004;Zoller 2009). Several 
studies have highlighted differences between primary and secondary 
interactions and also the requirement of palmitoylation for secondary 
interactions. The study by Berditchevski and colleagues in 2001 demonstrated 
that even though the EC2 domain of CD151 was important for its association 
with α3β1 (a primary interaction), its removal did not affect the association of 
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CD151 with tetraspanins CD9, CD63 and CD81 (secondary interactions) 
(Berditchevski et al. 2001). Separate studies demonstrated the importance of 
palmitoylation in facilitating tetraspanin-tetraspanin associations. For example in 
one study, it was shown that loss of CD151 palmitoylation weakened its 
association with tetraspanins CD63 and CD81 but did not affect its interaction 
with α3β1 (Berditchevski et al. 2002). In a separate study, Charrin and 
colleagues demonstrated that palmitoylation contributed to the association of 
CD9 with tetraspanins CD81 and CD53, and that mutation of CD9 
palmitoylation sites impairs this association (Charrin et al. 2002). These studies 
therefore demonstrate that secondary interactions involve regions below the 
extracellular domains, particularly involving the juxtamembrane cysteine 
residues. 
 
Tertiary interactions are indirect, weak associations that can be disrupted under 
detergent conditions such as Brij 96/97 and Triton X-100, but are maintained in 
milder detergents such as 1% Brij-35/58/99 and CHAPS. These interactions are 
also stabilised by palmitoylation. They include the association of tetraspanins 
with kinases such as protein kinase C and type II phosphatidylinositol 4 kinase 
(PI4KII) (Berditchevski et al. 1997;Claas et al. 2001;Mannion et al. 1996;Zhang 
et al. 2001). 
 
In addition to interacting with various proteins, tetraspanins can also associate 
with cholesterol and gangliosides. This association accounts for the lipid raft-like 
property of tetraspanins, whereby some tetraspanins partition in the insoluble, 
light membrane fractions of sucrose gradients under certain detergent 
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conditions (Hemler 2003;Yanez-Mo et al. 2009). Lipid rafts are currently 
described as dynamic nanoscale plasma membrane microdomains with a high 
level of lipid composition comprising mainly of sphingolipids, phospholipids and 
cholesterol as well as proteins (Lingwood and Simons 2010;Simons and Gerl 
2010;Simons and Sampaio 2011). Components of these microdomains are 
often defined by their resistance to cold non-ionic detergent lysis such as Triton 
X-100 (Simons and Gerl 2010;Simons and Ikonen 1997). Unlike the tetraspanin 
enriched microdomains which have high protein content and thus heavy 
densities, lipid rafts have lower buoyant densities due to the high lipid content 
and thus segregate into low density, light membrane fractions of sucrose 
gradients. Lipid rafts differ from TERMs, which are disrupted by Triton X-100 
and tend to segregate into high density, heavy fractions of sucrose gradients 
(Hemler 2003).  
 
The dynamics and partitioning of tetraspanins and raft components within 
tetraspanin-enriched microdomains and lipid rafts, respectively can be 
distinguished by use of fluorescence microscopy techniques such as 
fluorescence recovery after photobleaching and single-molecule tracking 
(Espenel et al. 2008;Krementsov et al. 2010). For example, a study by Espenel 
and colleagues analysed the membrane distribution and dynamics of 
tetraspanin CD9 within TERMs in comparison to that of CD55, a raft resident 
protein by using single-molecule tracking in live cells (Espenel et al. 2008). In 
that study, the authors found that CD9 molecules were distributed on the whole 
cell surface with localised areas whereby CD9 was enriched. These 
tetraspanin-enriched areas/microdomains were found to be stable in position 
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and shape. Furthermore, by comparing the membrane distribution and 
dynamics of CD9 and CD55, these authors found that the partitioning and 
dynamics of these two membrane proteins were different, whereby they 
demonstrated that CD55 was excluded from the tetraspanin-enriched 
areas/microdomains (Espenel et al. 2008). 
 
 A study by Charrin and colleagues demonstrated that tetraspanins (CD9, CD81 
and CD82) interact with cholesterol, since extraction with digitonin (a cholesterol 
precipitating reagent) also precipitated tetraspanin oligomers; and that these 
interactions were disrupted upon cholesterol depletion (Charrin et al. 2003). 
Other studies have demonstrated tetraspanins to associate with gangliosides; 
such as CD9 with ganglioside GM3, an interaction that promotes the 
association of CD9 with integrin α3 (Kawakami et al. 2002). In a separate study 
by Odintsova and colleagues, it was demonstrated that inhibition of ganglioside 
GD1a affected interactions of CD82 with other protein partners. Specifically, the 
association of CD82 with CD151 was decreased, whilst the CD82-EGFR 
interaction was enhanced by GD1a inhibition (Odintsova et al. 2006).  
 
The ability of tetraspanins to interact with various partners, bringing them in 
close proximity with other molecules thereby enhancing the formation and 
stability of functional complexes such as signalling molecules, has seen this 
protein family described as ‘molecular facilitators’, regulating various cellular 
processes through their organisation of the plasma membrane (Maecker et al. 
1997). It is through these interactions with themselves and other partner 
molecules, that tetraspanins are believed to modulate various cellular functions 
  Introduction 
 
45 
 
including adhesion strengthening, effects on signalling, tumour progression, 
immune cell functions, platelet function, infectious diseases, angiogenesis, 
oocyte fertilisation, protein trafficking and possibly many more (Zoller 2009). 
CD82 has been shown to be involved in some of these cellular processes as 
discussed below.  
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Figure 1.8: Tetraspanin-enriched microdomains. 
 
Tetraspanins organise numerous proteins including other tetraspanins, various 
transmembrane and cytosolic proteins into complexes termed as tetraspanin-
enriched microdomains (TERMs). Integrins such as α3β1 are the major non-
tetraspanin partners found in TERMs and can be recruited through their direct 
association with tetraspanin CD151. Other non-tetraspanin transmembrane 
partners include immunoglobulin superfamily members such as the EWI 
proteins (EWI-2 and EWI-F); growth factor receptors such as EGFR and 
membrane-bound growth factors such as HB-EGF. Cytoplasmic TERM-resident 
proteins include protein kinase C (PKC), type II phosphatidylinositol 4 kinase 
(PI4KII), actin-binding ezrin-radixin-moesin (ERM) family proteins, adaptor 
proteins (AP) and PDZ-domain-containing proteins such as syntenin-1. This 
figure was obtained from Stipp (Stipp 2010). 
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1.3.2 CD82  
 
CD82 (formerly known as KAI1, Tspan27) is a membrane glycoprotein 
belonging to the tetraspanin family (Table 1.1). The human CD82/KAI1 gene is 
located on chromosome 11p11.2 and encodes a 267 amino acid protein with a 
predicted molecular weight of 46-60 kDa due to glycosylation (Figure 1.9) (Dong 
et al. 1995;Jackson et al. 2005). It was later found that CD82/KAI1 was identical 
to several antigens that were previously characterised from human 
lymphocytes. These included R2, an antigen that was highly upregulated in 
activated T cells (Gaugitsch et al. 1991); C33, a membrane antigen 
immunoprecipitated by monoclonal antibodies C33 and M104, that was capable 
of inhibiting syncytium formation induced by human T-cell leukaemia virus type I 
(HTLV-1) (Fukudome et al. 1992;Imai et al. 1992); and IA4, an antigen widely 
expressed on the surface of lymphocytes and monocytes (Gil et al. 1992). 
According to the HUGO Gene Nomenclature Committee 
(http://www.genenames.org/data/hgnc_data.php?hgnc_id=6210), the currently 
approved gene symbol and name for KAI1, is CD82; therefore from henceforth, 
the KAI1 molecule will be referred to as CD82. 
 
1.3.2.1 Specific structural features of CD82 
 
CD82 contains the characteristic structural features shared by all family 
members as outlined in Figure 1.7. The bar protein structure illustrates the 
predicted location of these features for CD82 (Figure 1.9). Like the majority of 
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tetraspanins, the large extracellular loop (EC2) of CD82 contains six highly 
conserved cysteines thus forming three disulphide bonds (Figure 1.9; clear) 
(Charrin et al. 2009). In addition to these cysteine residues, the EC2 region of 
CD82 also contains three N-glycosylation sites, Asparagine (Asn, N)129, 
Asn157 and Asn198 (Figure 1.9; purple circles) (Liu and Zhang 2006). A report 
by White and colleagues demonstrated that CD82 was downregulated in more 
than 50% of the cancer cell lines that were analysed. They also found tissue-
specific heterogeneity in the molecular weight of CD82 based on the variability 
in the protein band pattern as determined by western blot analysis. This was 
concluded to be due to differences in N-linked glycosylation (White et al. 1998).  
 
Twelve tetraspanins including CD82 contain a putative tyrosine-based 
internalisation sorting motif (YXXΦ) in the C-terminal tail. In the case of CD82, 
this sequence is YSKV for tyrosine, serine, lysine and valine, respectively 
(Berditchevski and Odintsova 2007). The YXXΦ motif is recognised by the µ2 
chain of the clathrin adaptor protein-2 (AP-2) complex thus suggesting a 
possible role of this motif in the trafficking of tetraspanins and their associated 
proteins. However, a study by Xu and colleagues demonstrated that CD82 
undergoes lipid-dependent endocytosis, independent from the clathrin pathway 
(Xu et al. 2009). This study therefore indicates that the YXXΦ motif does not 
always predict the internalisation pathway. 
 
CD82 is palmitoylated and contains five juxtamembrane cysteine residues 
located at positions 5, 74, 83, 251 and 253, which are possible sites of 
palmitoylation (Figure 1.9; yellow circles) (Mazurov et al. 2007;Miranti 2009). 
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Mutations of these cysteine residues have previously been shown to disrupt 
protein-protein interactions including the association of CD82 with the HTLV-1 
Gag protein. These mutations were also found to reverse the inhibitory effects 
of wild-type CD82 on cell migration and invasion (Mazurov et al. 2007;Zhou et 
al. 2004). 
 
The transmembrane regions of tetraspanins including CD82 contain polar 
residues (Figure 1.9; red circles). Asparagine (Asn, N), glutamine (Gln, Q) and 
glutamic acid (Glu, E) are the polar residues located in the first, third and fourth 
transmembrane domains of CD82, respectively (Bari et al. 2009;Bienstock and 
Barrett 2001). These three polar residues are conserved in all CD82 proteins in 
vertebrates and are reported to be important for the interactions of CD82 with 
other tetraspanins such as CD9 and CD151. A study by Bari and colleagues 
demonstrated that mutations of all three polar residues to alanines markedly 
reduced the association of CD82 with CD9 and CD151. These authors also 
found that these polar residues were critical for the motility-inhibitory activity of 
CD82 since expression of the NQE CD82 mutant resulted in increased cell 
motility compared to wild-type CD82 (Bari et al. 2009). 
 
Additionally, the 5’ promoter region of the CD82 gene contains putative binding 
motifs for several transcription factors including activating protein 2 (AP2), p53 
and activating protein 1 (AP1) (Dong et al. 1997). This promoter region is 
reported to be important in the regulation of CD82 transcription (Dong et al. 
1997;Marreiros et al. 2003;Marreiros et al. 2005). 
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Figure 1.9: Schematic of the CD82 bar protein structure. 
 
The CD82 gene encodes a 267 amino acid protein. The schematic indicates the 
location of the main structural features of the CD82 protein including, four 
transmembrane domains (TM1-4) (pale blue boxes); a short extracellular loop 
(EC1); a very short intracellular loop located between TM2 and TM3; a large 
extracellular loop (EC2); short N- and C-termini; juxtamembrane cysteine 
residues, which are sites for palmitoylation (yellow circles); NQE polar residues 
(red circles); N-glycosylation sites (purple circles); and conserved cysteines 
including the CCG-motif (clear). This figure was adapted from Bienstock et al. 
and Jackson et al. (Bienstock and Barrett 2001;Jackson et al. 2005), according 
to the Universal Protein (UniProt) database 
(http://www.uniprot.org/uniprot/P27701) in association with the HUGO Gene 
Nomenclature Committee (HGNC). Abbreviations: C - cysteine; N - asparagine; 
Q - glutamine; and E - glutamic acid. 
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1.3.2.2 Effects of CD82 on immune cell signalling 
 
CD82 is abundantly expressed on B and T lymphocytes, granulocytes, 
monocytes, macrophages and natural killer cells (Wright et al. 2004b). Most of 
the early studies of CD82 in the 1990s were done in lymphoid cells, whereby it 
was particularly demonstrated that CD82 expression was upregulated following 
phytohaemagglutinin (PHA) stimulation of T cells. Furthermore, CD82 was 
found to inhibit syncytium formation induced by the human T-cell leukaemia 
virus type I (HTLV-1) (Fukudome et al. 1992;Gil et al. 1992;Imai et al. 1992). 
These studies suggest a possible role of CD82 in regulating T cells and 
possible implications on the immune response.  
 
CD82 is reported to interact with a range of immunoreceptors including B-cell 
and T-cell receptors; peptide receptors - major histocompatibility complex 
(MHC) class I & II; and co-receptors such as CD4, CD19 and EWI-2 (Table 1.2) 
(Wright et al. 2004b). CD82 is thought to have a role in regulating T cell 
signalling through its association with T-cell receptors. Full activation of T cells 
requires two signals; one generated by the engagement of T cell receptors on T 
cells with MHC-peptide complexes found on antigen presenting cells (APCs); 
and the second signal is generated by the association of surface molecules on 
T cells with those on the APCs. This provides a co-stimulatory signal that leads 
to a complete T cell immune response involving T cell proliferation and cytokine 
production (Witherden et al. 2000). Immobilisation of appropriate monoclonal 
antibodies can provide this second co-stimulatory signal in the absence of 
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APCs. It has been previously demonstrated that CD82 can deliver a co-
stimulatory signal for full activation of T cells resulting in enhanced cytokine 
production and cell differentiation, when anti-CD82 and anti-CD3 monoclonal 
antibodies were co-immobilised (Lagaudriere-Gesbert et al. 1998;Lebel-Binay et 
al. 1995).  
 
The Rho family of GTP-binding proteins including RhoA, Rac and cdc42 is 
implicated in T cell activation leading to gene transcription and cell 
differentiation. Like other GTP-binding proteins, their GTPase activity is 
regulated by the switch between inactive (GDP-bound) to active GTP-bound 
state, which is in turn regulated by guanosine exchange factor (GEF) molecules 
such as the Vav family of proteins including Vav1. Furthermore, the activity of 
GEF molecules and their association with adaptor proteins is regulated by 
tyrosine phosphorylation. A study by Delaguillaumie and colleagues 
demonstrated that CD82 engagement promotes T cell signalling involving Rho 
GTPases; whereby it was demonstrated that CD82 engagement induced 
tyrosine phosphorylation and association of Vav1 (a Rho-specific GEF) and the 
adaptor protein SLP76, leading to Rho GTPase activation. Furthermore, the 
authors demonstrated that inactivation of the Rho GTPases inhibited the CD82-
induced formation of membrane extensions (Delaguillaumie et al. 2002).  
 
Collectively, these studies highlight the intermediary role of CD82 in promoting 
T cell signalling by acting as a co-stimulator through its association with 
numerous immunoreceptors.  
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Molecular interactions of CD82 
Interacting molecules References 
Tetraspanins 
CD9, CD151 (Bari et al. 2009;Charrin et al. 2003) 
CD63 (Hoorn et al. 2012) 
CD81 (Charrin et al. 2003;Rubinstein et al. 1996) 
CD53 (Charrin et al. 2002) 
Molecules of the immune system 
CD4, CD8 (Imai and Yoshie 1993) 
CD19 (Horvath et al. 1998) 
MHC class I & II (Lagaudriere-Gesbert et al. 1997) 
EWI-2 (Zhang et al. 2003b) 
Integrins 
α3β1 (Berditchevski and Odintsova 1999;Odintsova et al. 2000) 
α4β1, α6β1 (He et al. 2005;Takahashi et al. 2007) 
αLβ2 (Tarrant et al. 2003) 
αvβ3 (Ruseva et al. 2009) 
Gangliosides 
GM2 (Todeschini et al. 2007) 
GM3 (Wang et al. 2007) 
Growth factors and growth factor receptors 
ProHB-EGF (Nakamura et al. 2000) 
EGFR (Odintsova et al. 2000;Odintsova et al. 2006) 
ErbB2, ErbB3 (Odintsova et al. 2003) 
c-Met (Takahashi et al. 2007) 
Intracellular signalling molecules 
PKC (Wang et al. 2007;Zhang et al. 2001) 
Other molecules  
KITENIN (Lee et al. 2004b) 
DARC (Bandyopadhyay et al. 2006) 
γ-glutamyl transpeptidase (Nichols et al. 1998) 
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Table 1.2: Transmembrane and cytosolic molecules that associate with 
tetraspanin CD82.  
 
Abbreviations: MHC I & II - major histocompatibility complex class I & II; proHB-
EGF - membrane-bound heparin-binding EGF-like growth factor; PKC - protein 
kinase C; KITENIN – KAI1 COOH-terminal interacting tetraspanin; DARC - duffy 
antigen receptor for chemokines. This table was adapted from Miranti (Miranti 
2009). 
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1.3.2.3 Effects of CD82 on growth factor signalling 
 
Tetraspanins have been previously shown to modulate growth factor signalling. 
For example, CD82 has been reported to associate with cell surface receptors 
and thereby regulate their biological activity. A study by Odintsova and 
colleagues demonstrated that CD82 directly associates with the epidermal 
growth factor receptor (EGFR); and that ectopic expression of CD82 
suppressed EGF-induced morphological changes including lamellipodial 
extensions and cell migration in epithelial cells (Odintsova et al. 2000). 
Furthermore, this work also demonstrated that the CD82-mediated attenuation 
in EGFR signalling correlated with an increased rate of receptor desensitisation 
through dephosphorylation of the receptor and its downstream signalling 
molecules; and also with an increase in the rate of ligand-dependent 
internalisation of the receptor. This negative effect of CD82 on EGF-induced 
signalling however was not found to affect the initial activation of the receptor, 
but rather the subsequent desensitisation following activation of the receptor 
(Odintsova et al. 2000). This group later proposed a molecular mechanism into 
the specific attenuating effect of CD82 towards EGFR to involve redistribution of 
the receptor into ganglioside-containing microdomains, as was observed in 
sucrose gradient fractions. It was also shown that the elevated expression of 
CD82 resulted in increased surface expression of ganglioside GD1a, which co-
localised together with CD82 and EGFR on the plasma membrane (Odintsova 
et al. 2003). Gangliosides are well-known to play crucial roles in regulating 
growth factor signalling. Specifically, GD1a has previously been shown to 
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promote EGFR dimerisation and thus downstream signalling, both in the 
presence and absence of a ligand (Liu et al. 2004b;Milani et al. 2010;Miljan and 
Bremer 2002).  
 
Another study by Danglot and colleagues also highlighted the involvement of 
CD82 in the regulation of EGFR signalling. They demonstrated that the tetanus 
neurotoxin-insensitive vesicle-associated membrane protein (TI-VAMP) was 
required for the transport of CD82 from the Golgi apparatus to the cell surface; 
and that depletion of either TI-VAMP and/or CD82 decreased the cell surface 
mobility of activated EGFR, which correlated with a decrease in MAPK 
signalling and also increased endocytosis of the receptor (Danglot et al. 2010).  
 
To further demonstrate the CD82-dependent modulation of EGFR signalling, 
Wang and colleagues demonstrated that CD82 played a role in promoting the 
suppression of EGFR signalling by activated PKCα. These authors 
demonstrated that EGFR is brought in close proximity with PKCα through an 
ordered complex involving CD82, caveolin-1 and ganglioside GM3. Thereby 
enabling activated PKCα to phosphorylate EGFR, leading to receptor 
internalisation and signalling suppression (Wang et al. 2007). 
 
Activation of the c-Met receptor by its ligand, hepatocyte growth factor (HGF) 
can induce cell proliferation, migration and survival via the PI3K and MAPK 
signalling pathways. A study by Takahashi and colleagues demonstrated the 
association of CD82 with c-Met (Takahashi et al. 2007). Furthermore, the 
authors demonstrated that ectopic expression of CD82 resulted in suppression 
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of HGF-induced cell migration via the reduced association of signalling adaptor 
proteins with c-Met, thereby inhibiting activation of downstream signalling 
pathways (Takahashi et al. 2007). 
 
Collectively, these studies demonstrate that CD82 negatively regulates growth 
factor signalling, partly through its direct association with growth factor 
receptors. This interaction appears to be critical for the CD82-mediated 
attenuation of growth factor signalling. It is possible that through this 
association, CD82 recruits the growth factor receptors to a multi-molecular 
complex consisting of negative regulators such as phosphatases to limit signal 
propagation.  
 
1.3.2.4 Roles of tetraspanins in malignant disease 
 
The ability of tetraspanins to associate with a range of transmembrane and 
cytoplasmic signalling molecules, recruit them into TERMs and thus modify their 
activity can have implications in malignant disease. Tetraspanins have been 
implicated in both progression and suppression of tumours (Boucheix and 
Rubinstein 2001;Maecker et al. 1997). Some family members such as CD151, 
Tspan8 and CD37 are reported to promote tumour progression (Lapalombella 
et al. 2012;Novitskaya et al. 2010;Richardson et al. 2011;Sadej et al. 2009); 
whilst the expression of others such as CD82 and CD9 is reported to inversely 
correlate with the metastatic potential of various cancers and is thus indicative 
of good prognosis (Dong et al. 1997;Jackson et al. 2005;Richardson et al. 
2011;Tonoli and Barrett 2005).  
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1.3.2.4.1 Tetraspanins and tumour progression 
 
CD151 is overexpressed in many tumour types including: breast, pancreatic, 
non-small cell lung cancer and colorectal cancer; and this is associated with 
poor prognosis and enhanced metastasis (Yang et al. 2008;Zoller 2009). The 
expression of CD151 is upregulated in 31% of human breast cancer with even 
higher expression levels, 40% and 45% in high grade and estrogen receptor-
negative tumours, respectively (Yang et al. 2008).  
 
CD151 has previously been reported to be involved in breast cancer 
tumourigenesis. A study by Sadej and colleagues demonstrated that high 
expression of CD151 in breast cancers correlated with decreased overall 
survival, whereby the five-year estimated survival rates for breast cancer 
patients were reported to be approximately 46% and 80% for CD151-positive 
and CD151-negative, respectively (Sadej et al. 2009). In that study, the authors 
further demonstrated the involvement of CD151 in breast cancer 
tumourigenesis. They found that depletion of CD151 in breast cancer cell lines 
resulted in a decrease in the tumourigenic potential of these cells when 
xenotransplanted in athymic nude mice, compared to tumour growth in mice 
with CD151-positive cells. Additionally, they found that CD151 modulated the 
response of breast cancer cells to endothelial cell-derived transforming growth 
factor beta (TGF-β). Thus, CD151 was identified as a key regulator of 
communication between tumour cells and endothelial cells (Sadej et al. 
2009;Sadej et al. 2010). In recent studies, CD151 was shown to regulate 
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proliferation of non-tumourigenic mammary epithelial cells (Novitskaya et al. 
2010). Furthermore, CD151 is reported to be overexpressed in subtypes of 
invasive breast cancer, resulting in poor overall survival and disease-free 
survival (Kwon et al. 2012).  
 
Together, these findings implicate CD151 in breast cancer tumourigenesis and 
disease progression. They thus identify CD151 as a potential prognostic marker 
for breast cancer and a viable therapeutic target in the management of this 
disease.  
 
1.3.2.4.2 Tetraspanins and tumour suppression 
 
Tetraspanins such as CD82 and CD9 are known to have tumour suppressive 
activity, whereby it is reported that expression of these tetraspanins inversely 
correlates with tumour invasion and metastasis in many malignancies including 
breast cancer (Hemler 2008;Liu and Zhang 2006;Richardson et al. 2011). The 
role of CD82 as a metastasis suppressor will be discussed further below. 
 
1.3.2.5 CD82 and metastasis suppression 
 
CD82 is ubiquitously expressed in normal human tissue with highest levels of 
expression being reported to be in lung, liver, prostate, kidney, placenta and 
bone marrow (Liu and Zhang 2006;Miranti 2009). CD82 is downregulated 
during the advanced stages of a wide variety of human cancers, both at mRNA 
and protein levels; and this is strongly correlated with poor prognosis. However, 
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mechanisms into inactivation of CD82 in human malignancies remain elusive. 
CD82 was initially proposed to be a prostate-specific metastasis suppressor 
(Dong et al. 1997;Liu and Zhang 2006;Miranti 2009). However, subsequent 
studies revealed that CD82 is a suppressor of the metastasis phenotype of 
many tumours (Jackson et al. 2005).  
 
It has previously been shown that CD82 is downregulated preferentially in 
estrogen receptor (ER)-positive breast cancers (Huang et al. 2005) and that in 
such cases, CD82 could be re-inducible with endocrine therapy involving ER-
antagonists such fulvestrant (Christgen et al. 2008;Christgen et al. 2009). In 
prostate cancer mouse models, downregulation of CD82 correlated with 
increased invasive potential, an effect that was reversed by re-expression of 
CD82 (El Touny and Banerjee 2007). These findings highlight the suppressive 
effect of CD82 on tumour cell invasion. The exact mechanisms of how CD82 
suppresses metastasis remain unclear, however it has been postulated that the 
CD82-mediated metastasis suppression could be via its inhibition of cell 
migration (Miranti 2009).  
 
1.3.2.5.1 CD82 and cell migration 
 
Cell migration can be promoted by multiple signalling pathways including 
receptor tyrosine kinase and integrin signalling. The latter involves adhesion-
dependent signalling molecules such as focal adhesion kinase (FAK); other 
signalling molecules including Src; adaptor proteins such as p130CAS (Crk-
associated substrate) and Crk, which ultimately promote cell detachment and 
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thus motility (Cabodi et al. 2010;Klemke et al. 1998). Integrins α3β1 and α4β1 
are amongst the proteins that have been reported to interact with CD82 (Table 
1.2), and this association is thought to be crucial for the function of CD82 as a 
metastasis suppressor (Jee et al. 2007). The association of p130CAS and Crk is 
reported to be crucial in facilitating cell migration; whereby it has previously 
been shown that coexpression of p130CAS and Crk resulted in a significant 
increase in cell migration on various extracellular matrices (ECM) (Klemke et al. 
1998).  
 
Specifically, a study by Zhang and colleagues demonstrated that expression of 
CD82 in a metastatic prostate cancer cell line reduced the migratory potential of 
these cells towards fibronectin and laminin ECM. These authors also observed 
that cells overexpressing CD82 had increased expression of FAK and low levels 
of p130CAS, resulting in decreased formation of the pro-migratory p130CAS-Crk 
complex. They concluded that CD82 inhibited cell motility through the FAK-Src-
p130CAS-Crk signalling pathway by downregulating the level of p130CAS and thus 
affecting formation of the pro-migratory p130CAS-Crk complex (Zhang et al. 
2003a). 
 
Sprouty2 is a member of the Sprouty protein family which are inducible 
inhibitors of signalling by receptor tyrosine kinases. Once phosphorylated, 
Sprouty proteins such as Sprouty2 can antagonise the MAPK signalling 
pathway through sequestration of Grb2. This therefore inhibits the recruitment 
of the Grb2-SOS complex to the activated receptor, ultimately inhibiting Ras 
activation (Kim and Bar-Sagi 2004). Overexpression of Sprouty2 has previously 
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been reported to result in suppression of cell migration via inhibition of MAPK 
signalling (Lee et al. 2004a). In a separate study by Mu and colleagues, it was 
demonstrated that CD82 suppresses HGF-induced hepatoma cell migration via 
up-regulation of Sprouty2. These authors demonstrated that overexpression of 
CD82 resulted in elevated levels of Sprouty2 and inhibition of cell migration (Mu 
et al. 2008). 
 
Collectively, these studies demonstrate that CD82 can suppress cell migration 
via different mechanisms. 
 
1.3.2.6 Other tetraspanin functions 
 
1.3.2.6.1 Oocyte fertilisation 
 
Besides having roles in malignancies, tetraspanins have also been implicated in 
various normal physiological processes such as oocyte fertilisation. Le Naour 
and colleagues previously demonstrated that tetraspanin CD9 was essential for 
oocyte-sperm fusion, whereby the fertility of knockout mice deficient in CD9 
(CD9-/-) was severely reduced (Le et al. 2000). This group later demonstrated 
that CD9 was not the only tetraspanin involved in fertilisation, but also CD81. 
They demonstrated that CD81 knockout mice (CD81-/-) also showed a reduction 
in fertility (40%), though not as severe as that observed in CD9-/- (95%). Mice 
lacking both CD9 and CD81 (double knockout mice CD9-/- CD81-/-) were 
completely infertile thus indicating that both CD9 and CD81 are required for 
effective fertilisation (Rubinstein et al. 2006). The expression of CD9 on oocytes 
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is mainly localised to the membranes of microvilli; and this expression is thought 
to be required in maintaining the size, shape and density of oocyte microvilli, 
thereby facilitating sperm-egg fusion (Hemler 2008;Runge et al. 2007). 
 
1.3.2.6.2 Platelet function 
 
Tetraspanins are expressed on the surface of platelets. These include CD9, 
CD151, CD63, Tspan9 and Tspan32, whereby CD9 is the most highly 
expressed tetraspanin on platelets (Haining et al. 2011). In vivo studies of 
tetraspanin-deficient mice demonstrated that tetraspanins are essential for 
modulating normal platelet function. Specifically, a report by Wright and 
colleagues demonstrated that CD151 knockout mice displayed abnormal 
haemostasis, whereby in vivo tail bleeding studies revealed prolonged bleeding 
times for CD151-null mice when compared to that for wild-type mice. 
Furthermore, the authors observed that CD151-null mice had a significantly 
higher tendency to re-bleed (P<0.05), compared to wild-type mice (Wright et al. 
2004a). Another study demonstrated that CD151-deficient platelets had a defect 
in spreading and clot retraction; effects which were proposed to be due to a 
defect in integrin signalling (Lau et al. 2004). 
 
1.3.2.7 Tetraspanin deficiencies and associated phenotypes in human 
 
Several clinical phenotypes have previously been described in correlation to 
tetraspanin deficiencies (Lazo 2007). For example, a study by Karamatic and 
colleagues described rare cases of three individuals who had a single 
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nucleotide insertion in exon 5 of CD151, which caused a frameshift mutation 
and a premature stop signal at codon 140. The mutation resulted in expression 
of a truncated protein lacking most of the integrin-binding large extracellular 
loop. Clinical phenotypes associated with this mutation in the CD151 gene 
included β-thalassemia minor, pretibial epidermolysis bullosa, neurosensory 
deafness and nephritis (Karamatic, V et al. 2004). This study demonstrated that 
CD151 played a key role in ensuring the integrity of basement membranes in 
the kidney, skin and inner ear. It also highlights the importance of CD151-
integrin associations for the molecular function of CD151. 
 
Tetraspanin TM4SF2 has previously been implicated in X-linked mental 
retardation, whereby a study by Zemni and colleagues identified mutations in 
the TM4SF2 gene located on chromosome Xp11.4 in patients with X-linked 
mental retardation. These mutations included an inactivating X;2 translocation 
breakpoint and a nucleotide transition that leads to a premature stop signal. The 
latter mutation leads to expression of a truncated protein lacking the fourth 
transmembrane domain and the C-terminal tail (Zemni et al. 2000).  
 
Other phenotypes associated with tetraspanin deficiencies include an 
immunodeficiency syndrome characterised by recurrent infectious diseases 
correlated with lack of CD53 antigen expression on neutrophils (Mollinedo et al. 
1997). Moreover, mutations in the peripherin/RDS gene have been implicated in 
a degenerative disease of the retina (van et al. 1999). Additionally, Tspan12 has 
been shown previously to be required for retinal vascular development whereby 
Tspan12-/- mice exhibited retinal vascular defects when compared to Tspan12+/+ 
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mice (Junge et al. 2009). It was later found in three Chinese patients that 
heterozygous mutations in Tspan12 resulted in autosomal dominant familial 
exudative vitreoretinopathy (FEVR), a hereditary vitreoretinal disorder 
characterised by abnormalities in the development of the retinal vessels (Yang 
et al. 2011). More recently, van Zelm and colleagues reported the first case 
study of a patient with antibody deficiency syndrome caused by a homozygous 
CD81 mutation (a homozygous G>A substitution) which resulted in complete 
lack of CD81 expression on B cells and this resulted in severe nephropathy and 
hypogammaglobulinemia (van Zelm et al. 2010). 
 
Considering the wide tissue distribution of tetraspanins and their involvement in 
numerous biological processes, it is perhaps surprising that defects in individual 
tetraspanins result in relatively mild phenotypes. Since these proteins are 
known for their association into multimolecular complexes, the mild phenotypes 
observed from studying individual molecules suggest that perhaps tetraspanins 
should be studied as a multimolecular unit. Perhaps then, the functional 
implications of their deficiencies would be more prominent as opposed to those 
identified for individual molecules. 
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1.4 Research objectives 
 
Preliminary experiments performed within our group using MCF-7 breast cancer 
cells demonstrated that overexpression of CD82 modulated the cellular 
response of these cells to Herceptin treatment. Specifically, activation of the 
PI3K/Akt pathway was found to be considerably delayed in Herceptin treated 
CD82-overexpressing cells when compared to control cells. Additionally, it was 
demonstrated that ErbB2 was readily degraded in the CD82-overexpressing 
cells following prolonged treatment with Herceptin when compared to control 
cells. Furthermore, after stimulation with heregulin, the peptide corresponding to 
the C-terminus of CD82 pulled down phosphorylated proteins within the 
molecular weight region similar to that of the ErbB proteins (Odintsova E, 
unpublished results). These findings led to the hypothesis that CD82 could 
potentiate the efficacy of Herceptin via two possible mechanisms; either by 
regulating the distribution and dynamics of the ErbB2/Herceptin complex or by 
modifying the recruitment of signalling molecules to the plasma membrane. 
Thus the aims of this project were to use breast cancer cell lines (BT474, 
SKBR3 and ZR75.30) expressing different levels of CD82 in order to:  
1. Determine whether ectopic expression of CD82 altered the cellular 
response of breast cancer cells to Herceptin treatment. 
2. Determine whether CD82 affected the distribution and dynamics of 
ErbB2 on the plasma membrane following Herceptin treatment. 
3. Determine whether ectopic expression of CD82 affected signalling 
downstream of the ErbB2 receptor.  
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2 MATERIALS AND METHODS 
 
2.1 Cell Culture Methods 
 
2.1.1 Maintenance of cell lines 
 
All cell lines used in this study and their corresponding features are outlined in 
Table 3.1. Comprehensive information of growth culture medium and 
supplements for all these cell lines can be found in Appendix I. Purchase 
information of all reagents and chemicals used can be found in Appendix II. 
 
Cells were cultured in complete growth medium at 37oC, in a 5% CO2 
humidified incubator. For sub-culturing, growth medium was aspirated and the 
cell monolayer was briefly rinsed twice with phosphate buffered saline (PBS) to 
remove traces of serum. Cells were subsequently detached by the addition of 
0.05% trypsin-EDTA to the monolayer, followed by incubation at 37oC for 3-5 
minutes to facilitate dispersal. Detached cells were resuspended in complete 
growth medium and pelleted by centrifugation at 400 g for 3 minutes. The 
supernatant was removed and the resulting pellet was resuspended with culture 
medium. Appropriate aliquots of the cell suspension were then transferred to a 
fresh culture vessel and incubated at 37oC, in a 5% CO2 humidified atmosphere 
for further propagation. 
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2.1.2 Cell freezing and thawing 
 
Cells in log phase were prepared for freezing by being detached, collected and 
centrifuged as described above in section 2.1.1. The supernatant was removed 
and the resulting cell pellet was resuspended in 1ml of freezing solution (10% 
dimethyl sulfoxide (DMSO) and 90% heat inactivated-fetal bovine serum (HI-
FBS)) (Appendix I). The suspension was transferred to a CryoTubeTM vial, 
which was then wrapped in paper towels and stored in a -80oC freezer for at 
least 24 hours, to ensure that the cells were gradually frozen prior to being 
transferred to liquid nitrogen for long-term storage. 
 
To recover frozen cells, the cryovials were placed in a 37oC water-bath for 2 
minutes and the thawed cells were transferred into 9ml of pre-warmed culture 
medium before centrifugation at 400 g for 3 minutes. The resulting pellet was 
resuspended with fresh complete medium and seeded onto a tissue culture 
vessel followed by incubation at 37oC, in a 5% CO2 humidified atmosphere. 
Cells were maintained in culture for a maximum period of 2 months before 
another batch was recovered. 
 
2.1.3 Mycoplasma testing 
 
Cells in culture were routinely tested for mycoplasma contamination using a 
MycoAlert® mycoplasma detection kit immediately prior to freezing; a few days 
after recovery from liquid nitrogen; and at frequent intervals during culture. In 
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case of detection of mycoplasma infection, the affected cell line(s) were treated 
with BM-Cyclin, an antibiotic kit for the elimination of mycoplasma from infected 
cell cultures that has little or no side effects to the cells at the recommended 
working concentrations. The kit was used according to the manufacturer’s 
guidelines, which involved changing the growth culture medium from the 
infected cells and replacing it with fresh medium supplemented with BM-cyclin 1 
at 10µg/ml and leaving it on the cells for at least three days, after which, it was 
replaced by fresh culture medium supplemented with BM-cyclin 2 at 5µg/ml for 
at least four days. The cycle was repeated for at least 2-3 weeks or until the 
cells eventually tested negative for mycoplasma. 
 
2.1.4 Cell transfection 
 
Transfection experiments were carried out using either FuGene® 6 or 
GeneJammer® transfection reagents, with cells at 50-80% confluency according 
to the manufacturer’s protocol. Tables 2.1 and 2.2 summarise the 
manufacturer’s guidelines for the volumes of transfection reagent:DNA in 
preparation of a complex mixture for FuGene and GeneJammer transfection 
reagents, respectively. For transient transfections, the cells were transfected as 
above using GeneJammer and were used in the relevant assays 48h post 
transfection. All plasmids used in this study are summarised in Table 2.3.  
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Table 2.1: Preparation guidelines for FuGene® 6 transfection reagent: DNA 
complex (3:1 ratio) in various tissue culture vessels. 
 
Tissue 
culture 
vessel 
Diameter of 
the well 
(mm) 
Volume of 
GeneJammer® 
per well 
(µl) 
Amount 
of DNA 
per well 
(3:2) ratio 
(µg)  
Final 
volume of 
transfection 
mixture 
(µl/well) 
Total 
volume of 
medium 
per well 
(ml) 
12-well 22 1.5 1 50 1.0 
60mm 60 6 4 200 6.0 
100mm 100 18 12 600 10.0 
 
Table 2.2: Preparation guidelines for GeneJammer® transfection reagent: DNA 
complex (3:2 ratio) in various tissue culture vessels.  
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2.1.5 Generation of stable CD82 knockdown cells 
 
CD82-depleted cell lines were generated by infection of ZR75.30 parental cells 
with viral particles containing short-hairpin RNA (shRNA) that specifically target 
wild-type CD82 (target sequence 5’-gcacgtccattccgaagactaca - 3’). Viral 
particles containing CD82-specific shRNA were generated by co-transfecting a 
plasmid mixture containing the pLVTHM-shCD82 lentiviral vector encoding 
CD82-specific shRNA, the packaging vector psPAX2 and the envelope plasmid 
pMD2G into a packaging cell line, HEK 293T cells using FuGene® 6. One day 
prior to transfection, the cells were detached and re-seeded at a concentration 
that would achieve a monolayer density of 50-80% confluency, suitable for 
transfection. Cells were transfected as described above in section 2.1.4 and 
were incubated at 37oC, 5% CO2 for 24 hours, after which the culture medium 
containing the complex mixture was removed and replaced with complete 
growth medium. The cells were further incubated for at least 48 hours to allow 
production of virus particles. For cellular transduction, culture medium 
containing viral particles was collected from the transfected HEK 293T cells, 72 
hours post transfection. The monolayer of HEK 293T cells was replenished with 
fresh medium and incubated further for use later for a second cellular 
transduction process. The collected medium was centrifuged at 400 g for 3 
minutes and the resulting supernatant was filtered through a 0.22 µm filter to 
remove all traces of 293T cells and debris. Polybrene® (8µg/ml) was added to 
the filtered supernatant to enhance the efficiency of viral infection. Immediately 
prior to transduction, growth medium was removed from a 50-80% confluent 
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monolayer of breast cancer cells, ZR75.30 and was replaced with the above 
culture medium containing viral titre. The transduced cells were incubated for 24 
hours before repeating the transduction steps again with a second batch of viral 
particles. 24 hours post the second viral transduction, culture medium 
containing viral titre was removed and the cells were replenished with fresh 
complete growth medium and cultured further appropriately followed by 
determination of the knockdown efficiency using flow cytometry and western 
blot analysis. A knockdown efficiency greater than 50% was considered to be 
successful and if achieved, the cells were sorted by Fluorescence Activated Cell 
Sorting (FACS) using an anti-CD82 mAb (IA4) in order to separate and collect a 
negative population of cells expressing low levels of CD82. These cells were 
termed ZR75.30/shCD82. A control cell line termed ZR75.30/GFP composed of 
empty vector was also prepared in parallel to the CD82 knockdown cells. 
Several batches of cells were frozen down soon after cell sorting for later use. 
Cells in culture were routinely checked for the level of CD82 knockdown by flow 
cytometry and western blot analysis. If the knockdown efficiency was being lost 
during culture, these cells were either re-sorted by FACS for a clear CD82 
negative population or another batch of pre-frozen cells was recovered.   
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2.1.6 Generation of stable cell lines overexpressing CD82 
 
In order to generate stable cell lines overexpressing wild-type CD82, SKBR3 
cells were transfected with the pZeoSV-CD82 plasmid using FuGene® 6, as 
described in section 2.1.4. Stable transfectants of BT474 cells overexpressing 
wild-type CD82 were generated by using retroviral transduction. This was 
achieved by co-transfection of 293T packaging cells with a plasmid mixture 
consisting of the CD82-enconding pBabe-puro-CD82 retrovirus plasmid along 
with the gag/pol packaging plasmid and the VSV.G envelope plasmid using 
FuGene 6 according to the manufacturer’s protocol. 72h post transfection, 
culture medium containing the virus was harvested from the packaging cells as 
described in section 2.1.5 and various dilutions of the virus were used to infect 
parental BT474 cells overnight. The pZeoSV-CD82 and pBabe-puro-CD82 
plasmids respectively contained a zeocin-resistance gene and puromycin-
resistance gene important for selection. 24 hours post transfection, culture 
medium containing the transfection mixture (SKBR3 cells) or virus (BT474 cells) 
was removed and replaced with complete growth medium supplemented with 
either 100µg/ml zeocin or 1µg/ml puromycin, for antibiotic resistance selection. 
The selection medium was replenished every 3 days and the cells were 
trypsinised and re-seeded at least once a week in order to speed up selection. 
Following the antibiotic resistance selection period, antibiotic-resistant colonies 
were pooled together and sorted by FACS using an anti-CD82 mAb (IA4) for the 
separation and collection of a positive population of cells overexpressing CD82. 
These cells were termed BT474/CD82High and SKBR3/CD82High. Empty vector 
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pBabe-puro and pZeoSV transduction/transfection were also carried out to form 
neotransfected control cell lines, namely, BT474/Puro and SKBR3/Zeo, 
respectively. All stable cell lines were maintained in complete growth culture 
medium, supplemented with the appropriate antibiotic, as outlined in Appendix I. 
Several batches of cells were frozen down soon after cell sorting for later use. 
Cells in culture were routinely checked for the level of CD82 expression by flow 
cytometry and western blot analysis. If the level of CD82 overexpression was 
being lost during culture, then these cells were either re-sorted by FACS for a 
clear CD82-overexpresing population or another batch of pre-frozen cells was 
recovered. 
 
Plasmid Source 
pLVTHM  Addgene # 12247 
psPAX2 Addgene # 12260 
pMD2.G Addgene # 12259 
pLVTHM-shCD82wt Generated in-house 
pZeoSV Invitrogen # V85001 
pZeoSV-CD82wt Generated in-house 
pBabe-puro Addgene # 1764 
pBabe-puro-CD82wt Generated in-house 
Gag/pol Addgene # 14887 
VSV.G Addgene # 14888 
pcDNA3.1(+) Invitrogen # V790-20 
pcDNA3.1-CD82wt Generated in-house 
pcDNA3.1-ErbB2-GFP Kindly provided by Dr T. Wohland (Liu et al. 2007) 
pcDNA3.1-EGFR-GFP Kindly provided by Prof. W. J. Gullick (Kent, UK) 
pcDNA3.1-KSR1-HA Kindly provided by Dr M. A. White (Dallas, Texas) 
 
Table 2.3: Summary of all plasmids used in this study. 
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2.1.7 Preparation of cells for cell sorting 
 
24 hours prior to cell sorting, confluent monolayers of cells were detached using 
0.05% trypsin-EDTA, centrifuged at 400 g for 3 minutes and the cell pellet was 
resuspended in complete growth culture medium before the cells were re-
seeded on to a fresh culture vessel. The following day, the cells were detached 
using Cell Dissociation Solution, centrifuged as above at 4oC and the cell pellet 
was resuspended in ice-cold 1% BSA supplemented with primary monoclonal 
antibodies followed by incubation for 1 hour on ice to allow antibody binding. 
The cells were then pelleted at 400 g for 3 minutes at 4oC and the resulting cell 
pellet was washed 3 times with wash buffer (1% BSA/PBS) followed by re-
centrifugation as described above. After the last wash, the cells were incubated 
for 1h in the dark with anti-mouse secondary antibodies conjugated to a 
fluorophore either fluorescein isothiocyanate (FITC) or phycoerythrin (PE). 
Following 1 hour incubation on ice in the dark, the cells were centrifuged and 
washed as described above. After the last wash, the cell pellet was 
resuspended with ice-cold complete culture medium and then filtered through a 
50µm CellTrics® disposable filter to ensure a suspension of single cells. Stained 
cells were then sorted by FACS using a Beckman Coulter MoFlow high speed 
cell sorter as following: for CD82High cells, the most positive population of cells 
was selected; for shCD82 GFP-containing cells, a GFP positive, PE negative 
population of cells was selected and collected. The sorted population of cells 
was seeded onto a tissue culture vessel followed by incubation at 37oC, in a 5% 
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CO2 humidified atmosphere and henceforth maintained in appropriate growth 
medium as outlined in Appendix I. 
 
2.1.8 Cell proliferation and viability in 2D 
 
To measure cell viability, the cells were seeded onto 6-well plates in complete 
growth media in the absence of selection antibiotics and maintained at 37oC, 
5% CO2. 24h post seeding, Herceptin was added to the culture medium at the 
following concentrations: 10, 20, and 50µg/ml followed by further incubation for 
72h. Each experiment included non-treated control cells that were grown only in 
complete culture medium in the absence of Herceptin and were maintained 
under the same conditions as the test samples. At the end of the incubation 
period, growth culture medium containing non-viable cells was removed from 
each well and collected into 15ml centrifuge tubes. Each well of cell monolayer 
was rinsed twice with PBS followed by trypsinisation. All wash solution was 
collected along with the non-viable cells in order to minimise loss of cells. The 
trypsinised cell suspension was collected into previously collected culture 
medium and centrifuged at 400 g for 3 minutes at room temperature. The 
resulting cell pellet was resuspended in 1ml of PBS. Cell viability was 
determined by Trypan Blue® exclusion cell counts using a haemocytometer. 
One part of cells was mixed with one part of trypan blue. Cell counts were 
carried out within 3 minutes of mixing with the dye. Cells that were not stained 
with the blue dye of trypan blue were counted as viable cells and conversely, 
blue stained cells were counted separately as non-viable cells. The number of 
cells per 1ml aliquot was equivalent to the cell count within one area of 16 
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squares of the haemocytometer multiplied by 2x104, accounting for the dilution 
factor (1:2) of cells with trypan blue. Percentage viability was calculated as: 
(number of viable cells/ml aliquot divided by the total number of cells/ml aliquot) 
multiplied by 100. At least three independent experiments were performed. 
 
2.1.9 Cell proliferation and viability in 3D 
 
Cells in log phase were trypsinised and centrifuged at 400 g for 3 minutes at 
room temperature. The cells were rigorously resuspended in complete growth 
medium. For growth in collagen, the cell suspension was mixed 1:1 (v/v) with 
1.6mg/ml rat tail collagen type I. Three drops of this collagen-cell mix 
(~1.5x103cells/40µl drop) were allowed to polymerise at 37oC before culture 
medium was added over them. For Herceptin treatment, Herceptin (10µg/ml) 
was added to the growth medium 24h post seeding. The cells were incubated at 
37oC, in a 5% CO2 humidified atmosphere for 14 days to allow colony formation. 
Culture medium was changed every 3 days and supplemented accordingly with 
Herceptin.  
 
For growth in Matrigel™, the cells were mixed 1:1 with 2% Matrigel (v/v) and 
300µl of this mixture (~1.5x103cells/300µl) was overlaid on top of a polymerised 
layer of 100% Matrigel. The cells were incubated at 37oC, 5% CO2 for 14 days 
to allow colony formation. For Herceptin treatment, Herceptin at 10µg/ml was 
prepared in 2% Matrigel and added to the cells 24h post seeding. This was 
replenished every 3 days. Colonies were analysed using a Zeiss Axiovert 25 
microscope and NIS-Elements BR 3.0 laboratory imaging software.  
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2.1.10 Cell migration assay 
 
Cell migration assays were performed using modified Boyden chambers with 
Transwell® polycarbonate membrane filter inserts of 8µm pore size, in 24-well 
tissue culture plates. The outer membrane of the inserts was coated with 
collagen (17.5µg/ml) overnight at 4oC and washed with PBS before the cells 
were added. SKBR3/Zeo and SKBR3/CD82High cells were detached using Cell 
Dissociation Solution, pelleted at 400 g for 3 minutes at room temperature and 
resuspended to 1x105 cells in 400µl of serum-free DMEM. The pre-coated 
inserts were assembled matrix side down into 24-well plates before the cells 
were added to the inner chamber of the inserts. For haptotactic migration 
assays, cells migrated toward serum-free medium containing no 
chemoattractant. For chemohaptotactic migration assays, cells migrated either 
towards complete DMEM medium containing 10% fetal-calf serum (FBS) or 
serum-free DMEM supplemented with either heregulin (10ng/ml), heparin-
binding EGF-like growth factor (HB-EGF) (10ng/ml) or transforming growth 
factor-beta 1 (TGF-β1) (10ng/ml). For Herceptin treatment, cells were 
resuspended in serum-free DMEM containing Herceptin (10µg/ml) prior to being 
added to the Transwell inserts. After 6h incubation at 37oC, 5% CO2, cells that 
had not migrated through the filter were removed by swabbing using cotton 
buds and the inner chamber was washed twice with PBS. Cells that had 
migrated to the lower surface of the filter were fixed with 3% paraformaldehyde 
(PFA), permeabilised with 0.1% Triton X-100 followed by three washes with 
PBS. The nuclei of migrated cells on the outer side of the membrane inserts 
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were stained using Hoechst 33342. The membranes were removed from the 
inserts, mounted on to glass slides and analysed using a Nikon Eclipse E600 
fluorescence microscope. Images were taken from five random fields per 
membrane and scored using ImageJ nuclear/cell counter program. Each of the 
test conditions per experiment was done in duplicate and three independent 
experiments were carried out. For each cell line, two additional Transwells of 
cells were used as control for the number of seeded cells prior to the migration 
assay. The cells in these wells were fixed, permeabilised, stained and mounted 
as described above after 1h of seeding. Number of migrated cells = the number 
of nuclei counted per microscopic field, captured at x 20 magnification.   
 
2.1.11 Cell invasion assay 
 
Cell invasion was measured using modified Boyden chambers with Transwell® 
polycarbonate membrane filter inserts. Matrigel diluted 1:3 in serum-free DMEM 
was used to coat the outer membranes of the Transwell® inserts; these were 
then incubated for 40 minutes at 37oC in order for the Matrigel to polymerise 
before use. Cells resuspended in serum-free DMEM were added to the inner 
chambers at 1x105 cells in 400µl. The inserts were placed into 24-well plates 
containing serum-free DMEM supplemented with heregulin (10ng/ml) and 
incubated at 37oC for 24, 48 and 72h. Cells that invaded through to the outer 
membrane into Matrigel were processed as described in the migration assay 
(section 2.1.10). The data was expressed as number of invaded cells per 
microscopic field from five randomly selected fields per membrane. Each 
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condition was done in duplicate and at least two independent experiments were 
performed. 
 
2.1.12 Inhibitor treatments 
 
The MEK inhibitor, U0126 was prepared in dimethyl sulfoxide (DMSO) as a 
10mM stock solution, which was subsequently diluted to a working 
concentration of 10µM in culture medium prior to use. Serum-starved 
SKBR3/Zeo and SKBR3/CD82High cells were treated with U0126 (10µM) for 30 
minutes, 1h and 6h at 37oC, 5% CO2. DMSO diluted in culture medium to the 
same solvent concentration as in the inhibitor preparation was added to the 
inhibitor-free controls. At the end of each incubation period, the cells were lysed 
as described below in section 2.2.1 of the Materials and Methods. Lysates of 
equal protein concentration were subjected to SDS-PAGE under reducing 
conditions followed by western blot analysis to probe for phosphorylated and 
total proteins.  
 
2.2 Biochemical Methods  
 
2.2.1 Cell Lysis 
 
For western blotting experiments, monolayers of cells in log phase were rinsed 
twice with PBS. Cellular proteins were then solubilised in Laemmli sample 
buffer supplemented with protease and phosphatase inhibitors (2mM 
phenylmethylsulfonyl fluoride (PMSF), 10µg/ml aprotinin, 10µg/ml leupeptin, 
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5mM sodium fluoride (NaF), 100µM sodium orthovanadate (Na3VO4) and 10mM 
tetrasodium pyrophosphate (Na4P2O7)). The lysates were boiled at 94
oC for 10 
minutes and stored at -80oC until use. 
 
2.2.2 Protein concentration determination 
 
Protein concentration was determined in all samples using the Bio-Rad Dc 
protein assay kit according to the manufacturer’s protocol. Bovine serum 
albumin (BSA) was serially diluted in Laemmli buffer to generate a standard 
curve of a concentration range of 0.4 – 3.2mg/ml with each protein assay. The 
protein concentration was determined in all test samples using the BSA 
standard curve and corrected to the dilution factor of 4. 
 
2.2.3 SDS-PAGE and western blot analysis 
 
Cell lysates with equal amount of protein, along with pre-stained protein 
markers were resolved on either a 10% or 12% SDS-PAGE (Table 2.4) under 
reducing or non-reducing conditions; transferred onto nitrocellulose membrane 
and incubated with appropriate primary antibodies overnight at 4oC, unless 
otherwise stated. For reducing conditions, β-mercaptoethanol was added to the 
samples as a reducing agent at a concentration of 5% of the total sample 
volume, before the samples were loaded onto polyacrylamide gels. After three 
washes (20 minutes/wash) at room temperature, using either phosphate 
buffered saline with Tween-80 (PBS-T) or Tris buffered saline with Tween-80 
(TBS-T) wash buffer (Appendix III), the membranes were incubated with 
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species-specific horseradish peroxidase-conjugated secondary antibodies for 
1h at room temperature, followed by three washes as detailed above. The wash 
buffer was removed at the end of the third wash and the membranes were 
rinsed with distilled water to remove salt residues. Protein bands were 
visualised using Enhanced Chemiluminescence Plus (ECL Plus) reagent and 
detected onto Amersham Hyperfilm™ x-ray film. Protein bands were identified 
according to their molecular weights comparable to the approximate molecular 
weight ladder of pre-stained protein markers. All non-commercial and 
commercial antibodies used in this study are summarised in Table 2.5 and 
Table 2.6, respectively.  
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Table 2.4: Components of a single mini SDS-PAGE running gel. 
 
 
Antibody Target 
antigen 
Source Application 
IA4 CD82 Kindly provided by Dr H. 
Conjeaud (Paris, France) 
Immunofluorescence 
and cell sorting 
M104 CD82 Kindly provided by Dr O. 
Yoshi 
(Osaka, Japan) 
Flow cytometry and 
Immunoprecipitation 
TS82b CD82 Kindly provided by Dr E. 
Rubinstein (Villejuif, France) 
Western blot 
 
Table 2.5: Non-commercial hybridoma antibodies used in this study.  
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Antibody Name/Clone Target antigen Molecular 
weight (kDa) 
Source Supplier Catalogue 
number 
4C5G PI4K - Bovine LGC Standards CRL-2538 
Akt Akt 1/2/3 60 Rabbit Cell Signaling 
Technology 
9272 
Alexa Fluor
®
 488  
F(ab’)2 fragment 
IgG (H+L) - Rabbit Invitrogen A11070 
Anti-Phosphotyrosine 
(4G10) 
Tyrosine-
phosphorylated 
proteins 
- Mouse Millipore 05-321 
CD82/KAI1 (C-16) C-terminus of KAI1 46 Rabbit Santa Cruz sc-1087 
c-erbB2 (Ab-17) (Clone 
e2-4001 + 3B5) 
Cytoplasmic 
domain of ErbB2 
185 Mouse NeoMarkers MS-730 
c-erbB2 (Ab-2) (Clone 
9G6.10) 
Extracellular 
domain of ErbB2 
185 Mouse NeoMarkers MS-229 
c-erbB3 (C-17) ErbB3 185 Rabbit Santa Cruz 
Biotechnology 
sc-285 
EGFR (Ab-15) 
(Clone H9B4) 
Cytoplasmic 
domain of EGFR 
170 (wild 
type) 
145 
(vIII variant) 
Mouse NeoMarkers MS-665 
Flotillin-2 (C42A3) Flotillin-2 49, 58 Rabbit Cell Signaling 3436 
HA-probe (F-7) HA-epitope tag - Mouse Santa Cruz sc-7392 
HA-probe (Y-11) HA-epitope tag - Rabbit Santa Cruz sc-805 
KSR1 (H-70) KSR1 97 Rabbit Santa Cruz sc-25416 
MEK1/2 MEK1/2 45 Rabbit Cell Signaling 
Technology 
9122 
p38 MAPK p38α, -β or -γ 
MAPK 
43 Rabbit Cell Signaling 
Technology 
9212 
p44/42 MAPK 
(Erk1/2) 
p44/42 MAPK 42, 44 Rabbit Cell Signaling 
Technology 
9102 
Pan-Ras H/K/N-Ras 21 Mouse Cytoskeleton BK008 
Phospho-Akt pAkt (Ser473) 60 Rabbit Cell Signaling 
Technology 
9271 
Phospho-ErbB2 pErbB2 
(Tyr1221/1222) 
185 Rabbit Cell Signaling 
Technology 
2249 
Phospho-ErbB2 pErbB2 (Tyr877) 185 Rabbit Cell Signaling 
Technology 
2241 
Phospho-ErbB3 (21D3) pErbB3 (Tyr1289) 185 Rabbit Cell Signaling 
Technology 
4791 
Phospho-MEK1/2 pMEK(Ser217/221) 45 Rabbit Cell Signaling 
Technology 
9121 
Phospho-p38 MAPK Ph p38 MAPK 
(Thr180/Tyr182) 
43 Rabbit Cell Signaling 
Technology 
9211 
Phospho-p44/42 MAPK Ph p44/42 MAPK 
(Thr202/Tyr204) 
42, 44 Rabbit Cell Signaling 
Technology 
9101 
Phospho-SAPK/JNK pSAPK/JNK 
(Thr183/Tyr185) 
46 (pJNK1) 
54 (pJNK2/3) 
Rabbit Cell Signaling 
Technology 
9251 
Phospho-Src family pSrc (Tyr416) 60 Rabbit Cell Signaling 
Technology 
2101 
Polyclonal Goat anti-
mouse Igs/HRP 
Mouse IgG, IgA, 
IgM 
- Mouse Dako P0447 
Polyclonal Goat anti-
rabbit Igs/HRP 
Rabbit IgG, IgA, 
IgM 
- Rabbit Dako P0448 
SAPK/JNK SAPK/JNK 46 (JNK1) 
54 (JNK2/3) 
Rabbit Cell Signaling 
Technology 
9252 
Src (36D10) Src 60 Rabbit Cell Signaling 
Technology 
2109 
β-Actin (Clone AC-15) β-Actin 42 Mouse Sigma-Aldrich A5441 
Table 2.6: Commercial antibodies used in this study. 
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2.2.3.1 Quantitative and statistical analysis of western blot images 
 
Quantification of western blots was carried out using ImageJ software. Blots of 
the same x-ray exposure time were used during the analysis in order to 
measure the relative intensity of the bands (Figure 2.1). Statistical significance 
of analysed data sets from at least three independent experiments was 
determined with the one-way ANOVA multiple comparison analysis followed by 
the Tukey-Kramer post-test unless otherwise stated, using GraphPad Prism 
software (GraphPad software Inc.). Significance was set at P< 0.05; and a P 
value of less than 0.001 was considered to be highly significant. The degree of 
significance was represented as (*) = P< 0.05; (**) = P< 0.01; and (***) = P< 
0.001.  
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Figure 2.1: Illustrate of quantitative analysis of western blots. 
 
Diagram shows an example of how western blot data was quantitatively 
analysed using ImageJ imaging software (National Institutes of Health). The 
intensity of the bands with the same x-ray film exposure time was determined 
as follows: A box was drawn around the band of interest, taking into account the 
x-ray film background both above and below the band. The selected region was 
measured before moving the box onto the next band/lane. The same procedure 
was applied to all bands and once all lanes were measured, the selected fields 
were then plotted as graphs, with each enclosed peak corresponding to the 
intensity of the band from the background. Values of the area under the 
enclosed peaks were then plotted as bar charts. 
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2.3 Protein activity 
 
2.3.1 Analysis of cell signalling 
 
For cell signalling experiments cells were incubated under serum-free 
conditions for 24h. Where indicated, Herceptin (10µg/ml) was added to the 
culture medium and the cells were incubated for the indicated time intervals 
followed by lysis in Laemmli buffer as described above.   
 
2.3.2 Kit-based Ras activation assay 
 
2.3.2.1 Sample preparation 
 
SKBR3/Zeo and SKBR3/CD82High cells in log phase were serum-starved 
overnight prior to the Ras activation assay. The next day, the cells were treated 
with a Ras activator, heregulin (10ng/ml) for 30min at 37oC, 5% CO2. At the end 
of the incubation period, the cells were immediately placed on ice and the cell 
monolayer was rinsed twice with ice-cold PBS. Cells were scraped into ice-cold 
lysis buffer, supplemented with 1X protease inhibitor cocktail and immediately 
clarified by centrifugation at 5000 g; 4oC for 2min. 15µl of lysates was removed 
for protein quantitation. The remaining cell lysate was transferred into fresh 
sample tubes and immediately snap frozen in liquid nitrogen before storage at -
70oC for future use (see below). The protein concentration in the lysates was 
determined using Precision Red Advanced Protein Assay (PRAPA) reagent. 
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The following control reactions were also prepared alongside each Ras 
activation assay: His-Ras as a quantitation estimate for endogenous Ras; whole 
cell lysate, as loading controls; positive and negative controls of Ras activity. As 
a positive control for the pull-down assay of active Ras, the cell lysate was 
loaded with a non-hydrolysable GTP analogue (GTPγS) and incubated at 37oC 
for 30mins with gentle rotation, in order to activate Ras. The reaction was 
terminated using ice-cold stop buffer. The same reaction was carried out for the 
negative control, by incubating the cell lysate with GDP to inactivate Ras. The 
sample was then immediately used in the pull-down assay as detailed below in 
section 2.3.2.2. 
 
2.3.2.2 Active Ras pull-down assay 
 
A commercially available Ras activation assay kit was used to determine Ras 
activity via a pull-down method involving sepharose beads conjugated with the 
Ras Binding Domain (RBD) region of the Raf kinase (Raf-RBD beads) 
(Cytoskeleton, Denver, USA). For the pull-down assay, frozen lysates (from 
section 2.3.2.1) were thawed in a room temperature water bath and immediately 
placed on ice upon thawing. Lysates at 300µg protein concentration were 
added to Raf-RBD beads and incubated for 1h at 4oC, with rotation to allow 
binding. At the end of the binding reaction, the Raf-RBD beads were pelleted by 
centrifugation at 5000 g, 4oC for 1min followed by two washes using ice-cold 
wash buffer. The resultant bead pellet was resuspended with 2X Laemmli buffer 
containing 5% β-Mercaptoethanol followed by SDS-PAGE and western blot 
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analysis. Active Ras was detected using mouse anti-Pan Ras monoclonal 
antibodies. 
 
2.3.3 Immunoprecipitation 
 
Mouse monoclonal antibodies were allowed to bind to goat anti-mouse 
immunoglobulin G (mIgG)-coupled agarose beads by incubation overnight at 
4oC with rotation, prior to the start of the assay. Protein G agarose beads were 
used as above for binding antibodies raised in rabbit. The next day whilst 
working on ice, monolayers of cells were rinsed twice with ice-cold PBS and the 
proteins were solubilised in 1% Brij-98, 1% Triton X-100 or a mixture of Brij-
98/Triton X-100 (0.8%/0.2% v/v) lysis buffer supplemented with protease and 
phosphatase inhibitors as described in section 2.2.1 for 1-3h at 4oC with 
rotation. The insoluble material was pelleted at 12, 000 g for 10min and the 
solubilised lysate was precleared by incubation with non-coated agarose beads 
for 1h at 4oC with rotation. The precleared sample of equal protein 
concentration was added to pre-washed antibody-conjugated agarose beads 
and incubated on a rotor wheel at 4oC for overnight binding. The following day, 
the reaction beads were washed three times with wash buffer and the immune 
complexes were eluted using 1X Laemmli buffer at room temperature. As 
loading controls, whole cell lysates of equal protein concentration were 
prepared in 4X Laemmli buffer alongside the immunoprecipitation samples. 
Samples were resolved on 10-12% SDS-PAGE under reducing and non-
reducing conditions as described in section 2.2.3.   
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2.4 Cell Fractionation 
 
2.4.1 Lysate preparation 
 
Cells were scraped into PBS, centrifuged at 400 g for 3 minutes at 4oC followed 
by two washes of the resulting cell pellet with PBS. For lysis with detergent, the 
washed cell pellet was resuspended in ice-cold 1% Triton X-100, prepared in 
25mM MES buffer (2-(N-morpholino)ethanesulfonic acid) (pH 6.5) 
supplemented with 10µg/ml aprotinin, 10µg/ml leupeptin and 2mM PMSF. The 
suspension was transferred into fresh eppendorf tubes and placed onto a rotor 
wheel to lyse at 4oC for 30 minutes. For detergent-free mechanical lysis, the 
washed cell pellet was resuspended in ice-cold sodium carbonate buffer 
(100mM, pH 11.0) supplemented with 10µg/ml aprotinin, 10µg/ml leupeptin and 
2mM PMSF, followed by homogenisation using a Dounce homogeniser and 
subsequently by sonication. At the end of the lysis period, the sample was 
successfully passed through a 25G hypodermic needle twenty times, followed 
by centrifugation at 12, 000 g, 4oC for 1 minute to remove any air bubbles and 
cell debris. Protein content was measured and equilibrated on the solubilised 
protein lysate, as detailed in section 2.2.2. 
 
2.4.2 Fractionation in a sucrose gradient 
 
The resulting homogenate from section 2.4.1 was mixed with equal volume of 
90% (w/v) sucrose prepared in 25mM MES buffer supplemented with protease 
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and phosphatase inhibitors, and was overlaid with two volumes of 35% (w/v) 
sucrose, followed by one volume of 5% sucrose (w/v; both in MES). Samples 
were centrifuged at 100,000 g for 16 hours at 4oC in a Beckman SW60 rotor. 
The next day, 10 fractions of 400µl were collected from the meniscus of the 
gradient into labelled eppendorf tubes. The pellet was resuspended in 400µl of 
Laemmli buffer supplemented with protease inhibitors. Equal amounts of each 
fraction were mixed with 4x Laemmli loading buffer and the protein distribution 
was analysed by SDS-PAGE followed by Western blotting as described in 
section 2.2.3. 
 
2.5 Staining and imaging methods 
 
2.5.1 Flow cytometry 
 
Sub-confluent cell monolayers were detached using Cell Dissociation Solution, 
centrifuged at 400 g for 3 minutes and the cell pellet was thoroughly 
resuspended in ice-cold 1% HI-BSA to ensure a suspension of single cells. 
Prior to the addition of primary antibodies, the 96-well plate was incubated with 
1% HI-BSA for 20 minutes at 4oC in order to block non-specific binding to the 
wells. At the end of the 20min incubation, the blocking solution was decanted 
and 150µl of primary mouse monoclonal antibodies (diluted in 1% HI-BSA) or 
hybridoma supernatant was added to each well; to which 50µl of the cell 
suspension was subsequently added. Following a gentle mix, the plate was 
incubated on ice for 1 hour to allow binding. The cells were pelleted at 400 g for 
3 minutes at 4oC. The supernatant was decanted and the pellet was washed 
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three times with wash buffer (1% HI-BSA/PBS). At the end of the last wash, the 
cell pellet was resuspended with 150µl of anti-mouse FITC- or PE-conjugated 
secondary antibodies and incubated on ice for 1 hour in the dark. The plate was 
subsequently centrifuged and the cell pellet was washed three times as 
described above. After the last wash, the cell pellet was resuspended with 250µl 
of ice-cold PBS and transferred into FACS tubes containing 250µl of 2% 
paraformaldehyde (PFA). Stained cells were analysed using a Coulter Epics XL 
flow cytometer (Becton Dickinson). The data was analysed using Windows 
Multiple Document Interface (WinMDI) FACS analysis software version 2.9. 
 
2.5.2 Fluorescence recovery after photobleaching (FRAP) 
 
2.5.2.1 Sample preparation 
 
For FRAP experiments, SKBR3/Zeo and SKBR3/CD82High cells were 
transfected with either EGFR-GFP or ErbB2-GFP. Where indicated, Herceptin 
(10µg/ml) was added for 1h before FRAP. The cells were seeded on 4-well 
chambered Lab-Tek coverglass for 48h followed by transfection with the 
appropriate plasmid using GeneJammer® transfection reagent as described in 
section 2.1.4 and Table 2.2. Before the experiment, growth medium was 
replaced by phenol-red-free complete culture medium supplemented with 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer solution to a 
final concentration of 10mM.  
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2.5.2.2 FRAP assay and analysis 
 
Live-cell confocal imaging was performed using the Zeiss LSM510 META 
confocal microscope with a 63x/1.4 NA planapochromat oil objective at 37oC 
using a temperature-controlled microscope chamber. Two images of the 
selected cell were taken before GFP in a selected rectangular region of interest 
(ROI) was continuously bleached for using the 488nm laser line at 60% laser 
power. The intensity of the laser power was chosen to give >50% loss of 
fluorescence in the selected bleached region. Image acquisition was at low 
intensity laser power (488nm laser line at 7% laser power) so as not to affect 
the recovered fluorescence. Fluorescence recovery in the bleached region was 
recorded for ~550 sec (70 frames at 7 sec intervals). Only cells expressing 
moderate levels of GFP-tagged protein were selected for scanning. At least 12 
individual cells were bleached and imaged under the same conditions for each 
FRAP assay; independent experiments were repeated three times. All 
fluorescence intensities were corrected for background by subtracting the 
background intensity from the fluorescence intensity within the bleached region. 
These values were then normalised to the fluorescence intensity prior to the 
bleaching pulse. The mobile fraction (Mf) was calculated using the following 
equation Mf = (F∞ - F0) / (Fi - F0), whereby Fi is the initial fluorescence intensity 
prior to bleaching; F0 is the fluorescence intensity immediately after bleaching; 
and F∞ is fluorescence intensity at the point when recovery reaches a plateau. 
This equation was previously described by Axelrod and colleagues (Axelrod et 
al. 1976). 
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3 RESULTS AND DISCUSSION 
 
 
 
3.1 Ectopic expression of CD82 modulates the cellular response of breast 
cancer cells to Herceptin treatment 
 
3.1.1 Generation of breast cancer cell lines with different expression 
levels of CD82 
 
In order to investigate the role of CD82 in Herceptin-mediated cellular 
responses, we established cell lines with different expression levels of CD82 
from breast cancer cell lines BT474, SKBR3 and ZR75.30. These cell lines 
were chosen because they overexpress the ErbB2 receptor which is targeted by 
Herceptin and also for the fact that they are responsive to Herceptin treatment. 
Additionally, two of these cell lines (BT474 and SKBR3) have low levels of 
endogenous CD82 expression. ZR75.30 cells express moderate levels of 
endogenous CD82 and they were used to study the function of CD82 using a 
shRNA approach. Table 3.1 summarises the characteristics of these cell lines. 
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Table 3.1: Characteristics of the breast cancer cell lines used in this 
study. 
 
Comprehensive information of propagation medium and supplements for all 
these cell lines can be found in Appendix I. Abbreviations: AC - 
adenocarcinoma; ER - estrogen receptor; IDC - invasive ductal carcinoma; L - 
luminal subtype; PR - progesterone receptor; CRUK - Cancer Research UK. 
This table was adapted from Hoeflich et al. and Kao et al. (Hoeflich et al. 
2009;Kao et al. 2009). 
 
 
 
CD82-encoding plasmids were used to generate stable cell lines expressing 
wild-type CD82; SKBR3 parental cells were transfected with pZeoSV-CD82 
plasmids whilst retroviral transduction (using pBabe-puro-CD82 and packaging 
plasmids) was adapted for BT474 cells as outlined in sections 2.1.4 and 2.1.6 of 
the Materials and Methods. In the case of BT474 cells, retroviral transduction 
was used due to low transfection efficiency of this cell line when transfected 
with the pZeoSV-CD82 plasmid. The pBabe-puro-CD82 and pZeoSV-CD82 
plasmids carried a puromycin- or zeocin-resistance gene, respectively. The 
transduced/transfected cells were selected for antibiotic resistance by culturing 
in complete growth medium supplemented with either 1µg/ml puromycin 
(BT474) or 100µg/ml zeocin (SKBR3). Colonies of antibiotic resistant cells were 
pooled together and tested for the expression levels of CD82 by flow cytometry 
before cell sorting using the anti-CD82 mouse mAb, IA4 and anti-mouse FITC-
conjugated secondary antibodies. These cells were named BT474/CD82High and 
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SKBR3/CD82High. Control cell lines either transduced or transfected with empty 
vectors, pBabe puro and pZeoSV were also prepared in parallel to the CD82-
overexpressing cells; these control cells were named BT474/Puro and 
SKBR3/Zeo, respectively. The expression levels of CD82 in sorted cells were 
tested by western blot analysis as shown in Figure 3.1A. BT474/Puro and 
SKBR3/Zeo cells were found to express comparable low levels of endogenous 
CD82 (Figure 3.1A, lanes 1 and 3). In BT474/CD82High cells, the level of CD82 
was increased by almost 2-fold when compared to that of BT474/Puro cells 
(Figure 3.1A, compare lane 1 to 2). This increase in the levels of CD82 was 
further confirmed by flow cytometry as shown in Figure 3.1B. Isotype control 
traces are shown in black.  
 
The level of increase in CD82 expression was higher in the SKBR3 cells 
compared to that of BT474 cells. Western blot analysis and flow cytometry data 
demonstrates that CD82 was considerably increased in the SKBR3/CD82High 
cells compared to SKBR3/Zeo cells (Figures 3.1A, compare lanes 3 to 4; 3.1B, 
right panel). The flow cytometry graph shows a strong shift to the right in the 
CD82 peak for SKBR3/CD82High cells (pale blue peak) away from that of control 
cells (dark blue peak). This shift is indicative of at least a 9-fold increase in the 
surface expression of CD82 in SKBR3/CD82High cells compared to SKBR3/Zeo 
cells (Figure 3.1B, right panel).  
 
Additionally, this panel of generated cell lines was assessed in order to 
determine whether overexpression of CD82 affected the expression levels of 
ErbB2. As expected, these cell lines were found to overexpress the ErbB2 
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receptor protein, whereby the highest expression levels were observed in the 
SKBR3 cell lines than in the BT474 cell lines (Figure 3.1C, comparing lanes 3 & 
4 to lanes 1 & 2). Furthermore, these data show that CD82 overexpression 
does not affect the expression levels of ErbB2. The level of ErbB2 in the CD82-
overexpressing cells, BT474/CD82High and SKBR3/CD82High was comparable to 
that in their corresponding control cell lines, BT474/Puro and SKBR3/Zeo 
(Figure 3.1C). This was further confirmed by flow cytometry as shown in Figure 
3.1D.  
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Figure 3.1: Generation of stable CD82-overexpressing breast cancer cells. 
 
The expression levels of CD82 was analysed by western blotting and flow 
cytometry. (A) & (C) Cell lysates of equal protein concentration were resolved 
by either 12% SDS-PAGE under non-reducing conditions (CD82) or by 10% 
SDS-PAGE under reducing conditions (ErbB2) followed by western blotting. 
CD82 was detected using mouse anti-CD82 monoclonal antibody (mAb), 
TS82b; whilst ErbB2 was detected using mouse anti-ErbB2 mAb, Ab-17. β-Actin 
was used as a loading control and verification of equal protein concentration in 
all samples. (B) & (D) Cells were incubated on ice for 1h with either mouse anti-
CD82 (M104) mAb or mouse anti-ErbB2 (Ab-2) mAb. 4C5G monoclonal 
antibody against phosphatidylinositol 4-kinase was used as an isotype control 
(black peaks). Cell surface staining of CD82 (B) and ErbB2 (D) were detected 
by flow cytometry following incubation for 1h on ice with anti-mouse FITC-
conjugated secondary antibodies. Data analysis was carried out using WinMDI 
FACS analysis software (version 2.9). 
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In addition to CD82-overexpressing cells, a cell line was generated whereby the 
level of CD82 was stably depleted from ZR75.30 cells. In order to knockdown 
CD82, ZR75.30 parental cells were infected with lentiviral particles containing 
shRNA that specifically targets wild-type CD82 as detailed in the Materials and 
Methods. Following flow cytometry analysis to determine the transduction 
efficiency, the cells were sorted by FACS using an anti-CD82 mAb (IA4) 
whereby a negative population of cells expressing low levels of CD82 was 
collected. These cells were named ZR75.30/shCD82. Control cells 
(ZR75.30/GFP) were also prepared following infection of ZR75.30 parental cells 
with lentiviral particles expressing an empty vector. Analysis of the sorted cells 
by western blot and flow cytometry confirmed that knockdown of CD82 was 
successfully achieved as shown in Figure 3.2. Western blot analysis shows that 
the level of CD82 was decreased by at least 80% in ZR75.30/shCD82 cells 
compared to the control ZR75.30/GFP cells (Figure 3.2, left panel). This was 
confirmed further by flow cytometry; the graph of which, shows that the peak for 
CD82 shifted to the left in ZR75.30/shCD82 cells (green peak) away from that of 
ZR75/GFP cells (red peak) thus indicative of low surface levels of CD82 in the 
depleted cells (Figure 3.2, right panel). ZR75.30/shCD82 and ZR75.30/GFP 
cells were used later in the project to confirm some of the CD82-mediated 
effects and will therefore be discussed in great detail in the later chapters. 
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Figure 3.2: Generation of stable CD82-depleted breast cancer cells. 
 
Knockdown of CD82 was analysed by western blotting and flow cytometry. For 
western blot analysis, lysates were resolved by 12% SDS-PAGE under non-
reducing conditions followed by detection using anti-CD82 mAb, TS82b. Cell 
surface expression of CD82 was determined by flow cytometry using M104, 
mouse anti-CD82 mAb. Since the ZR75.30 cells were transfected with green 
fluorescence protein (GFP)-containing plasmids, anti-mouse phycoerythrin 
(PE)-conjugated secondary antibodies were used for surface staining detection 
by flow cytometry. Control cells (ZR75.30/GFP) were positive for both GFP and 
PE; whilst the CD82-depleted cells (ZR75.30/shCD82) were positive for GFP, 
but negative for PE. Plotted are data following gating for PE. 4C5G monoclonal 
antibody against phosphatidylinositol 4-kinase was used as an isotype control 
(black peak). 
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3.1.2 The cellular response of CD82-overexpressing breast cancer cells 
to Herceptin treatment when cultured as 2D monolayers 
 
As a starting point, the generated CD82-overexpressing cells (BT474/CD82High 
and SKBR3/CD82High) were assessed for their response to Herceptin treatment 
in comparison to control cells (BT474/Puro and SKBR3/Zeo). The cells were 
treated with increasing concentrations of Herceptin (10, 20 and 50µg/ml) for 
72h. Non-treated (Herceptin-free) cells were used as an additional control. At 
the end of the incubation period, the cells were harvested and counted using 
Trypan blue staining as outlined in the Materials and Methods section 2.1.8. 
The effect of Herceptin on cell viability was determined as percentage viable 
cells at each treatment condition relative to that of non-treated controls.  
 
The percentage of viable cells decreased in response to Herceptin in a 
concentration-dependent manner (Figure 3.3). Comparison of the response of 
CD82-overexpressing cells to that of control cells at each concentration of 
Herceptin revealed subtle differences between the cell line pairs. Specifically, 
Herceptin at 10µg/ml caused a 23% and 30% decrease in cell viability in 
BT474/CD82High and SKBR3/CD82High, respectively when compared to control 
cells, BT474/Puro (6%) and SKBR3/Zeo cells (17%); (Figure 3.3). Further 
analysis of this data from three independent experiments revealed no 
statistically significant difference between the cell line pairs in their response to 
Herceptin treatment at all concentrations (P>0.05) as determined by the one-
way ANOVA multiple comparison analysis with the Tukey-Kramer post-test, 
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using GraphPad Prism software, whereby statistical significance was set at 
P<0.05 (Figure 3.3). This suggests that ectopic expression of CD82 did not 
affect the response of SKBR3 and BT474 cells to Herceptin when cultured as 
2D monolayers on plastic. The response of control cells to Herceptin treatment 
is consistent with other reports, whereby a concentration-dependent decrease 
in cell viability was also observed in SKBR3 and BT474 cells following 
Herceptin treatment (Junttila et al. 2009;Pickl and Ries 2009;Tseng et al. 2006). 
As they were only minimal differences in cellular responses to increasing 
concentrations of Herceptin (i.e. viability decreased from ~75% at 10µg/ml to 
~65% at 50µg/ml), all subsequent experiments were carried out using 10µg/ml 
of the reagent. 
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Figure 3.3: The effect of Herceptin on cell viability. 
 
The indicated cell lines were seeded onto 6-well plates for a total of 96h. 
Herceptin was added to the culture medium at the indicated final concentrations 
24h after seeding followed by incubation for a further 72h at 37oC, 5% CO2. At 
the end of this incubation period, the cells were detached and counted using 
Trypan blue. Viable and non-viable cells were counted separately on the basis 
of trypan blue staining. Cell viability was determined as a ratio of non-stained 
viable cells from the total number of cells counted per 1ml aliquot, and 
compared to the non-treated (Herceptin-free) controls as a percentage. Error 
bars correspond to standard deviation. Statistical comparison between the cell 
line pairs at each concentration was performed with the one-way ANOVA 
multiple comparison analysis with the Tukey-Kramer post-test, using GraphPad 
Prism software, whereby statistical significance was set at P<0.05. Data shown 
is a summary of at least three independent experiments. Abbreviation: ns – not 
significant (P>0.05). 
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3.1.3 Ectopic expression of CD82 plays a role in the cellular response of 
ErbB2-positive breast cancer cells to Herceptin treatment when 
cultured in 3D extracellular matrix substrata 
 
3.1.3.1 The effect of CD82 on cell growth in 3D collagen and its 
contribution to the cellular response to Herceptin treatment 
 
Tumour growth is promoted by interplay between tumour cells and the 
surrounding microenvironment. Components of the tumour microenvironment 
include stromal cells and a protein-rich extracellular matrix (ECM). Cancer cells 
are routinely grown in vitro in 3D extracellular matrix substrata such as collagen 
and Matrigel in order to recapitulate the in vivo architecture and physiological 
functions of tumour cells (Weigelt and Bissell 2008). In this regard, the effect of 
CD82 expression on the cellular response to Herceptin treatment was 
investigated in cells cultured in 3D ECM substrata. SKBR3 and BT474 cells 
expressing different levels of CD82 were seeded as single cell suspension 
embedded in collagen and were cultured for 14 days in complete medium to 
allow formation of colonies. Herceptin (10µg/ml) was added to the culture 
medium 24h post seeding. Growth medium was replenished every 3 days and 
was appropriately supplemented with Herceptin. Non-treated (Herceptin-free) 
cells were used as controls. Each condition was prepared in duplicate. 40 
images were captured at high magnification (using a x20 objective for SKBR3; 
and a x32 objective for BT474 cells) using a Zeiss Axiovert 25 microscope, from 
which the size and surface area of at least 90 colonies were analysed using the 
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NIS-Elements BR 3.0 laboratory imaging software; further data analysis was 
carried out using GraphPad Prism software.  
 
Figure 3.4A shows that SKBR3 cells grown in collagen formed variably sized 
spherical colonies with smooth edges. SKBR3/CD82High cells formed colonies of 
significantly smaller size (P<0.01) when compared to SKBR3/Zeo cells (Figure 
3.4A, top panel). The colony size was reduced by 29% in the CD82-
overexpressing cells indicating a profound effect of CD82 on cell proliferation 
(Figure 3.4B, compare the solid-filled dark blue bar with the chequered light 
blue bar). BT474 cells grown in collagen formed smaller colonies than SKBR3 
cells with slightly irregular edges (Compare Figure 3.4C with 3.4A). Importantly, 
similar to SKBR3 cells, elevated expression of CD82 in BT474 cells resulted in 
a 19% reduction in colony size (Figure 3.4D, compare the chequered bar to the 
solid-filled bar). 
 
As expected, Herceptin treatment resulted in a decrease in cell proliferation 
reflected by a highly significant (P<0.001) reduction in colony size in control 
cells. Specifically, in SKBR3/Zeo and BT474/Puro cells, incubation with 
Herceptin caused a 58% and 41% reduction in colony size, respectively 
(Figures 3.4B and 3.4D, compare the solid-filled bar to the bar with vertical 
lines, respectively). Surprisingly, the cytostatic effect of Herceptin was less 
pronounced in the CD82-overexpressing cells: treatment with Herceptin 
resulted in a 26% and 16% reduction in colony size in SKBR3/CD82High and 
BT474/CD82High cells, respectively when compared to non-treated cells (Figures 
3.4B and 3.4D, compare bars with horizontal lines to the chequered bars). The 
  Results and Discussion 
 
107 
 
fact that the Herceptin-induced cytostatic effect was less pronounced in the 
CD82-overexpressing cells suggests a probable CD82-mediated resistance 
mechanism to Herceptin, which at this stage seems to be dependent on the 
ECM substrata. This notion was investigated further by carrying out similar 
experiments using 3D Matrigel ECM substrata as described in the subsequent 
section. 
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Figure 3.4: Ectopic expression of CD82 inhibits cell growth and 
contributes to the cellular response to Herceptin in 3D collagen. 
 
SKBR3 and BT474 cells were embedded in rat tail collagen type I as described 
in the Materials and Methods section 2.1.9; and were cultured for 14 days in the 
presence or absence of Herceptin. Images of the formed colonies were 
captured using a Zeiss Axiovert 25 microscope with a x 20 objective (A) for 
SKBR3 cells; and a x 32 objective (C) for the BT474 cells (bar = 200µm). 
Morphological analysis was performed with the NIH-Elements BR 3.0 laboratory 
imaging software. 40 images were captured at each condition and the surface 
area of at least 90 colonies from the captured images was measured. The mean 
area relative to that of non-treated (Herceptin-free) control cells was plotted as 
percentage from at least three independent experiments (B & D). Error bars 
correspond to standard deviation. Asterisks represent the statistical significance 
as determined by the one-way ANOVA multiple comparison analysis with the 
Tukey-Kramer post-test, using GraphPad Prism software, whereby statistical 
significance was set at P<0.05; (** P<0.01) and (*** P<0.001) were considered 
highly significant. Abbreviations: HC – Herceptin; ns – not significant. 
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3.1.3.2 The effect of CD82 expression on cell growth and the cellular 
response to Herceptin of cells cultured in 3D Matrigel 
 
In addition to the 3D collagen studies, the contribution of CD82 on cell growth 
and the cellular response to Herceptin were investigated in cells cultured in 3D 
Matrigel ECM substrata. Matrigel is derived from the Engelbreth-Holm-Swarm 
murine tumour and it is rich in laminin-111, type IV collagen, enactin and 
proteoglycan. Thus composition of Matrigel resembles that of the basement 
membrane and therefore can be used in vitro to simulate the in vivo behaviour 
of tumour cells (Hughes et al. 2010;Kleinman and Martin 2005;Weigelt and 
Bissell 2008). In our experiments, both pairs of SKBR3 and BT474 cells were 
seeded in 3D Matrigel as described in the Materials and Methods (section 2.1.9) 
and were cultured for 14 days in the presence and absence of Herceptin. Cell 
proliferation was determined by measuring the perimeter of at least 90 formed 
colonies, from which surface area was analysed.  
 
Results from these experiments revealed that SKBR3 and BT474 cells grown in 
3D Matrigel formed colonies of different morphology: grape-like for the former 
and compact round-shaped for the latter (Figures 3.5A and 3.5C). Notably, 
colonies formed by BT474 cells grown in Matrigel were bigger in size (by 
appearance) than colonies formed in collagen (Compare Figure 3.4C and 
Figure 3.5C). The pattern of growth in Matrigel due to the ectopic expression of 
CD82 and the response to Herceptin of both control and CD82-overexpressing 
SKBR3 and BT474 cells was comparable to that observed in collagen. Firstly, 
  Results and Discussion 
 
112 
 
the expression of CD82 caused a significant reduction in colony size; 30% 
reduction in SKBR3 and 20% in BT474 cells when compared to controls (Figure 
3.5B and Figure 3.5D; compare the chequered bars to the solid-filled bars). 
Secondly, treatment with Herceptin caused a highly significant (P<0.001) 
reduction in colony size in the control cell lines: 54% and 52% in SKBR3/Zeo 
and BT474/Puro, respectively compared to non-treated cells (Figures 3.5B and 
3.5D; compare the bars of vertical lines to the solid-filled bars). Similar to data 
for collagen, CD82-overexpressing cells displayed a poor response to Herceptin 
treatment when compared to non-treated cells: 14% and 13% in 
SKBR3/CD82High and BT474/CD82High, respectively (Figures 3.5B and 3.5D; 
compare the bars of horizontal lines to the chequered bars). Collectively, these 
data from experiments in 3D collagen and Matrigel show a poor response of 
CD82-overexpressing cells to Herceptin when compared to control cells, thus 
suggesting that CD82 expression status might play a role in predicting response 
to Herceptin. 
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Figure 3.5: The effect of CD82 expression on cell growth in 3D Matrigel 
and its contribution to the cellular response to Herceptin. 
 
Vector control and CD82-overexpressing SKBR3 and BT474 cells were 
embedded in Matrigel as described in the Materials and Methods under section 
2.1.9. The cells were cultured for 14 days in the presence and absence of 
Herceptin. Images of the formed colonies were captured using a Zeiss Axiovert 
25 microscope with a x 20 objective (A) for SKBR3 cells; and a x 32 objective 
(C) for the BT474 cells (bar = 200µm). Morphological analysis was performed 
with the NIH-Elements BR 3.0 laboratory imaging software. 40 images were 
captured at each condition and the surface area of at least 90 colonies from the 
captured images was measured. The mean area relative to that of non-treated 
(Herceptin-free) control cells was plotted as percentage from at least three 
independent experiments (B & D). Error bars correspond to standard deviation. 
Asterisks represent the statistical significance as determined by one-way 
ANOVA multiple comparison analysis with the Tukey-Kramer post-test, using 
GraphPad Prism software, whereby statistical significance was set at P<0.05; 
(** P<0.01) and (*** P<0.001) were considered highly significant. Abbreviations: 
HC – Herceptin; ns – not significant. 
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3.1.4 CD82 suppresses the migration of SKBR3 cells towards various 
attractants 
 
CD82 is known to suppress cell migration and invasion of cancer cells (Bari et 
al. 2009;Jee et al. 2007;Zhou et al. 2004). Herein, cell migration assays were 
performed in order to investigate CD82- and Herceptin-mediated effects on the 
migration of SKBR3 breast cancer cells. These experiments were performed 
using a modified Boyden Chamber protocol as described in section 2.1.10 of 
the Materials and Methods. The cells were left to migrate towards heregulin 
(HrG) for 6h. Heregulin is a ligand for ErbB3 and ErbB4 and is known to 
regulate migration. Figure 3.6A demonstrates that the number of cells seeded at 
the start of the migration assay was comparable for both cell lines used in the 
assay. Consistent with other studies, ectopic expression of CD82 in 
SKBR3/CD82High cells significantly inhibited cell migration (P<0.001) when 
compared to control SKBR3/Zeo cells (Figure 3.6B, top panel; and Figure 3.6C, 
compare the solid-filled dark blue bar with the chequered light blue bar). These 
data show that CD82 inhibited cell migration towards heregulin by at least 50% 
in the SKBR3/CD82High cells compared to control cells (Figure 3.6C, compare 
the solid-filled dark blue bar with the chequered light blue bar).  
 
Next, we investigated whether Herceptin treatment affected cell migration; and if 
it does, whether CD82 modulated the Herceptin-mediated effect on cell 
migration. In the assay described above, the cells were left to migrate towards 
heregulin (10ng/ml) in the presence or absence of Herceptin (10µg/ml) (Figure 
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3.6B, bottom panel). By considering the SKBR3/Zeo cells first, it is clear that 
treatment with Herceptin resulted in a highly significant inhibition of cell 
migration (P<0.001) towards heregulin when compared to non-treated cells. 
Migration was reduced by at least 50% in the Herceptin-treated SKBR3/Zeo 
cells compared to non-treated cells (Figure 3.6C; compare the solid-filled dark 
blue bar with the dark blue bar of vertical lines). In contrast, the anti-migratory 
effect of Herceptin was less pronounced in the CD82-overexpressing cells when 
compared to non-treated cells. The number of migrated cells towards heregulin 
was comparable in both non-treated and Herceptin-treated SKBR3/CD82High 
cells (Figure 3.6C; compare the light blue bar of horizontal lines with the light 
blue chequered bar). The fact that SKBR3/Zeo cells were responsive to the 
anti-migratory effect of Herceptin suggests that heregulin-induced migration of 
SKBR3/Zeo cells is in part, ErbB2-dependent. However, overexpression of 
CD82 interrupts this mechanism of migration, abrogating the anti-migratory 
effect of Herceptin and thus rendering the SKBR3/CD82High cells less 
responsive to Herceptin. 
 
To test the specificity of the CD82-mediated effect on the migration of SKBR3 
cells, haptotactic and chemohaptotactic migration assays were carried out using 
either complete media containing 10% FBS; serum-free media containing no 
attractant; or serum-free media supplemented with either HB-EGF (10ng/ml) or 
TGF-β1 (10ng/ml) as chemoattractants. Migration towards heregulin (HrG) was 
used as a control. These growth factors were chosen because they are reported 
to regulate migration in many cell types (Kim et al. 2011a;Kim et al. 2011b;Lin et 
al. 2011) and also for the diversity of the growth factor receptors they bind to: 
  Results and Discussion 
 
118 
 
HB-EGF is a ligand for both EGFR and ErbB4; TGF-β1 is a multifunctional 
peptide of the transforming growth factor beta superfamily and signals via TGF-
β1 type I and type II cell surface receptor (Massague 2008).  
 
As shown in Figure 3.6D, the chemohaptotactic migration of SKBR3/CD82High 
cells to both HB-EGF and TGF-β1 was remarkably reduced compared with that 
of SKBR3/Zeo cells. The migratory potential of SKBR3/Zeo cells towards these 
growth factors was approximately two-fold higher when compared to that of 
CD82-overexpressing cells (SKBR3/CD82High). Notably, migration towards HB-
EGF in SKBR3/Zeo cells was considerably higher than towards TGF-β1 and 
HrG. However, SKBR3/CD82High cells migrated similarly under all three growth 
conditions (Figure 3.6D). Surprisingly however, migration of SKBR3/CD82High 
cells in the presence of complete medium containing 10% FBS was increased 
by at least 16% compared with that of SKBR3/Zeo cells (Figure 3.6D). These 
results demonstrate that the initial observation of the CD82-mediated inhibition 
of cell migration was not limited to heregulin-induced migration, but that it can 
also be observed with other growth factors including the highly potent 
chemoattractant, HB-EGF. Furthermore, these data highlight the diversity of the 
anti-migratory effect of CD82 suggesting that CD82 exerts this effect by not only 
regulating ErbB2, but also other growth factor receptors, although the 
observation with fetal-calf serum suggests presence of alternative pro-migratory 
factors. At this stage however, we were not able to identify this molecule(s) or 
its corresponding receptor(s). 
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Figure 3.6: Ectopic expression of CD82 and Herceptin treatment suppress 
the migratory potential of SKBR3 cells. 
 
SKBR3/Zeo and SKBR3/CD82High cells were prepared for migration as 
described under section 2.1.10 of the Materials and Methods. (A) In parallel to 
the migration experiments, some cells were prepared on membrane filters as 
representative of the total number of cells plated for the migration assay. These 
cells were left to adhere for 1h post seeding, then stained with Hoechst 33342 
and mounted onto glass slides. (B and C) For cell migration experiments, the 
cells were left to migrate for 6h at 37oC, 5% CO2 towards heregulin (10ng/ml), in 
the presence or absence of Herceptin (10µg/ml). Images were captured with a 
x20 objective using a Nikon Eclipse E600 fluorescence microscope. Migration 
was quantified by counting the number of nuclei from five randomly selected 
fields per membrane. Each test condition was done in duplicate per experiment 
and three independent experiments were carried out. Images were scored using 
ImageJ nuclear/cell counter program. (D) For haptotactic migration assays, cells 
migrated toward serum-free medium containing no chemoattractant. For 
chemohaptotactic migration assays, cells migrated either towards complete 
DMEM medium containing 10% fetal-calf serum (FBS) or serum-free DMEM 
supplemented with either heregulin (HrG), heparin-binding EGF-like growth 
factor (HB-EGF) or transforming growth factor-beta 1 (TGF-β1). All growth 
factors were at a final concentration of 10ng/ml. Number of migrated cells = the 
number of nuclei counted per microscopic field, captured with a x20 objective. 
Statistical significance was determined by the one-way ANOVA multiple 
comparison test with the Tukey-Kramer post-test, using GraphPad Prism 
software, whereby significance was set at 0.05; (*** P<0.001). 
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3.1.4.1 CD82 expression inhibits the invasion of SKBR3 cells towards 
heregulin  
 
In addition to the migration assays, the effect of CD82 expression on the 
invasiveness of SKBR3 cells was also investigated. In a pilot experiment using 
control cells (SKBR3/Zeo), the migratory potential of SKBR3 cells over an 
increasing time interval was examined in order to determine the optimal time 
point for the basis of the invasion assays. These assays were performed as 
detailed in section 2.1.11 of the Material and Methods. After incubation for 24, 
48 and 72h, cells invaded into the Matrigel were fixed, stained and counted. 
Figure 3.7A shows that cells invaded into the Matrigel were readily detected 
after 24h incubation, and that the number of invaded cells increased gradually 
with time. Since the highest number of invaded cells was detected at 72h in the 
pilot experiment, this then was the time point used in subsequent invasion 
assays involving both SKBR3/Zeo and SKBR3/CD82High cells. As expected, 
ectopic expression of CD82 in SKBR3 cells reduced the invasiveness of these 
cells by almost 50% (Figures 3.7B and C). Although the invasion assays 
described here were performed in the absence of Herceptin, it would have been 
interesting to determine whether Herceptin had an effect on cell invasion, in 
particular in the CD82-overexpressing cells. Taken together, these data 
demonstrate an anti-migratory effect of Herceptin and a potent inhibitory effect 
of CD82 on both cell migration and invasion.  
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Figure 3.7: CD82 suppresses the invasive potential of SKBR3 cells 
towards heregulin. 
 
Invasion assays were performed using modified Boyden chambers with 
polycarbonate membrane filter inserts coated with Matrigel as detailed in 
section 2.1.11 of the Materials and Methods. (A) Cells were left to invade into 
the Matrigel using heregulin (10ng/ml) as chemoattractant at 37oC, 5% CO2 for 
24, 48, and 72h. Invaded cells were stained with Hoechst 33342, mounted onto 
glass slides and counted. (B & C) Matrigel invasion of SKBR3 cells after 72h 
incubation. Images were captured with a x20 objective using a Nikon Eclipse 
E600 fluorescence microscope. Invasion was quantified by counting the number 
of nuclei from five randomly selected fields per membrane. Each test condition 
was done in duplicate per experiment and at least two independent experiments 
were carried out. Images were scored using ImageJ nuclear/cell counter 
program. Number of invaded cells = the number of nuclei counted per 
microscopic field, captured with a x20 objective. Data shown as mean ± 
standard deviation. Asterisk represents the statistical significance as 
determined by a two-tailed, unpaired Student’s t test using GraphPad Prism 
software. Significance was set at 0.05, whereby (*P<0.05). 
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3.1.5 Discussion  
 
Although Herceptin is currently approved for the treatment of ErbB2-
overexpressing metastatic breast cancer, resistance to this drug is a common 
problem. In addition, several clinical studies demonstrating the activity of 
Herceptin as monotherapy for this patient group reported low overall (complete 
and partial) response rates ranging between 12% and 26% (Baselga et al. 
1996;Cobleigh et al. 1999;Vogel et al. 2002), indicative that almost two thirds of 
patients with ErbB2-overexpressing metastatic breast cancer do not respond to 
Herceptin. The mechanisms by which Herceptin exerts its effects, as well as 
mechanisms of resistance have been the subject of many studies (Austin et al. 
2004;Nahta and Esteva 2007;Pegram et al. 1999;Pickl and Ries 2009;Tseng et 
al. 2006;Valabrega et al. 2007;Yeon and Pegram 2005). Here, we provide 
evidence to suggest that tetraspanin CD82 modulates the response of ErbB2-
positive breast cancer cell lines to Herceptin. We generated CD82-
overexpressing breast cancer cells as a model system to investigate the role of 
CD82 in the responsiveness of SKBR3 and BT474 cells to Herceptin treatment 
in several assays including viability, proliferation, migration and invasion. The 
efficacy of Herceptin has been demonstrated in vitro in various ErbB2-positive 
breast cancer cell lines, including SKBR3 and BT474 cells (Ginestier et al. 
2007;Junttila et al. 2009;Tseng et al. 2006;Weigelt et al. 2010). Here, our data 
demonstrate for the first time that ectopic expression of tetraspanin CD82 
negatively modulates the response of SKBR3 and BT474 breast cancer cells to 
Herceptin.  
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There is conflicting data regarding the response of breast cancer cells to 
Herceptin under different culture conditions. For example, a report by Pickl and 
Ries demonstrated that breast cancer cells including SKBR3 when cultured in 
3D extracellular matrix substrata, responded better to the antiproliferative effect 
of Herceptin than in 2D cultures (Pickl and Ries 2009). However, in a separate 
study by Weiglet and colleagues, SKBR3 cells were found to be resistant to the 
anti-proliferative effect of Herceptin when cultured as 3D colonies though they 
were responsive as 2D monolayers (Weigelt et al. 2010). Herein, we found that 
the response of control cells (SKBR3/Zeo and BT474/Puro) to Herceptin 
treatment was in agreement to previously published reports (Junttila et al. 
2009;Pickl and Ries 2009;Tseng et al. 2006), whereby cells cultured in 3D ECM 
substrata responded better to Herceptin treatment than as 2D monolayers. In 
addition, we observed that ectopic expression of CD82 resulted in a poor 
response to Herceptin, particularly in cells cultured in 3D ECM as discussed 
below.  
 
The use of 3D culture models in vitro is of physiological relevance, as it enables 
emulation of in vivo cellular structure and function of cancer cells. Such model 
systems therefore provide rationale to study not only drug response, but also 
investigation of potential drug targets and elucidation of their molecular 
mechanisms of action (Schmeichel and Bissell 2003). In this regard, we 
examined the effect of CD82 expression on proliferation of SKBR3 and BT474 
cells grown in 3D extracellular matrix substrata. We found that when the cells 
were grown in collagen and Matrigel extracellular matrices, ectopic expression 
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of CD82 resulted in suppression of cell proliferation, as reflected by a decrease 
in colony size of CD82-overexpressing cells when compared to control cells. 
These data are indicative of the antiproliferative metastasis suppressive 
characteristic of CD82. Indeed, these data are in agreement with previously 
published reports demonstrating the antiproliferative effect of CD82 in other 
cancer cell lines (Bandyopadhyay et al. 2006;Choi et al. 2009;Joshi et al. 
2010;Ruseva et al. 2009). Although CD82 is characterised as a metastasis 
suppressor protein, the mechanisms by which it exerts its metastasis 
suppressive function remain to be fully elucidated (Jackson et al. 2005;Miranti 
2009;Tonoli and Barrett 2005). Nonetheless, several mechanisms have been 
proposed in an effort to understand how CD82 suppresses cell proliferation. For 
example, a study by Bandyopadhyay and colleagues identified Duffy antigen 
receptor for chemokines (DARC), an endothelial cell surface protein as an 
interacting partner for CD82. The authors demonstrated that CD82-expressing 
cancer cells attached to vascular endothelial cells via a CD82-DARC-mediated 
interaction thus leading to inhibition of tumour cell proliferation and induction of 
cellular senescence (Bandyopadhyay et al. 2006). Elsewhere, CD82 was 
reported to downregulate Rac1 and cell proliferation by inhibiting the 
PI3K/Akt/mTOR signalling pathway (Choi et al. 2009).  
 
In addition to studying the effect of CD82 on cell proliferation in 3D ECM culture 
models, we also investigated the effect of CD82 expression on cellular 
response to Herceptin treatment under these culture conditions. When the cells 
were grown in 3D collagen and Matrigel, we found that CD82-overexpressing 
cells displayed a weaker response to Herceptin than control cells; this was 
  Results and Discussion 
 
128 
 
consistently observed in both SKBR3 and BT474 cells. However, this CD82-
mediated effect on Herceptin response was more prominent in BT474 than 
SKBR3 cells. The fact that control cells displayed a stronger response to 
Herceptin than CD82-overexpressing cells indicates that under these culture 
conditions, control cells rely mainly on ErbB2 in order to proliferate and form 
colonies, which was significantly inhibited by Herceptin treatment. On the other 
hand, the expression of CD82 adds a level of complexity to this ErbB2 
dependency thus rendering the cells less responsive to Herceptin treatment. 
 
Although these data do not currently offer explanations into the mechanism by 
which CD82 disrupts this ErbB2-dependent proliferation, it is reasonable to 
speculate based on the current data and previously published reports. One 
possible mechanism by which CD82 might modulate the cellular response to 
Herceptin under 3D cultures is by affecting the compartmentalisation of ErbB2. 
It has been previously reported that ectopic expression of CD82 caused re-
distribution of EGFR into ganglioside-containing microdomains on the plasma 
membrane (Odintsova et al. 2003). One of the main characteristics of 
tetraspanins is their ability to interact with one another as well as with other 
proteins thereby forming tetraspanin-enriched microdomains (TERMs), which 
are structural platforms that can modulate the activity of component molecules 
(Hemler 2005;Odintsova et al. 2006;Yanez-Mo et al. 2009). It is feasible that 
under different 3D culture conditions, membrane microdomains such as TERMs 
constituting CD82 and its binding partners are formed thus allowing differential 
clustering of CD82-associated proteins, which can lead to activation of different 
signalling pathways such as integrin and growth factor signalling. It has been 
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previously reported that growth of cells under 3D conditions whereby cells are in 
contact with the extracellular matrix induces interdependency and cross-talk 
between growth factor receptor and β1 integrin signalling (Bissell et al. 1999;Liu 
et al. 2004a;Wang et al. 1998;Weaver et al. 1997). Indeed, more recent studies 
have demonstrated that addition of growth factor receptor and β1 integrin 
inhibitory agents to breast cancer cells results in a concomitant downregulation 
of both receptors thus leading to growth arrest (Park et al. 2006;Weigelt et al. 
2010). CD82 is widely known to interact with β1 integrins including α3β1, α4β1, 
α5β1 and α6β1 (Berditchevski 2001). It is therefore possible that in CD82-
overexpressing cells, CD82 induces clustering of ErbB2 and β1 thereby 
promoting cross-talk downstream of these receptors. The consequence of this 
could be that inhibition of ErbB2 signalling by Herceptin could lead to 
compensatory mechanisms in the form of β1 signalling thus rendering CD82-
overexpressing cells less responsive to Herceptin. Interestingly, we found that 
BT474 cells express higher levels of α3, α6 and β1 integrins compared to 
SKBR3 cells; however, ectopic expression of CD82 did not affect the 
endogenous expression levels of these integrins (Appendix IV – supplementary 
Figure 1). The fact that BT474 cells express higher integrin levels than SKBR3 
cells could explain why the CD82-mediated poor response to Herceptin under 
3D culture conditions was more prominent in BT474 than in SKBR3 CD82-
overexpressing cells. 
 
Another possible mechanism by which CD82 modulates the cellular response to 
Herceptin could be that overexpression of CD82 results in hindrance of 
Herceptin from accessing its epitope on ErbB2. Being that tetraspanins are 
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small transmembrane molecules and that Herceptin binds to domain IV of the 
ErbB2 extracellular domain which is also near the plasma membrane, it is 
feasible that in control cells (SKBR3/Zeo and BT474/Puro) whereby the 
expression levels of CD82 are low, that Herceptin binds readily or indeed more 
efficiently to the ErbB2 receptors whilst its binding capacity is limited in the 
CD82-overexpressing cells. Indeed, it is reported in the literature that epitope 
inaccessibility is one of the mechanisms of resistance to Herceptin (Valabrega 
et al. 2007). As mentioned earlier, a study by Nagy and colleagues 
demonstrated that the binding capacity of Herceptin to ErbB2 was low in a 
Herceptin-resistant breast cancer cell line. These authors found that the 
Herceptin-resistant cell lines expressed high levels of MUC4, a membrane-
associated mucin known to mask membrane proteins when compared to the 
sensitive cell lines. Furthermore, they demonstrated that knockdown of MUC4 
restored the binding capacity of Herceptin (Nagy et al. 2005). It is thus possible 
that like MUC4, that CD82 could be masking the Herceptin epitope on ErbB2 in 
our model system of CD82-overexpressing cells thus rendering these cells less 
responsive to Herceptin treatment. 
 
One of the hallmarks of cancer is to acquire the capability to invade 
neighbouring tissue and form metastases at a distant tissue site (Hanahan and 
Weinberg 2011). In order to form distant metastases, tumour cells must invade 
the microenvironment, leave the primary tumour and migrate to a secondary 
site (Leber and Efferth 2009). Cell motility is therefore important during invasion 
and metastasis. As CD82 has been shown to be a metastasis suppressor 
(Dong et al. 1995;Jackson et al. 2005;Liu and Zhang 2006), it has also been 
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shown to inhibit cell migration and the invasiveness of many cancer cell lines 
(Bari et al. 2009;Jee et al. 2007;Todeschini et al. 2007;Yang et al. 2001;Zhang 
et al. 2003a). Herein, our data from experiments with SKBR3 cells are 
consistent with previously reported observations and demonstrate the CD82-
mediated suppression of cell migration and invasion using collagen and Matrigel 
extracellular matrices, respectively. We observed that overexpression of CD82 
resulted in a significant reduction (P<0.001) in the migratory potential of 
SKBR3/CD82High cells, when compared to that of SKBR3/Zeo cells. 
 
Furthermore, in an effort to determine whether Herceptin treatment affected cell 
migration and also whether ectopic expression of CD82 played a role in any 
Herceptin-mediated inhibition of cell migration, SKBR3/Zeo and 
SKBR3/CD82High cells were left to migrate in the presence and absence of 
Herceptin, using heregulin as a chemoattractant. We found that Herceptin 
significantly (P<0.001) inhibited cell migration in SKBR3/Zeo cells, but its anti-
migratory effect was less pronounced in SKBR3/CD82High cells. Migration was 
reduced by at least 50% in the Herceptin-treated SKBR3/Zeo cells compared to 
non-treated cells; whilst the number of migrated cells was comparable in both 
non-treated and Herceptin-treated SKBR3/CD82High cells. These data suggest 
that the heregulin-induced migration of SKBR3/Zeo cells is ErbB2-dependent, 
which can be inhibited by Herceptin treatment. Since heregulin is a ligand for 
ErbB3, then heregulin-induced migration of SKBR3/Zeo cells is likely to be due 
to signalling downstream of ErbB2/ErbB3 heterodimers. However, in the case of 
CD82 overexpression (SKBR3/CD82High), this ErbB2-mediated mechanism of 
migration is altered in a way that the cells appear to be less-responsive to the 
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anti-migratory effect of Herceptin. This suggests that in SKBR3/CD82High cells, 
the heregulin-induced cell migration may not ErbB2-dependent. Since SKBR3 
cells also express EGFR as well as ErbB2 and ErbB3, it is possible that in 
SKBR3/CD82High cells, heregulin-induced migration is as a result of 
EGFR/ErbB3 signalling, instead of ErbB2/ErbB3 signalling as proposed for 
SKBR3/Zeo cells. On the other hand, the poor response of SKBR3/CD82High 
cells to the anti-migratory effect of Herceptin could be due to signalling via 
alternative signalling pathways. As discussed earlier for the poor response of 
SKBR3/CD82High cells to the antiproliferative effect of Herceptin in 3D ECM, it is 
possible that ectopic expression of CD82 promotes signalling from other 
receptors other than ErbB2. Notably, this alternative signalling was responsive 
to the suppressive effect of CD82 on migration in both non-treated and 
Herceptin-treated cells. 
 
In order to determine the specificity of the anti-migratory effect of CD82 and 
determine whether it is specific for only ErbB2, we examined the haptotactic 
and chemohaptotactic migratory potential of SKBR3 cells under serum-free, 
complete medium with 10% FBS or serum-free medium supplemented with 
either HB-EGF or TGF-β1 chemoattractants; HrG used as a control. From these 
experiments, we found that CD82 consistently suppressed migration under all 
conditions with the exception of 10% FBS; whereby in the latter condition, the 
CD82-mediated effect was reversed. Since both HB-EGF and HrG are ligands 
for other members of the EGFR family (EGFR and ErbB4; ErbB3 and ErbB4, 
respectively), whereby ligand binding induces receptor homo- and hetero-
dimerisation of which ErbB2 is the preferred heterodimerisation partner, the 
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exact specificity of the anti-migratory effect of CD82 for this receptor family is 
not quite clear. It is widely known that CD82 associates with EGFR, ErbB2 and 
ErbB3 and that it negatively regulates EGFR signalling (Odintsova et al. 2000). 
From our current study and reports from others, SKBR3 cells are known to 
express EGFR, ErbB2 and ErbB3, but not ErbB4; therefore it is feasible that 
CD82 can suppress migration by regulating either of these receptors. The fact 
that CD82 also suppressed TGF-β1-induced migration suggests that the anti-
migratory effect of CD82 is diverse and is not limited to regulating signalling of 
just the EGFR family, but also other receptors. However, the reverse result 
observed with 10% serum is indicative that not all receptors are regulated by 
CD82. 
 
The complexity into the diverse suppressive effect of CD82 on cell migration is 
further demonstrated by reports in literature aimed at identifying the 
mechanism(s) by which CD82 regulates cell migration. For example, Zhang and 
colleagues identified the FAK-Src- p130CAS-CrkII signalling pathway to be 
responsible for the CD82-mediated suppression of cell migration of a metastatic 
prostate cancer cell line. They proposed that CD82 suppressed migration in 
these cells by inhibiting formation of the pro-migratory p130CAS-CrkII complex 
through downregulation of p130CAS expression (Zhang et al. 2003a). Both FAK 
and Src are reported to play an important role in mediating integrin signalling 
(Zhao and Guan 2009). In a separate study, Ruseva and colleagues proposed 
that the association of CD82 with the integrin superfamily in particular integrin 
αvβ3 contributed to the metastasis suppressive effect of CD82 through 
inhibition of cell migration as a consequent of enhanced cellular attachment. 
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The authors demonstrated not only the association of CD82 with αvβ3, but also 
an increase in αvβ3-mediated cell adhesion and consequently, reduced motility 
of ovarian cancer cells upon expression of CD82 (Ruseva et al. 2009). Both 
these studies demonstrate the ability of CD82 to suppress integrin-mediated cell 
migration. On the other hand, a study by Takahashi and colleagues 
demonstrated that the association of CD82 with c-Met resulted in suppression 
of HGF-induced cell migration due to decreased association of signalling 
adaptor proteins to the c-Met receptor, in the CD82-overexpressing cells 
(Takahashi et al. 2007). 
 
CD82 is not the only tetraspanin reported to modulate the response of ErbB2-
positive breast cancer cells to Herceptin. A recent report by Yang and 
colleagues demonstrated that knockdown of tetraspanin CD151 sensitised 
ErbB2-positive breast cancer cells including SKBR3 and BT474 cells to ErbB2-
targeted drugs that included Herceptin (Yang et al. 2010). This emerging body 
of evidence in addition to our findings presented herein is indicative that 
tetraspanins may play a role in regulating drug sensitivity and thus warrants 
further studies.  
 
Taken together, our current data suggest a modulatory role of CD82 in the 
cellular response of ErbB2-positive breast cancer cells to Herceptin treatment 
possibly by regulating the compartmentalisation of the ErbB2 receptor and/or its 
downstream signalling. Although the exact mechanism(s) of how CD82 exerts 
its effects are not yet clear at this stage, the above proposed mechanisms will 
be investigated further in the following sections.  
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3.2 The effect of CD82 expression on the distribution and dynamics of 
ErbB proteins 
 
3.2.1 CD82 interacts with ErbB2 receptor tyrosine kinase 
 
CD82 has previously been shown to associate with the ErbB proteins, however 
the interaction of CD82 and ErbB2 was found to be cell-type specific (Odintsova 
et al. 2003). Therefore, it was important for the purpose of this study to 
determine whether CD82 associated with ErbB2 in our model system of BT474 
and SKBR3. Possible interactions of CD82 and ErbB2 were studied by 
immunoprecipitation as described in the Materials and Methods under section 
2.3.3.  
 
Figures 3.8A & C illustrate that ErbB2 coimmunoprecipitated with the anti-CD82 
antibody in both control and CD82-overexpressing cells. The amount of ErbB2 
in complex with CD82 was significantly (P<0.001) higher in SKBR3/CD82High 
cells when compared to that in SKBR3/Zeo cells (Figure 3.8A, lanes 3 & 4). 
Densitometric analysis of the blots revealed that at least 17% of total ErbB2 was 
in complex with CD82 in SKBR3/CD82High cells, when compared to 3% in 
SKBR3/Zeo cells (Figure 3.8B). In contrast, the amount of ErbB2 that co-
immunoprecipitated with CD82 was comparable in both BT474/Puro and 
BT474/CD82High cells (Figure 3.8C, lanes 3 &4). At least 9% of total ErbB2 was 
detected to be in complex with CD82 in both BT474/Puro and BT474/CD82High 
cells (Figure 3.8D). Control experiments show that the anti-CD82 mAb 
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efficiently precipitated CD82; whereby distinction between control and CD82-
overexpressing cells is clearly visible based on the amount of precipitated CD82 
(Figures 3.8A & C, lanes 3 & 4, lower panels). The low molecular weight bands 
(red arrow) detected in the whole cell lysates with the anti-CD82 antibody are 
likely to be non-specific bands, since they are not detected in the precleared 
immune complexes (Figures 3.8A & C, compare lanes 1 & 2 and lanes 3 & 4, 
red arrow). The interaction of CD82 with ErbB2 was confirmed in 
SKBR3/CD82High cells under different lysis conditions: 1% Brij-98; and a mixture 
of 0.5% Brij-98 + 0.5% Triton X-100; although the amount of ErbB2 found in 
complex with CD82 was lower in more stringent detergent conditions (Appendix 
IV, Supplementary Figure 2). The fact that the ErbB2-CD82 complex is 
disrupted by more stringent detergent conditions, but is retained in milder 
detergent conditions (1% Brij-98) suggests that this interaction is not direct. 
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Figure 3.8: CD82 associates with ErbB2 in SKBR3 and BT474 cells.  
 
(A) SKBR3 and (C) BT474 cells were prepared for the immunoprecipitation 
assay as described in the Materials and Methods under section 2.3.4. Cells 
were lysed using a mixture of 0.8% Brij-98 + 0.2% Triton X-100 lysis buffer for 
4h at 4oC with rotation. Immune complexes were precipitated using mouse IgG 
agarose beads conjugated with M104 mouse anti-CD82 mAb followed by 
western blot analysis using anti-ErbB2 (Ab-17) and anti-CD82 (KAI1 C-16) 
antibodies. (B and D) Densitometric analysis of the blots, plotted as percentage 
of total protein. Data shown is one representative of at least two independent 
experiments. Asterisks represent the statistical significance as determined by a 
two-tailed, unpaired Student’s t test, using GraphPad Prism software. 
Significance was set at 0.05, whereby (*** P<0.001). 
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3.2.2 Ectopic expression of CD82 changes the compartmentalisation of 
ErbB2  
 
Tetraspanins are known to affect the membrane compartmentalisation of not 
just tetraspanins, but also of non-tetraspanin proteins (Berditchevski 2001;Claas 
et al. 2001;Odintsova et al. 2003). In the present study, the role of CD82 in the 
membrane distribution of ErbB2 was investigated in Herceptin treated (10µg/ml; 
1h) and non-treated (Herceptin-free) cells, by fractionation in a sucrose gradient 
as outlined in section 2.4 of the Materials and Methods. Ten fractions were 
collected from the top of the gradient and protein distribution within these 
gradient fractions was determined by western blot analysis. Following lysis with 
Triton X-100, any proteins distributed within low density fractions 2-5 were 
considered to be in membrane microdomains that are insoluble to lysis with this 
detergent whilst distribution within high density fractions 6-10 was considered to 
be in detergent-soluble membrane microdomains.  
 
Figures 3.9A and B (top panels) illustrate that in the absence of Herceptin, 93% 
of ErbB2 was distributed within the dense detergent-soluble fractions, 6-10 in 
SKBR3/Zeo cells. No ErbB2 was detected in the detergent-insoluble fractions, 
1-5. A similar distribution of CD82 was observed under the same conditions in 
these cells, whereby 96% of CD82 was detected in fractions 6-10 (Figures 3.9C 
and D, top panel). However, 4% of total CD82 was also detected in the buoyant 
fraction 5 (Figure 3.9C, upper top panel). Treatment of these cells with 
Herceptin resulted in a change in the distribution of both ErbB2 and CD82. By 
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comparing the distribution of ErbB2 in non-treated and treated cells, we found 
that Herceptin treatment caused redistribution of ErbB2 to the heavier fractions; 
whereby significantly (P<0.05) less ErbB2 was detected in fraction 6 of the 
Herceptin-treated SKBR3/Zeo cells compared to that in same fraction of non-
treated cells (Figure 3.9A upper top panel; lane 6). On the other hand, CD82 
was redistributed to the light membrane fractions following Herceptin treatment 
(Figure 3.9C upper top panel, lane 5). Densitometric analysis of the blots 
revealed that the amount of CD82 redistributed to fraction 5 following Herceptin 
treatment was increased by ~6% when compared to that of non-treated 
SKBR3/Zeo cells (Figure 3.9D, top graph, compare the dark blue bar to the 
purple bar). 
 
Interestingly, we found that in SKBR3/CD82High cells, the amount of ErbB2 in 
fraction 6 was markedly decreased with the concomitant increase of the protein 
in fraction 3 (Figure 3.9A top panel; compare lanes 3 and 6 of SKBR3/Zeo and 
SKBR3/CD82High cells). Densitometric analysis of the blots revealed that at least 
1.5% of total ErbB2 was redistributed to fraction 3 in non-treated 
SKBR3/CD82High cells. Furthermore, we found that treatment with Herceptin 
(10µg/ml, 1h) increased the amount of ErbB2 in this fraction by 8-fold, when 
compared to the amount in the same fraction of non-treated cells (Figure 3.9B 
top panel, fraction 3; compare the light blue bar to the green bar). No signal was 
detected in the first two fractions. Similarly, we found that CD82 was distributed 
in both dense and light membrane fractions in non-treated and Herceptin-
treated SKBR3/CD82High cells (Figure 3.9C, lower top panel). 86% of total CD82 
was detected in dense fractions, 6-10; whilst 14% of CD82 was detected in the 
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light fractions, 2 and 3 in the non-treated cells (Figure 3.9D top panel, light blue 
bars). Treatment with Herceptin induced further redistribution of CD82 into 
fractions 4 and 5, which was hardly detectable in non-treated cells (Figure 3.9C, 
lower top panel). Similar observations were made when cells were lysed under 
different lysis conditions (Appendix IV, Supplementary Figure 3). 
 
We also investigated the membrane distribution of other tetraspanins (CD9, 
CD151 and CD63) (Figure 3.10). Similar to the distribution of CD82, we found 
that CD9 was distributed in both detergent-insoluble and soluble fractions. 
Specifically, in SKBR3/Zeo cells, CD9 was detected in the detergent-insoluble 
fractions 2, 3 and 5; as well as in the detergent-soluble fractions 6-10. However, 
in SKBR3/CD82High cells, CD9 was detected in fractions 2, 5, and 6-10, with 
hardly detectable amount in fraction 3 (Figure 3.10A). On the other hand, the 
distribution of tetraspanins CD151 and CD63 was localised only to the dense 
fractions, 6-10 (Figure 3.10). Notably, treatment with Herceptin did not affect the 
membrane distribution of CD9, CD151 and CD63 in both SKBR3/Zeo and 
SKBR3/CD82High cells.  
 
Contrary to the observations in SKBR3 cells, ectopic expression of CD82 in 
BT474 cells had no effect on the distribution of ErbB2. The receptor was only 
distributed within the dense gradient fractions 7-10, in both control and CD82-
overexpressing cells (Figures 3.9A and B, bottom panels). Furthermore, we 
found that treatment of these cells with Herceptin did not affect the distribution 
of ErbB2. Similar to the distribution of ErbB2, CD82 was only detected in the 
dense gradient fractions, with majority (69% and 66%) being detected in 
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fractions 7, 8 and 9 in BT474/Puro and BT474/CD82High cells, respectively 
(Figure 3.9C, bottom panel). However, treatment with Herceptin induced a shift 
in the distribution of CD82 into heavier fractions, with less amount of CD82 (8% 
and 2%) being detected in fraction 6 following Herceptin treatment in both 
BT474/Puro and BT474/CD82High cells, respectively (Figure 3.9C bottom panel, 
lane 6; and Figure 3.9D).  
 
The distribution pattern of flotillin-2, a component of lipid rafts (Bickel et al. 
1997;Salzer and Prohaska 2001;Slaughter et al. 2003;Zhao et al. 2011) was 
also analysed. Like ErbB2 and CD82, we found that flotillin-2 was also 
distributed in the low-density fractions 2, 3 and 4; and in the high-density 
fractions mainly 7-10, in both SKBR3 and BT474 cells (Figure 3.9E). 
Densitometric analysis of the blots revealed that treatment with Herceptin 
resulted in redistribution of flotillin-2. Specifically, the amount of flotillin-2 
detected in fractions 2, 3 and 4 was increased by at least 3-fold, following 
Herceptin treatment in the SKBR3/CD82High cells when compared to that of non-
treated cells (Figure 3.9F, top panel). This effect appeared to be cell-type 
specific, since it was not observed in the BT474 cells (Figure 3.9F, bottom 
panel). Based on the distribution pattern of flotillin-2 in the low-density fractions 
in both SKBR3 and BT474 cells, we concluded that fractions 2 and 3 are the 
typical raft fractions, insoluble following lysis with 1% Triton X-100. 
 
The fact that ectopic expression of CD82 resulted in redistribution of ErbB2 to 
raft microdomains, particularly in SKBR3/CD82High cells and not in 
BT474/CD82High cells suggests that this CD82-mediated effect could be cell-
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type specific. In addition, the fact that Herceptin treatment increased the amount 
of ErbB2 and flotillin-2 distributed within these raft fractions, particularly in 
fraction 2 implies that the distribution of ErbB2 to these microdomains could be 
functionally significant in the regulation of this receptor. 
  Results and Discussion 
 
145 
 
 
  Results and Discussion 
 
146 
 
 
 
  Results and Discussion 
 
147 
 
 
  Results and Discussion 
 
148 
 
 
 
  Results and Discussion 
 
149 
 
 
 
  Results and Discussion 
 
150 
 
 
  Results and Discussion 
 
151 
 
 
Figure 3.9: CD82 changes the compartmentalisation of ErbB2. 
 
SKBR3 and BT474 cells were treated with Herceptin (10µg/ml) for 1h prior to 
lysis. Non-treated and treated cells were lysed in ice-cold 1% Triton X-100 and 
the resulting homogenate of equal protein concentration was centrifuged in a 
discontinuous sucrose density gradient composed of 90%, 35% and 5% (w/v) 
sucrose. 10 fractions were collected from the meniscus of the gradient and the 
pellet was resuspended in Laemmli buffer supplemented with protease and 
phosphatase inhibitors. Equal amounts of each fraction were mixed with 4X 
Laemmli loading buffer and the protein distribution was analysed by SDS-PAGE 
under reducing and non-reducing conditions followed by western blot analysis 
using antibodies against (A) ErbB2 (Ab-17); (C) CD82 (TS82b); and (E) Flotillin-
2 (C42A3). (B; D and F) Summary of density ratios, plotted as percentage of 
total protein from at least two independent experiments. Asterisks represent the 
statistical significance as determined by the one-way ANOVA multiple 
comparison test with the Tukey-Kramer post-test, using GraphPad Prism 
software. Significance was set at 0.05, whereby (*P<0.05) and (*** P<0.001). 
Abbreviations: SK - SKBR3; BT - BT474; 82H - CD82High; HC - Herceptin; P - 
pellet. 
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Figure 3.10: The effects of CD82 expression and Herceptin treatment on 
the distribution of other tetraspanins following lysis with Triton X-100. 
 
SKBR3/Zeo and SKBR3/CD82High cells were treated with Herceptin (10µg/ml) 
for 1h prior to lysis. Non-treated and treated cells were lysed in ice-cold 1% 
Triton X-100 followed by fractionation as described in the Materials and 
Methods under section 2.4. The resulting homogenate of equal protein 
concentration was centrifuged in a discontinuous sucrose density gradient 
composed of 90%, 35% and 5% (w/v) sucrose. 10 fractions were collected from 
the meniscus of the gradient and the pellet was resuspended in Laemmli buffer 
supplemented with protease and phosphatase inhibitors. Equal amounts of 
each fraction were mixed with loading buffer and the protein distribution was 
analysed by SDS-PAGE under non-reducing conditions followed by western 
blot analysis and probing for the indicated proteins.  
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3.2.3 The use of fluorescence recovery after photobleaching (FRAP) to 
monitor the membrane dynamics of ErbB receptors in live cells 
 
3.2.3.1 Herceptin reduces the mobility of ErbB2 in the plasma 
membrane 
 
FRAP experiments were performed on live cells expressing fluorescent-tagged 
proteins. A region of the cell was irreversibly bleached using a high laser power 
followed by monitoring the diffusion of non-bleached fluorescent molecules from 
the surrounding area into the bleached region. The diffusion of non-bleached 
molecules into the bleached region is termed fluorescence recovery (Lippincott-
Schwartz et al. 2001;Reits and Neefjes 2001). Herein FRAP analysis was 
performed in order to monitor the membrane dynamics of GFP-tagged ErbB2 
and EGFR receptors transfected into cells stably expressing CD82. These 
experiments were performed in non-treated and Herceptin-treated cells. Where 
indicated, Herceptin (10µg/ml) was added to the cells at least 1h prior to FRAP 
analysis. Two parameters were deduced from these experiments; the mobile 
fraction and the rate of mobility of fluorescent molecules within a defined region 
of interest (ROI). Both these parameters were determined from the fluorescence 
recovery curve. Specifically, we aimed to determine the effect of Herceptin on 
the mobility of ErbB2 and also to determine whether CD82 affected the mobility 
of EGFR and ErbB2 receptors. SKBR/Zeo and SKBR3/CD82High cells were 
transiently transfected with GFP-tagged ErbB2. Details of FRAP analysis are 
outlined in the Materials and Methods under section 2.5.2.  
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Representative images captured during FRAP analysis are shown in Figure 
3.11A. For each FRAP experiment, 10-12 cells expressing similar levels of 
ErbB2-GFP in the absence and presence of Herceptin were analysed. The 
images on the left show fluorescence within the region of interest (ROI) 
(rectangle) before bleaching; central images were acquired immediately after 
bleaching; and images on the right represent recovery at a given time point after 
bleaching. From these images, it is clear that ErbB2-GFP was highly expressed 
on the plasma membrane prior to bleaching and that photobleaching of greater 
than 50% was achieved in the region of interest, plus a clear indication of 
fluorescence recovery of ErbB2-GFP molecules into this region over time. 
Additionally, these images clearly demonstrate that photobleaching was 
restricted only to the defined ROI and did not bleach the entire cell. 
Furthermore, these data illustrate that non-treated cells recovered faster than 
the Herceptin-treated cells (Figure 3.11A; compare top right image to the 
bottom right).  
 
Figure 3.11B is a representative graph of typical raw data plotted as 
fluorescence intensity against time. It shows that fluorescence recovery 
normalised from the pre-bleach fluorescence values (Fi) can be plotted against 
time. Such analysis was adapted for all FRAP data; therefore, all subsequent 
FRAP plots herein represent normalised fluorescence recovery plotted against 
time. Figure 3.12A shows the fluorescence recovery curve of ErbB2-GFP in 
non-treated and Herceptin-treated SKBR3/Zeo and SKBR3/CD82High cells of 
pooled results from three independent experiments. These experiments 
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revealed that ErbB2 is highly mobile, as represented by fluorescence recovery 
of at least 80% and high mobile fraction values of non-treated cells (Figure 
3.12A, top plots and Figure 3.12B). Notably, we found that the mobility of ErbB2 
was comparable in both SKBR3/Zeo and SKBR3/CD82High cells. The 
fluorescence recovery plots for both cell lines superimposed onto one another, 
indicative that ectopic expression of CD82 does not affect the mobility of ErbB2 
in the plasma membrane (Figure 3.12A, top plots). Furthermore, calculations of 
the mobile fractions were in agreement with the plotted data, whereby 72.5% 
and 64.4% of ErbB2 was mobile in non-treated SKBR3/Zeo and 
SKBR3/CD82High cells, respectively (Figure 3.12B and Figure 3.12C; compare 
the dark blue-filled bar to the light blue-filled bar). Analysis of the statistical 
significance of the marginal difference in the mobile fraction values revealed 
that this difference was not statistically significant. In addition, no statistical 
difference was found between the TD values (the diffusion time at half 
fluorescence recovery) of non-treated SKBR3/Zeo and SKBR3/CD82High cells, 
88.8s and 78.5s, respectively (Figure 3.12B).  
 
On the other hand, we found that treatment with Herceptin significantly impeded 
ErbB2 fluorescence recovery in both cell lines. Only 60% fluorescence recovery 
was detected within the bleached region of both SKBR3/Zeo and 
SKBR3/CD82High cells following Herceptin treatment (Figure 3.12A, comparing 
both top plots to the bottom plots). This was also reflected in the mobile fraction 
calculations, whereby the fraction of mobile ErbB2 was consistently found to be 
lower in the Herceptin treated cells compared to that of non-treated cells; 41.3% 
and 42% in treated SKBR3/Zeo and SKBR3/CD82High cells compared to 72.5% 
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and 64.4% in non-treated cells, respectively (Figure 3.12B and Figure 3.12C). 
Statistical analysis carried out on these data revealed that the percentage of 
mobile ErbB2 in each cell line was significantly reduced (P<0.001), following 
Herceptin treatment (Figure 3.12C). Consequently, Herceptin treatment resulted 
in an increase in recovery time as represented by TD, the diffusion time at half 
fluorescence recovery. Non-bleached ErbB2-GFP molecules in Herceptin 
treated cells took longer to diffuse into the bleached region to achieve half 
fluorescence recovery than in the non-treated cells. Specifically, in Herceptin-
treated SKBR3/Zeo and SKBR3/CD82High cells, the diffusion time at which half 
of the fluorescence was recovered was 102s and 95s compared to 89s and 79s 
in non-treated cells, respectively (Figure 3.12B). However, differences between 
TD values of non-treated verses treated or indeed between control verses 
CD82-overexpressing cells were found not be statistically significant. These 
data demonstrate that even though Herceptin treatment reduces the mobility of 
ErbB2 within the plasma membrane, the rate of diffusion was comparable 
between control and CD82-overexpressing cells.  
 
Collectively, these data demonstrate that treatment with Herceptin reduced the 
mobility of ErbB2 in the plasma membrane, thus suggesting that Herceptin may 
function by immobilising ErbB2.  
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Figure 3.11: Kinetic analysis of fluorescence recovery after 
Photobleaching (FRAP). 
 
(A) An example of the images used during FRAP analysis. It illustrates non-
treated and Herceptin-treated (10µg/ml, minimum 1h) cells before bleaching; 
immediately after bleaching; and an image at any given time (seconds) 
postbleaching ErbB2 fluorescence in a region of interest (rectangle). Scale bar 
= 5µm. (B) An illustration of a typical raw data plot explaining the kinetic 
analysis of FRAP plotted as fluorescence intensity against time. Figure was 
adapted from Lippincott-Schwartz et al. and Reits et al. (Lippincott-Schwartz et 
al. 2001;Reits and Neefjes 2001). The mobile fraction was calculated using the 
following equation: Mf = (F∞ - F0) / Fi - F0); whereby Fi is the initial fluorescence 
intensity prior to bleaching; F0 is the fluorescence intensity immediately after 
bleaching; and F∞ is the fluorescence intensity at the point when recovery 
reaches a plateau, as previously described by Axelrod et al. (Axelrod et al. 
1976). TD is the diffusion time at half fluorescence recovery.  
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Figure 3.12: The effects of CD82 and Herceptin on the membrane 
dynamics of ErbB2. 
 
(A) SKBR3/Zeo and SKBR3/CD82High cells stably expressing CD82 were 
transiently transfected with a plasmid encoding ErbB2-GFP. All cell lines were 
prepared for FRAP as described in section 2.5.2 of the Materials and Methods. 
Fluorescence recovery in a bleached region of live cells was monitored by 
scanning 70 frames per cell, at 7 seconds intervals until 550 seconds post 
bleach. For each experiment, 10-12 individual cells were bleached and scanned 
under the same conditions. Shown is pooled data from three independent 
experiments. (B) Summary of the mobile fraction values. (C) Statistical analysis 
of the mobile fraction values. Asterisks represent statistical significance as 
determined by the one-way ANOVA multiple comparison test with the Tukey-
Kramer post-test, using GraphPad Prism software. Significance was set at 0.05, 
whereby (***P<0.001). Data shown as mean ± standard deviation (SD). 
Abbreviations: ns – not significant; HC – Herceptin. 
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3.2.3.2 The effect of CD82 in regulating the dynamics of EGFR on the 
plasma membrane 
 
EGFR, another member of the ErbB family also associates with CD82; and it 
has previously been reported that CD82 attenuates EGFR signalling partly by 
changing the compartmentalisation of EGFR (Odintsova et al. 2000;Odintsova 
et al. 2003). As an additional control for the experiments described above for 
ErbB2, the same experiments were carried out using EGFR. In these 
experiments, SKBR3/Zeo and SKBR3/CD82High cells stably expressing CD82 
were transiently transfected with EGFR-GFP followed by FRAP analysis. As 
illustrated in Figures 3.13A and C, expression of CD82 had a subtle negative 
effect on the mobility of EGFR in the plasma membrane. The percentage of 
mobile EGFR-GFP was marginally reduced in SKBR3/CD82High cells when 
compared to that in SKBR3/Zeo cells; 15.4% and 24.1%, respectively (Figure 
3.13B). However, statistical analysis of this data revealed no statistical 
difference between the two cell lines. Thus, these data indicate that under our 
experimental conditions, we were not able to detect any influence of tetraspanin 
CD82 in modulation of the membrane dynamics of ErbB2 and EGFR. 
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Figure 3.13: The effect of CD82 on the membrane dynamics of EGFR. 
 
(A) SKBR3/Zeo and SKBR3/CD82High cells stably expressing CD82 were 
transiently transfected with a plasmid encoding EGFR-GFP. All cell lines were 
prepared for FRAP as described in section 2.5.2 of the Materials and Methods. 
Fluorescence recovery in a bleached region of live cells was monitored by 
scanning 70 frames per cell, at 7 seconds intervals until 550 seconds post 
bleach. At least 10 individual cells were bleached and scanned under the same 
conditions for each FRAP assay; and 3 individual experiments were carried out. 
(B) Summary of the mobile fraction values. (C) Statistical analysis of the mobile 
fraction values as determined by the two-tailed unpaired Student’s t-test, using 
GraphPad Prism software. Significance was set at 0.05. Data shown as mean ± 
standard deviation (SD). Abbreviation: ns – not significant. 
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3.2.4 Discussion  
 
Our earlier experiments demonstrated that CD82 modulates the cellular 
response of ErbB2-positive breast cancer cells to Herceptin treatment. 
Consequently, we postulated that CD82 could be exerting these effects by 
regulating the distribution and downstream signalling of the ErbB2 receptor. We 
explored these hypotheses by initially investigating the effect of CD82 
expression on the distribution and dynamics of ErbB2. Since the association of 
CD82 and ErbB2 was previously reported to be cell type specific (Odintsova et 
al. 2000), we begun by determining whether this interaction occurred in our 
model system of SKBR3 and BT474 cells. From our immunoprecipitation 
experiments, we demonstrated that CD82 associated with ErbB2 in both 
SKBR3 and BT474 cells. In SKBR3 cells, the amount of ErbB2 in complex with 
CD82 was higher in the CD82-overexpressing cells than in vector control cells. 
Contrary however, in BT474 cells, both control and CD82-overexpressing cells 
had comparable levels of ErbB2 in complex with CD82. The fact that the ErbB2-
CD82 interaction was detected in control cells (SKBR3/Zeo and BT474/Puro 
cells) suggests that the association is not an artefact as a result of CD82 
overexpression. In addition, the fact that no significant increase in the amount of 
ErbB2 in complex with CD82 was observed in BT474/CD82High cells when 
compared to BT474/Puro cells, as was observed between SKBR3/Zeo and 
SKBR3/CD82High cells suggests that the increase in the association could be 
cell-type specific in terms of complex composition and distribution. In view of the 
fact that the ErbB2-CD82 interaction is disrupted under stringent detergent 
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conditions and thus suggesting that the association is not direct, it is possible 
that components of the ErbB2-CD82 complex are different between SKBR3 and 
BT474 cells. It is possible that in SKBR3/CD82High cells, the membrane 
distribution of ErbB2 favours its association with CD82 more than its distribution 
in BT474/CD82High cells. Indeed, the distribution of ErbB2 within membrane 
fractions was found to be different between SKBR3 and BT474 cells, as 
discussed below.  
 
It has previously been reported that CD82 changes the compartmentalisation of 
both EGFR and ErbB2 as assessed by fractionation in a sucrose gradient in 
other cell lines (Odintsova et al. 2003). Here, we found that ectopic expression 
of CD82 in ErbB2-overexpressing cells resulted in a change in the distribution of 
both ErbB2 and CD82 from detergent-soluble microdomains to detergent-
insoluble membrane raft microdomains. Notably, we observed that the 
proportion of ErbB2 redistributed to the raft microdomains was enriched by at 
least 8-fold following Herceptin treatment. The fact that ErbB2 and CD82 had 
similar distribution characteristics particularly in the detergent-insoluble fractions 
suggests that both proteins are likely to be in the same complex. In view of the 
fact that the CD82-mediated distribution of ErbB2 to light membrane fractions 
was specifically observed in SKBR3/CD82High cells but not in the 
BT474/CD82High cells suggests that partitioning of ErbB2 to raft microdomains 
could be dependent on the expression levels of CD82. It is possible that the 
redistribution of ErbB2 in the light membrane fractions was not detected in 
BT474 due to differences in the expression levels of CD82 in these cells 
compared to that in SKBR3 cells. As previously mentioned, CD82 was 
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overexpressed by at least 9-fold in the SKBR3/CD82High cells when compared 
to 2-fold in BT474/CD82High cells. It is therefore feasible that overexpression of 
CD82 to the level observed in SKBR3/CD82High cells results in changes in the 
distribution and/or dynamics of not only CD82 itself, but also its association 
partners such as ErbB2. Indeed Odintsova and colleagues previously reported 
a change in the distribution of both EGFR and ErbB2 to light membrane 
fractions in mammary epithelial HB2 cells, in which CD82 was overexpressed 
by ~15 fold compared to control cells (Odintsova et al. 2003).  
 
The fact that ErbB2 was redistributed to the raft fraction and that the proportion 
of the receptor redistributed to this fraction was increased following Herceptin 
treatment suggests that Herceptin could be inducing clustering of ErbB2 within 
raft domains. These data also suggest a possible role of lipid rafts or 
components of these microdomains in modulating the function of ErbB2. Lipid 
rafts are cholesterol- and sphingolipid-enriched membrane microdomains, 
characterised by their partitioning in low density fractions of a sucrose gradient 
and their resistance to solubilisation by cold detergent lysis (Orr et al. 2005). 
Gangliosides are components of lipid rafts and have been implicated by several 
studies in the regulation of ErbB proteins, including ErbB2 (Milani et al. 
2007;Milani et al. 2010;Nagy et al. 2002;Orr et al. 2005;Zurita et al. 2004). 
Specifically, Nagy and colleagues previously reported that clusters of ErbB2 co-
localised with lipid rafts and that the latter influenced the association properties 
and activity of ErbB2. The authors found that crosslinking of lipid rafts caused 
segregation of ErbB2 clusters from lipid rafts, which consequently resulted in 
decreased ErbB2/ErbB3 heterodimerisation, reduced ligand-induced tyrosine 
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phosphorylation of ErbB2 and downstream adaptor molecules (Nagy et al. 
2002). Others demonstrated the involvement of specific gangliosides in the 
membrane distribution and activity of ErbB2. For example, ganglioside GM3 
was reported to colocalise with ErbB2, to play a key role in retaining the 
receptor in lipid rafts, and it was also found to be strongly associated with 
tyrosine-phosphorylated ErbB2 (Milani et al. 2007;Sottocornola et al. 2006). 
Moreover, CD82 has previously been reported to colocalise with gangliosides 
and cholesterol and to be partially distributed in low-density gradient fractions 
(Charrin et al. 2003;Delaguillaumie et al. 2004;Odintsova et al. 2003;Todeschini 
et al. 2007;Todeschini et al. 2008). Gangliosides and cholesterol have 
previously been reported to play a role in modulating the integrity of tetraspanin-
enriched microdomains (TERMs) and the function of individual tetraspanins, as 
it has been shown particularly for CD82 (Charrin et al. 2003;Delaguillaumie et 
al. 2004;Odintsova et al. 2006;Todeschini et al. 2007;Todeschini et al. 2008). 
The link between CD82, gangliosides and cholesterol is reported to be crucial 
for the metastasis suppressive function of CD82. Disruption of lipid rafts and 
TERMs by cholesterol depletion or via inhibition of ganglioside biosynthesis has 
been shown to result in inhibition of CD82-induced adhesion, a decrease in the 
ability of CD82 to induce tyrosine phosphorylation of various CD82-associated 
proteins, and abolishes the suppressive effect of CD82 on cell migration 
(Delaguillaumie et al. 2004;Odintsova et al. 2006;Todeschini et al. 
2007;Todeschini et al. 2008). Altogether, these reports highlight the significance 
of our findings that in addition to the distribution of ErbB2 and CD82 into 
TERMs, approximately 1.5% and 14%, respectively of these proteins are 
redistributed to the raft microdomains upon ectopic expression of CD82 in 
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SKBR3/CD82High cells, which is increased following Herceptin treatment. These 
findings thus suggest a probable functional relevance of this distribution that 
warrants further investigation. 
 
We also examined the membrane distribution of other tetraspanins under the 
same conditions to those mentioned above. Notably, we found that tetraspanin 
CD9 also partitioned in both light and heavy membrane fractions of a sucrose 
gradient as CD82, but was not affected by Herceptin treatment. Additionally, we 
observed that the membrane distribution of tetraspanins CD151 and CD63 was 
solely detected in the detergent-soluble membrane fractions (Figure 3.10). The 
fact that we observed two distinct patterns of membrane distribution for the 
panel of tetraspanins that we studied in this project, not only demonstrates the 
specificity of our results but also demonstrates that our findings are not an 
artefact induced by overexpression of CD82. Furthermore, our results are in 
agreement with other reports and further corroborate the notion of the existence 
of distinct tetraspanin-enriched microdomains. In this regard, the evidence 
presented herein supports the existence of CD82-enriched microdomains, as 
previously proposed by Odintsova and colleagues (Odintsova et al. 2006), 
whereby they differ from the classical detergent-soluble tetraspanin-enriched 
microdomains by partially partitioning in the detergent-insoluble gradient 
fractions; they vary in the tetraspanin content; and are also likely to consist of 
gangliosides, ErbB2, tetraspanin CD9 amongst other molecules.  
 
Since our fractionation experiments demonstrated that expression of CD82 
changed the compartmentalisation of ErbB2, FRAP analysis was performed in 
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order to examine the membrane dynamics of ErbB2 and EGFR. These 
experiments were specifically performed in order to determine the effects of 
CD82 expression and Herceptin treatment on the dynamics of these receptors. 
We found that both proteins were mobile, but displayed different diffusion 
characteristics; whereby ErbB2 was found to be more mobile than EGFR. The 
mobility of each protein was determined from calculations of the mobile fraction 
based on the fluorescence recovery after photobleaching within a defined 
region of interest. From these values, we found that a higher fraction of ErbB2 
was mobile compared to that of EGFR in both control and CD82-overexpressing 
cells. Notably, we found that the membrane dynamics of both ErbB2 and EGFR 
were not affected by expression of CD82 under our experimental conditions; 
since the lateral diffusion of the receptors on the plasma membrane was 
comparable in both SKBR3/Zeo and SKBR3/CD82High cells. Although we were 
unable to detect any CD82-mediated effect on the membrane dynamics of 
EGFR and ErbB2 under these experimental conditions, it is still possible that 
CD82 may have a role in modulating the membrane mobility of these receptors 
under different experimental conditions. Indeed, the effect of CD82 on the 
diffusion of EGFR has previously been investigated by Danglot and colleagues 
whereby they demonstrated that depletion of TI-VAMP, a membrane protein or 
depletion of its cargo, CD82 in HeLa cells resulted in decreased mobility of 
activated EGFR (Danglot et al. 2010). Additionally, it is widely known that 
tetraspanins including CD82 are palmitoylated; and several studies have 
previously demonstrated the importance of palmitoylation for the stability and 
formation of tetraspanin-enriched microdomains (TERMs) (Berditchevski et al. 
2002;Charrin et al. 2002;Yang et al. 2002;Zhou et al. 2004). Specifically, 
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palmitoylation of CD82 has been shown to regulate not only the 
compartmentalisation of CD82, but also its association with other tetraspanins, 
ultimately affecting its cellular function. Moreover, it has previously been 
reported that disruption of CD82 palmitoylation reverses the functions of wild-
type CD82 (Zhou et al. 2004). Since palmitoylation is important for the assembly 
of TERMs, we postulate that disruption of CD82 palmitoylation may affect the 
compartmentalisation and/or the membrane dynamics of ErbB proteins. It would 
be interesting to investigate this further using a palmitoylation-deficient CD82 
mutant in comparison to the effects of wild-type CD82. 
 
FRAP experiments in which the cells where treated with Herceptin revealed a 
decrease in the cell surface dynamics of ErbB2. These observations suggest 
that Herceptin could be functioning by immobilising ErbB2 possibly by inducing 
the formation of immobile surface aggregates of the receptor and/or by inducing 
internalisation of the receptor under our experimental conditions. However, both 
of these notions are opposed by data from a previously published extensive 
study by Austin and colleagues into the dynamics of Herceptin-bound ErbB2, 
whereby the authors demonstrated that Herceptin-bound ErbB2 is not a static 
pool, but is rather dynamic, undergoing slow internalisation and is efficiently 
recycled to the cell surface. Furthermore, the authors found no significant effect 
of Herceptin on the surface levels of ErbB2, thereby opposing the notion of 
receptor degradation (Austin et al. 2004). It should be noted that although this 
study by Austin was carried out using SKBR3 cells like we have used herein, 
there were differences between our present study and theirs which could 
explain the opposing effects described above. Firstly, in their study, SKBR3 
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cells were seeded on to poly-L-lysine-coated glass slides, whilst in our study the 
cells were cultured on non-coated coverglass chambers. Secondly, they used 
radiolabelled and fluorescence-labelled Herceptin to monitor the dynamics of 
endogenous ErbB2 whilst we studied transiently transfected GFP-tagged ErbB2 
and non-labelled Herceptin. Thirdly, the study by Austin was carried out using 
flow cytometry to monitor the effect of Herceptin on the surface levels of ErbB2 
whilst herein we used FRAP. Finally, both studies differed in the duration of the 
assays: we monitored the surface dynamics of ErbB2 within approximately 10 
minutes whilst the time-points in Austin’s study were in hours. It is difficult to 
draw conclusions since both studies differ in the experimental design. Thus at 
this stage of our current study, it remains unclear as to the reason behind the 
decrease in the surface mobility of ErbB2 following Herceptin treatment.  
 
Taken together, these data highlight a profound ability of CD82 to modulate the 
distribution of ErbB2. These data also suggest that Herceptin may function by 
affecting the compartmentalisation and diffusion of ErbB2. Furthermore, the 
CD82-mediated redistribution of ErbB2 to the raft fractions suggests a possible 
role of CD82 in ErbB2 signalling and will thus be investigated further in the 
following section.  
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3.3 The effects of CD82 and Herceptin on cell signalling downstream of 
the ErbB2 receptor 
 
3.3.1 Ectopic expression of CD82 results in increased MAPK signalling at 
basal level 
 
The EGF-family of growth factor ligands including heregulin can lead to 
activation of the ligandless ErbB2 and kinase-dead ErbB3 receptors through 
heterodimerisation. Once activated the ErbB receptors can in turn activate two 
key signalling pathways, the PI3K/Akt and MAPK pathways (Figures 1.4 and 
1.6, respectively) (Hynes and MacDonald 2009). In order to verify whether 
ectopic expression of CD82 affects heregulin-induced ErbB signalling, 
SKBR3/Zeo and SKBR3/CD82High cells were serum-starved overnight prior to 
stimulation with heregulin for the indicated time intervals. Lysates were 
collected at the end of each time point followed by western blot analysis for the 
phosphorylation pattern of various proteins of the PI3K and MAPK signalling 
pathways.  
 
The C-terminal domain of ErbB3 contains six YXXM motifs, which when 
phosphorylated serve as a docking site for the SH2 domain of p85 (Olayioye et 
al. 2000;Smirnova et al. 2012). The tyrosine residue 1289 of ErbB3 resides 
within the YXXM sequence motif. Thus phosphorylation of ErbB3 at this site 
(Y1289) would couple the receptor to the PI3K pathway. As shown in Figure 
3.14A, both SKBR3/Zeo and SKBR3/CD82High cells displayed comparable 
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levels of phosphorylated ErbB3 (Y1289) at basal level (lanes 1 and 6). 
Stimulation with heregulin, a ligand for ErbB3 (and ErbB4) resulted in elevated 
levels of phosphorylated ErbB3. However, the phosphorylation pattern was 
different between control and CD82-overexpressing cells. Specifically, in 
SKBR3/Zeo cells, stimulation of cells with heregulin resulted in a gradual 
increase in ErbB3 phosphorylation, which peaked at 5 minutes of heregulin 
stimulation followed by a steady decrease over time (Figure 3.14A). In contrast, 
the highest level of phosphorylated ErbB3 was observed as early as 2 minutes 
of heregulin stimulation in SKBR3/CD82High cells followed by a gradual 
decrease at 5 and 15 minutes, before dephosphorylation occurred by 30 
minutes post stimulation (Figure 3.14A). Figure 3.14B (top graph) shows the 
densitometric analysis of the blots. Akt, which is phosphorylated following 
activation of ErbB3, displayed a similar kinetic pattern to that of phosphorylated 
ErbB3; with comparable levels of phosphorylated protein at basal level in both 
control and CD82-overexpressing cells (Figures 3.14A and B, bottom graph). 
These data suggest that ectopic expression of CD82 could have a role in 
modulating the formation of heregulin-induced ErbB3 heterodimers with other 
ErbB receptors that leads to activation of ErbB3 and its downstream PI3K 
pathway. 
 
Analysis of the phosphorylation pattern of ErbB2 revealed that this receptor was 
constitutively active in both control and CD82-overexpressing cells. 
Interestingly, we observed a difference in phosphorylation of ErbB2 at basal 
level between the two cell lines; whereby the CD82-overexpressing cells 
displayed significantly high levels of activated ErbB2 when compared to control 
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cells (Figure 3.14A, compare lanes 1 and 6). This definitive result was observed 
with two different antibodies targeting separate phosphorylation sites of ErbB2, 
namely tyrosines 877 and 1221/1222.  
 
Phosphorylation of ErbB2 at Y877 couples the receptor to Src and its 
downstream targets including focal adhesion kinase (FAK) and the pro-
migratory p130CAS-CrkII complex (Cabodi et al. 2010;Muthuswamy et al. 1999). 
In accordance to this, analysis of Src phosphorylation at Y416 revealed a 
similar pattern to that observed for pErbB2 (Y877), whereby high levels of pSrc 
were detected in SKBR3/CD82High cells than those in SKBR3/Zeo cells, at basal 
level (Figure 3.14A and Figure 3.14C).  
 
Phosphorylation of ErbB2 at Y1221/1222 couples the receptor to the MAPK 
signalling pathway through binding of Shc, a scaffolding protein which when 
phosphorylated leads to the recruitment of Grb2, an adaptor molecule; and 
SOS, a Ras guanosine nucleotide exchange factor (Alroy and Yarden 
1997;Muthuswamy et al. 1999). Accordingly, we examined the phosphorylation 
pattern of MEK1/2, Erk1/2, p38 and JNK MAPK proteins. Similar to ErbB2 
phosphorylation, we observed that all MAPK proteins listed above were 
phosphorylated at higher basal level in the CD82-overexpressing cells when 
compared to control cells (Figure 3.14A, compare lanes 1 and 6 of 
corresponding blots). In addition to differences in levels of phosphorylated 
proteins at the basal level between control and CD82-overexpressing cells, we 
also observed differences in the phosphorylation kinetics of signalling proteins 
downstream of ErbB2 following heregulin stimulation. Specifically, we found that 
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in SKBR3/Zeo cells, the levels of phosphorylated ErbB2 detected at basal level 
were maintained 2 minutes after stimulation before dephosphorylation by 5 
minutes, to almost undetectable levels (Figure 3.14A). Dephosphorylation was 
maintained 15 minutes post stimulation, but the level of phosphorylated protein 
began to marginally rise again by 30 minutes of stimulation. In contrast, equal 
levels of phosphorylated ErbB2 were detected in SKBR3/CD82High cells after 2 
and 5 minutes of ligand stimulation. Receptor dephosphorylation occurred 
within 15 minutes of stimulation and was maintained by 30 minutes. 
Phosphorylated ErbB2 after 15 and 30 minutes of stimulation was still clearly 
detectable in the SKBR3/CD82High cells compared to SKBR3/Zeo cells (Figure 
3.14A). Notably, the phosphorylation kinetics of activated ErbB2 was 
comparable for both phosphorylation sites Y877 and Y1221/1222 (Figure 3.14A; 
Figures 3.14C and D, top graphs). However, the phosphorylation kinetic pattern 
of activated MAPK proteins was different to that of pErbB2. Stimulation with 
heregulin resulted in a steady increase in the levels of phosphorylated MAPK 
proteins in SKBR3/Zeo cells. In contrast however, the level of phosphorylated 
MAPK proteins remained comparable to the basal levels in SKBR3/CD82High 
cells (Figure 3.14A and D). A representative densitometric plot for the MAPK 
proteins is shown for phosphorylated Erk1/2 (Figure 3.14D, bottom plot). These 
data suggest a possibility of alternative signalling between the control cells and 
CD82-overexpressing cells. In order to ensure that the difference in 
phosphorylation levels observed at basal level in both cell lines was not due to 
changes in total protein expression levels, we also examined the expression 
levels of total proteins under the same conditions. As shown in Figure 3.14E, no 
changes in the expression levels of total proteins were observed between 
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control and CD82-overexpressing cells. Particularly, both cell lines displayed 
comparable levels of total proteins at basal level (Figure 3.14E, compare lanes 
1 and 6).  
 
Analysis of the total tyrosine phosphorylation profile following heregulin 
stimulation revealed a similar pattern of high protein phosphorylation at basal 
level in the CD82-overexpressing cells when compared to control cells (Figure 
3.14F, compare lanes 1 and 6). Of key interest were the bands detected above 
175 kilodaltons (kDa) and at around 60kDa, which could correspond to the ErbB 
receptors (185kDa) and Src family kinases (60kDa) (Figure 3.14F, red arrows).  
 
In order to determine whether the above described increase in phosphorylation 
of ErbB2 and MAPK proteins at basal level observed in the CD82-
overexpressing cells was a result of serum-starvation, we assessed the 
phosphorylation levels of ErbB2 and MAPK proteins in cells maintained under 
complete growth medium without serum starvation. As shown in Figure 3.14G, 
elevated levels of phosphorylated ErbB2, MEK and Erk proteins were detected 
in the CD82-overexpressing cells when compared to that of control cells. These 
findings were thus indicative that the observed phenomenon of CD82-mediated 
increase in phosphorylation of ErbB2 and MAPK proteins was not an artefact of 
serum starvation. 
 
Collectively, these data indicate that whilst ectopic expression of CD82 does not 
affect basal phosphorylation of ErbB3, it does facilitate ligand-induced receptor 
heterodimerisation and thus activation of ErbB3 and its downstream PI3K/Akt 
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pathway. Additionally, we present evidence here suggesting that ectopic 
expression of CD82 in ErbB2-positive breast cancer cells results in elevated 
ErbB2 phosphorylation under both serum-free and normal culture conditions, 
which subsequently leads to activation of Src family kinases and the MAPK 
signalling cascade. These findings thus imply a possible role of CD82 in 
regulating ErbB signalling.  
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Figure 3.14: The effect of CD82 expression on heregulin-induced 
signalling. 
 
SKBR3/Zeo and SKBR3/CD82High cells were seeded on plastic until log phase. 
The cells were serum-starved overnight prior to stimulation with heregulin 
(10ng/ml) for the indicated time intervals. Lysates were collected at the end of 
each time-point and subsequently blotted for the indicated molecules using 
antibodies specific for: (A) phosphorylated proteins; (E) total protein levels; and 
(F) phosphotyrosine. Shown are representative blots from at least three 
independent experiments. (B-D) Summary of protein density ratios determined 
as phosphorylated/total protein from at least three independent experiments. 
Data shown as mean ± standard deviation. Asterisks represent the statistical 
significance as determined by the one-way ANOVA multiple comparison test 
with the Tukey-Kramer post-test, using GraphPad Prism software. Significance 
was set at 0.05, whereby (*P<0.05), (**P<0.01) and (***P<0.001). (G) Blots 
demonstrating the expression levels of phosphorylated ErbB2, MEK and Erk 
proteins from lysates collected from cells cultured in complete growth medium 
without serum starvation. 
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3.3.2 The effects of CD82 expression and Herceptin treatment on ErbB 
signalling 
 
Since the data presented above implied a possible role of CD82 in modulating 
ErbB2 signalling under serum-free and normal culture conditions, we 
investigated this further with a specific aim to determine whether ectopic 
expression of CD82 affected the Herceptin-mediated effect on ErbB2 signalling 
under serum-free conditions. SKBR3/Zeo and SKBR3/CD82High cells were 
serum-starved overnight prior to treatment with Herceptin (10µg/ml) for the 
indicated time intervals. At the end of the incubation period, lysates were 
collected and the phosphorylation pattern of ErbB2 and ErbB3 along with 
various downstream target molecules of the PI3K and MAPK pathways was 
assessed.  
 
Treatment with Herceptin for 30 minutes had minimal effect on ErbB2 
phosphorylation in both cell lines. The level of ErbB2 phosphorylation detected 
after 30 minutes of Herceptin treatment was comparable to that of non-treated 
cells (Figure 3.15A, compare lanes 1 & 2; lanes 5 & 6). On the other hand, 
longer incubations of cells with the drug resulted in a gradual decrease in 
protein phosphorylation levels in a time-dependent manner. Specifically, 
treatment with Herceptin for 1h caused ~50% reduction in phosphorylated 
ErbB2 in both cell lines, which was maintained even after 4h incubation (Figures 
3.15A, compare lanes 3 & 4; 7 & 8). Densitometry analysis is presented in 
Figures 3.15B and C. Notably, ErbB2 phosphorylation at Y877 and Y1221/1222 
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residues displayed a similar kinetic pattern of marginal change to the level of 
protein phosphorylation within 30 minutes of Herceptin treatment, followed by 
dephosphorylation after 1h of treatment. 
 
ErbB2 is the preferred heterodimerisation partner for all ErbB members (Yarden 
and Sliwkowski 2001). The fact that the C-terminal tail of activated ErbB3 
contains six docking sites for p85 regulatory subunit of PI3K, makes it a potent 
receptor for recruiting p85 and thus activation of the PI3K signalling pathway; 
ultimately leading to phosphorylation of Akt. Therefore, formation of 
ErbB2/ErbB3 heterodimers would potently lead to activation of the PI3K 
pathway. One of the proposed mechanisms of action for Herceptin is its ability 
to inhibit PI3K signalling by promoting Akt dephosphorylation through enhanced 
PTEN phosphatase activity (Nagata et al. 2004;Valabrega et al. 2007). Indeed, 
several studies have demonstrated the Herceptin-mediated inhibitory effect on 
PI3K/Akt signalling (Le et al. 2005a;Nagata et al. 2004). In this regard, we 
proceeded with experiments to examine the cellular response of CD82-
overexpressing cells to Herceptin treatment in comparison to control cells by 
use of western blot analysis. In agreement with previously published reports, we 
found that treatment of SKBR3/Zeo and SKBR3/CD82High cells with Herceptin 
resulted in a decline in the levels of phosphorylated ErbB3 in a time-dependent 
manner. Specifically, treatment for 30 minutes had minimal effect on the level of 
phosphorylated ErbB3 in both cell lines (Figure 3.15D; compare lanes 1 & 2; 5 
&6). On the other hand, we found that longer incubation of cells with the drug 
for up to 4h resulted in dephosphorylation of ErbB3 to almost undetectable 
levels (Figures 3.15D and E). Notably, no differences in the amount of 
  Results and Discussion 
 
188 
 
phosphorylated ErbB3 at basal level were observed between SKBR3/Zeo and 
SKBR3/CD82High cells (Figure 3.15D, lanes 1 and 5). Additionally, both cell lines 
responded to Herceptin in a similar manner with comparable kinetics (Figure 
3.15E). 
 
Assessment of the effects of CD82 expression and Herceptin treatment on the 
phosphorylation of Akt revealed similar results to those described above for 
phosphorylated ErbB3. Firstly, we found that ectopic expression of CD82 did 
not affect the phosphorylation of Akt at basal level; since comparable levels of 
phosphorylated Akt were detected in non-treated SKBR3/Zeo and 
SKBR3/CD82High cells (Figure 3.15D, compare lanes 1 and 5). Secondly, 
treatment with Herceptin resulted in a time-dependent inhibition of Akt 
phosphorylation, with a kinetic pattern that was comparable in both control and 
CD82-overexpressing cells (Figures 3.15D and F). The effect of Herceptin on 
Akt phosphorylation was more pronounced 4h after treatment - at least a 60% 
decrease in phosphorylated Akt was observed at this time-point compared to a 
24% reduction observed after 1h treatment in both cell lines (Figure 3.15F).  
 
In addition to PI3K signalling, we also investigated the effects of CD82 and 
Herceptin on MAPK signalling. Consistent with our previously described data, 
we observed higher levels of phosphorylated MAPK proteins in non-treated 
CD82-overexpressing cells when compared to non-treated control cells (Figure 
3.15G, compare lanes 1 and 5). In general, both cell lines had a similar kinetic 
pattern in their response to Herceptin treatment; whereby treatment with 
Herceptin for 30 minutes induced an initial increase in phosphorylation of MAPK 
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proteins that decreased over time. Besides the initial observation of higher 
levels of phosphorylated proteins at basal level in the CD82-overexpressing 
cells when compared to controls, we did not observe any CD82-mediated effect 
on the cellular response to Herceptin between the cell lines, under these 
experimental conditions. Assessment of the effect of Herceptin on protein 
phosphorylation relative to the phosphorylation levels of non-treated cells 
revealed no differences between SKBR3/Zeo and SKBR3/CD82High cells in their 
response to Herceptin under these experimental conditions (Figure 3.15I). 
Although the CD82-overexpressing cells show higher levels of phosphorylated 
proteins when compared to control cells following Herceptin treatment (Figure 
3.15G), further analysis of the data relative to non-treated controls revealed that 
this was in accordance to the initially high basal levels (Figure 3.15I).  
 
Similar results were observed with BT474 cells under the same conditions. 
These experiments revealed a similar CD82-mediated effect of elevated 
phosphorylation of ErbB2 and MAPK proteins at basal level in BT474/CD82High 
cells when compared to BT474/Puro cells. Additionally, treatment with 
Herceptin resulted in Akt dephosphorylation in the BT474 cells, albeit with a 
kinetic pattern different to that observed in SKBR3 cells (Appendix IV, 
Supplementary Figure 4).  
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Figure 3.15: The effects of CD82 expression and short incubations of 
Herceptin on ErbB signalling. 
 
SKBR3/Zeo and SKBR3/CD82High cells in log phase were serum-starved 
overnight prior to treatment with Herceptin (10µg/ml) for the indicated time 
intervals. Lysates were collected at the end of each time-point and 
subsequently blotted for the indicated molecules in order to evaluate: (A) ErbB2 
phosphorylation; (D) PI3K/Akt signalling; and (G) MAPK signalling. (B; C; E; F 
and H) Summary of protein density ratios determined as phosphorylated/total 
protein from three independent experiments. (I) Densitometry ratios of pAkt and 
pErk determined as phosphorylated/total protein, relative to non-treated control. 
Data shown as mean ± standard deviation. Asterisks represent the statistical 
significance as determined by the one-way ANOVA multiple comparison test 
with the Tukey-Kramer post-test, using GraphPad Prism software. Significance 
was set at 0.05, whereby (**P<0.01) and (*** P<0.001). 
  Results and Discussion 
 
196 
 
 
In addition to the short time-course experiments of Herceptin treatment 
described above, analysis of signalling was performed after longer incubations 
of cells with Herceptin (treatment for up to 72h). From these experiments, it was 
clear that the previously described inhibitory effect of Herceptin on Akt 
phosphorylation was maintained for up to 48h of treatment, in both SKBR3/Zeo 
and SKBR3/CD82High cells. However, we observed that by 72h of Herceptin 
treatment the phosphorylation levels of Akt had increased to levels observed at 
baseline in both cell lines (Figures 3.16A and B). In contrast, longer incubations 
of cells with Herceptin had minimal inhibitory effect on MAPK signalling at 24 
and 48h in SKBR3/Zeo cells (Figures 3.16A, C and D). In fact, we observed that 
in the SKBR3/Zeo, but not SKBR3/CD82High cells, prolonged treatment with 
Herceptin resulted in a switch in signalling pathways. Specifically, MAPK 
signalling became more prominent with increased levels of phosphorylated 
MAPK proteins being observed especially at 24 and 48h of Herceptin treatment 
when Akt phosphorylation was significantly inhibited (Figures 3.16A and D). 
Conversely, in the CD82-overexpressing cells, treatment with Herceptin for 
longer incubations resulted in a time-dependent gradual decrease in 
phosphorylation levels of MAPK proteins (Figures 3.16A and D). These data 
thus suggest a CD82-mediated effect of modulating the cellular response to 
prolonged treatment with Herceptin. 
 
These experiments were also performed in BT474/Puro and BT474/CD82High 
cells albeit with somewhat contrasting findings. Specifically, the phosphorylated 
level of Akt after 24h of Herceptin treatment was comparable to that detected at 
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baseline in both cell lines (Appendix IV, Supplementary Figure 5, compare lane 
1 &2; 5 & 6). The Herceptin-mediated Akt dephosphorylation occurred at 48h 
and 72h of treatment. Notably, the switch in signalling pathways from the 
inhibited PI3K to MAPK signalling as observed in the SKBR3/Zeo cells was not 
apparent in BT474 cells. Phosphorylation of MAPK proteins and Akt followed a 
similar kinetic pattern in both BT474/Puro and BT474/CD82High cells (Appendix 
IV, Supplementary Figure 5). 
 
Collectively, these findings further support the notion of a possible role of CD82 
in modulating ErbB signalling that is specific for the MAPK signalling cascade. 
Additionally, these data demonstrate the ability of Herceptin to inhibit not only 
the PI3K/Akt signalling pathway, but also the MAPK signalling cascade. 
  Results and Discussion 
 
198 
 
 
 
 
  Results and Discussion 
 
199 
 
 
 
 
 
  Results and Discussion 
 
200 
 
 
 
Figure 3.16: The effects of CD82 expression and long incubations of 
Herceptin on ErbB signalling. 
 
SKBR3/Zeo and SKBR3/CD82High cells in log phase were serum-starved 
overnight before treatment with Herceptin (10µg/ml) for the indicated time 
intervals. Lysates were collected at the end of each time-point and 
subsequently blotted for the indicated molecules in order to evaluate: (A) 
PI3K/Akt and MAPK signalling. (B and C) Summary of protein density ratios 
determined as phosphorylated/total protein from three independent 
experiments. (D) Densitometry ratios of pAkt and pErk determined as 
phosphorylated/total protein, relative to non-treated control. Data shown as 
mean ± standard deviation. Asterisks represent the statistical significance as 
determined by the one-way ANOVA multiple comparison test with the Tukey-
Kramer post-test, using GraphPad Prism software. Significance was set at 0.05, 
whereby (*** P<0.001). 
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3.3.2.1 The effect of CD82 depletion on the basal levels of 
phosphorylated Erk 
 
In order to verify whether the high basal levels of phosphorylated MAPK 
proteins previously observed in CD82-overexpressing cells was CD82-
dependent; we assessed Erk phosphorylation in CD82-depleted cells under the 
same conditions. ErbB2-positive breast cancer cells depleted in CD82 
(ZR75.30/shCD82) were generated via a lentiviral transduction method using 
lentiviral constructs containing short hairpin RNA (shRNA) that specifically 
targets wild-type CD82 as described in section 2.1.5 of the Materials and 
Methods. Control cell lines (ZR75.30/GFP) expressing an empty vector were 
also generated. Western blot analysis shows that the level of CD82 was 
decreased by at least 80% in ZR75.30/shCD82 cells compared to control cells 
(Figure 3.17A). The cells were serum-starved overnight; and where indicated, 
Herceptin (10µg/ml) was added for the indicated time intervals. Analysis of Erk 
phosphorylation in the CD82-depleted cells revealed no sign of high levels of 
basal phosphorylated Erk that was consistently observed previously in the 
CD82-overexpressing cells. Rather, in three independent experiments, we 
consistently observed comparable levels of phosphorylated Erk at basal level in 
ZR75.30/shCD82 when compared to control cells (Figure 3.17B, compare lanes 
1 and 5). Densitometry analysis is presented in Figure 3.15C. Notably, the 
response to Herceptin of both ZR75.30/GFP and ZR75.30/shCD82 cells was 
comparable. The fact that depletion of CD82 had no effect on the 
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phosphorylation levels of Erk in these cells suggests cell type specific 
mechanisms. 
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Figure 3.17: The effect of CD82 depletion on the basal levels of 
phosphorylated Erk1/2. 
 
ZR75.30/shCD82 cells stably expressing low levels of CD82 were generated by 
lentiviral transduction using lentiviral constructs containing short hairpin RNA 
(shRNA) that specifically target wild-type CD82. (A) Knockdown of CD82 was 
confirmed by western blot analysis from lysates of sorted cells. (B) 
ZR75.30/GFP and ZR75.30/shCD82 cells in log phase were serum-starved 
overnight before treatment with Herceptin (10µg/ml) for the indicated time 
intervals. Lysates were collected at the end of each time-point and 
subsequently blotted for the indicated molecules. (C) Summary of protein 
density ratios determined as phosphorylated/total protein. Shown are 
representative blots from three independent experiments.  
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3.3.3 Suppression of heregulin-induced Ras activation in CD82-
overexpressing cells 
 
Since the data presented above indicate an increase in phosphorylation of 
ErbB2 and MAPK proteins in this model system of CD82-overexpressing breast 
cancer cells, we next examined whether CD82 affected the activity of Ras, a 
small GTPase upstream of the MAPK pathway, but downstream of the ErbB2 
receptor. As outlined in Figures 1.4 and 1.6, MAPK signalling propagates 
extracellular signals upon receptor activation. Ras plays a central role in 
activating several signalling pathways downstream of receptor tyrosine kinases 
including the PI3K and MAPK signalling pathways. We examined the activity of 
Ras in serum-starved and heregulin-stimulated SKBR3/Zeo and 
SKBR3/CD82High cells using a commercially available kit as outlined in the 
Materials and Methods, section 2.3.2. This is a pull-down assay involving the 
use of sepharose beads conjugated with the Ras Binding Domain (RBD) region 
of Raf-1 kinase (Raf-RBD beads). Raf-1 kinase is one of the downstream 
targets of activated Ras and was thus used as an affinity substrate. In parallel to 
the test samples, control samples were also prepared whereby lysates were 
loaded with either a non-hydrolysable GTP analogue, GTPγS or GDP in order 
to activate or inactivate Ras, respectively.  
 
As shown in Figure 3.18A (lanes 2 and 7), comparable levels of active Ras 
were detected in the whole cell lysates of both SKBR3/Zeo and 
SKBR3/CD82High cells. And as expected, pre-loading samples with GTPγS 
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resulted in elevated levels of active Ras. Notably; this was comparable in both 
control and CD82-overexpressing cells (Figure 3.18A, compare lanes 3 and 8). 
Accordingly, pre-loading the samples with GDP resulted in decreased levels of 
active Ras in both cell lines (Figure 3.18A, compare lanes 3 & 4; 8 & 9). 
Surprisingly, comparable levels of active Ras were observed under serum-
starved basal conditions in both control and CD82-overexpressing cells (Figure 
3.18A, lanes 5 & 10; Figure 3.18B, compare the dark blue filled bar with the light 
blue chequered bar). This particular result implies that the previously described 
CD82-mediated effect on MAPK signalling could be downstream of Ras 
proteins. 
 
Interestingly, differences in Ras activity were observed between the cell lines 
upon heregulin stimulation. Significantly (P<0.001) lower levels of active Ras 
were detected in heregulin-stimulated SKBR3/CD82High cells when compared to 
SKBR3/Zeo cells (Figure 3.18A, compare lanes 6 & 11; Figure 3.18B, compare 
the dark blue bar of vertical lines with the line blue bar of horizontal lines). 
Densitometric analysis of the immunoblots revealed at least a 78% decrease in 
Ras activity in SKBR3/CD82High cells upon stimulation with heregulin for 30 
minutes when compared to stimulated control cells (Figure 3.18B). This 
reduction in heregulin-induced Ras activity in the CD82-overexpressing cells 
can be correlated to our previously described results that demonstrated a 
decrease in phosphorylated MAPK proteins in SKBR3/CD82High cells following 
stimulation with heregulin for 30 minutes, compared to control SKBR3/Zeo cells 
(Figure 3.14A, compare lanes 5 & 10).  
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Collectively, these findings imply that the CD82-mediated effect on MAPK 
signalling could be independent of Ras. In addition, these findings also indicate 
a possible dual modulatory role of CD82 in MAPK signalling that is dependent 
on the physiological conditions; a stimulatory role during resting cellular states 
and an inhibitory role in conditions of prolonged ligand stimulation. The fact that 
we observed herein a CD82-mediated increase in ErbB2 and MAPK 
phosphorylation, but no corresponding increase in Ras activity at basal level 
suggests a possibility of CD82 modulating an intermediary molecule that can in 
turn modulate MAPK signalling independent of Ras. 
  Results and Discussion 
 
207 
 
 
 
 
  Results and Discussion 
 
208 
 
 
Figure 3.18: Suppression of heregulin-induced Ras activation in CD82-
overexpressing cells. 
 
SKBR3/Zeo and SKBR3/CD82High cells were serum-starved overnight; and 
where indicated, heregulin (HrG) (10ng/ml) was added for 30 minutes prior to 
lysis. The cells were lysed and assayed for Ras activity using a pull-down 
method involving sepharose beads conjugated with the Ras binding domain of 
Raf-1 kinase as an affinity substrate as described in the Materials and Methods 
under section 2.3.2. Controls included whole cell lysates; histidine-tagged Ras 
(His-Ras); GTPγS- and GDP-loaded lysates for endogenous, active and 
inactive Ras, respectively. (A) Samples were resolved by 12% SDS-PAGE 
under reducing conditions and blotted for active Ras using the anti-pan-Ras 
mAb. (B) Densitometric analysis of active Ras in non-stimulated and heregulin-
stimulated samples for the results shown in (A). A.D.U. = arbitrary densitometry 
units. Shown are representative blots with mean ± standard deviation from four 
independent experiments. Asterisks represent the statistical significance as 
determined by the one-way ANOVA multiple comparison test with the Tukey-
Kramer post-test, using GraphPad Prism software. Significance was set at 0.05, 
whereby (***P<0.001). 
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3.3.4 No interaction was detected between CD82 and kinase suppressor 
of Ras 1 (KSR1) 
 
Since the above described Ras activity data implies that the CD82-mediated 
effect on MAPK signalling could be downstream of the Ras protein, we next 
assessed whether CD82 affected MAPK signalling by modulating KSR1 (kinase 
suppressor of Ras 1). As previously discussed, KSR1 is a scaffold protein that 
binds all three-tier MAPK proteins (Raf-MEK-Erk) of the Erk signalling pathway, 
downstream of Ras. In resting cells, KSR1 is retained in the cytoplasm through 
its association in a multi-protein complex that includes MEK (Figure 1.6). Upon 
Ras activation, KSR1 translocates to the plasma membrane where it interacts 
with Raf thus leading to Erk phosphorylation (Fehrenbacher et al. 2009). 
Specifically, we investigated whether CD82 associated with KSR1 under serum-
free and heregulin-stimulated conditions in transiently transfected cells. SKBR3 
parental cells were co-transfected with HA-KSR1 and non-tagged CD82, 
followed by immunoprecipitation using anti-HA antibodies and blotting for both 
HA and CD82. As shown in Figure 3.19A (lanes 3 and 4), no association 
between KSR1 and CD82 was detected in both non-stimulated and heregulin-
stimulated cells under these experimental conditions. These data indicate that 
CD82 does not affect Ras activity at basal conditions and neither does it directly 
interact with KSR1 under these experimental conditions. These data thus imply 
a possible alternative pathway that differs from the classical linear Ras-Raf-
MEK-Erk signalling pathway in our model system. It is possible that in CD82-
overexpressing cells, MAPK signalling occurs in a manner involving the growth 
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factor receptors, but with a caveat that signal propagation is in part independent 
of Ras. 
 
 
Figure 3.19: No direct association between CD82 and KSR1 was detected. 
 
SKBR3 parental cells were transiently co-transfected with HA-tagged kinase 
suppressor of Ras 1 (HA-KSR1) and non-tagged CD82. The cells were serum-
starved overnight; and where indicated, stimulated with heregulin (10ng/ml) for 
5 minutes. Lysates were subjected to immunoprecipitation with anti-HA 
antibodies and subsequently blotted for the indicated molecules. 
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3.3.5 Suppression of the MEK/Erk pathway leads to alternative MAPK 
signalling 
 
Since the above described data indicated that the CD82-mediated increase in 
phosphorylated MAPK proteins could be downstream of Ras, we next examined 
the point of regulation within the Erk pathway. The aim of these experiments 
was to determine the point at which signalling from the growth factor receptors 
converges with the MAPK signalling cascade, downstream of Ras. As a starting 
point, we looked at targeting the kinase activity of MEK1/2, the MAPKK 
upstream of Erk MAPK, but downstream of Ras. The selective and potent MEK 
inhibitor, U0126 (10µM) was used as described in the Materials and Methods 
under section 2.1.12 followed by assessment of its effects on Erk 
phosphorylation. Initially, a pilot experiment was performed in order to 
determine the optimal time point for the basis of the inhibition assays. Serum-
starved SKBR3/Zeo and SKBR3/CD82High cells were treated with U0126 (10µM) 
for 30 minutes, 1h and 6h followed by western blot analysis for the detection of 
phosphorylated Erk.  
 
As shown in Figure 3.20A, there was complete inhibition of Erk phosphorylation 
in both cell lines, following treatment with U0126. Furthermore, this negative 
effect of U0126 on Erk phosphorylation was evident as early as 30 minutes of 
treatment with the inhibitor (Figure 3.20A, lanes 2 and 6) and was maintained 
even up to 6h of treatment (Figure 3.20A, lanes 4 and 8). Notably, U0126 was 
equally effective at inhibiting Erk phosphorylation in both control and CD82-
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overexpressing cells, thereby abolishing the CD82-mediated increase in basal 
phosphorylation of Erk. Furthermore, U0126 treatment did not affect the 
expression levels of total Erk (Figure 3.20A).  
 
Interestingly, we observed that inhibition of Erk phosphorylation with U0126 for 
30 minutes resulted in an increase in p38 MAPK phosphorylation in both control 
and CD82-overexpressing cells (Figure 3.20A, compare lanes 1 and 2; 5 and 
6). However, this U0126-mediated induction of p38 MAPK signalling was time 
dependent, as it was abolished by 1h of treatment (Figure 3.20A, lanes 3 and 
7). Furthermore, the levels of phosphorylated p38 MAPK returned back to 
baseline levels by 6h treatment with U0126 (Figure 3.20A; compare lanes 1 and 
4; 5 and 8). This U0126-mediated effect on the phosphorylation kinetics of p38 
MAPK was confirmed by densitometric analysis of the blots (Figure 3.20B). 
Since treatment with U0126 for 30 minutes was sufficient to inhibit Erk 
phosphorylation whilst affecting the p38 MAPK signalling pathway, this time 
point was thus adopted for the subsequent inhibition assays. 
 
Further to the observation in the pilot experiment that inhibition of the Erk 
pathway with U0126 for 30 minutes led to elevated p38 MAPK phosphorylation, 
we next used these conditions to determine whether this compound affected 
any other MAPK signalling pathways. From these experiments, we were able to 
confirm that indeed treatment of cells with U0126 for 30 minutes resulted in a 
significant (P<0.01) increase in phosphorylation of p38 MAPK in both control 
and CD82-overexpressing cells (Figure 3.20C, lanes 2 and 4; Figure 3.20D). In 
addition, we observed that the p38 MAPK pathway was not the only MAPK 
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pathway affected; since a similar effect was observed for the JNK signalling 
pathway (Figure 3.20C). These observations were confirmed by densitometric 
analysis of the blots from two independent experiments (Figures 3.20D and E). 
Notably, there was no indication of any CD82-mediated effect on the cellular 
response to the MEK1/2 inhibitor, since both control and CD82-overexpressing 
cells responded similarly to U0126 treatment.   
 
Collectively, these data are indicative that the CD82-mediated effect on Erk 
phosphorylation at basal level is not due to a direct effect on Erk1/2, but is 
rather localised to a target(s) upstream of Erk1/2. These data also further 
supports the notion that the regulatory target for the CD82-mediated effect on 
Erk phosphorylation is downstream of Ras. The fact that inhibition of the Erk 
pathway induced p38 and JNK MAPK signalling further demonstrates crosstalk 
between the MAPK signalling pathways. 
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Figure 3.20: Suppression of the MEK/Erk pathway with U0126 leads to 
alternative MAPK signalling. 
 
SKBR3/Zeo and SKBR3/CD82High cells in log phase were serum-starved 
overnight prior to the assay. The next day, the cells were treated with the 
MEK1/2 inhibitor, U0126 (10µM) for (A) 30 minutes, 1h and 4h at 37oC, 5% 
CO2. (C) The cells were treated with U0126 for 30 minutes followed by western 
blot analysis. U0126 was prepared in dimethyl sulfoxide (DMSO) as a 10mM 
stock solution and was diluted in serum-free medium to a working concentration 
of 10µM prior to use. DMSO diluted in serum-free medium to the same solvent 
concentration as in the inhibitor preparations was added to the inhibitor-free 
controls. At the end of the incubation period, the cells were lysed. Lysates of 
equal protein concentration were subjected to SDS-PAGE under reducing 
conditions followed by western blot analysis for the detection of the indicated 
molecules. (B, D and E) Densitometric analysis of the blots; A.D.U. = arbitrary 
densitometry units. Shown are representative blots with mean ± standard 
deviation from two independent experiments. Asterisks represent the statistical 
significance as determined by the one-way ANOVA multiple comparison test 
with the Tukey-Kramer post-test, using GraphPad Prism software. Significance 
was set at 0.05, whereby (*P<0.05) and (**P<0.01). ns – not significant. 
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3.3.6 Discussion 
 
Having demonstrated that ectopic expression of CD82 and Herceptin treatment 
resulted in changes in the membrane distribution of ErbB2, we next investigated 
the effects of CD82 expression and Herceptin treatment on ErbB signalling 
under various experimental conditions. We assessed the impact of CD82 
expression on the phosphorylation of ErbB receptors and signalling molecules 
of the PI3K and MAPK pathways in heregulin stimulated and non-stimulated 
cells. From these experiments we found that ectopic expression of CD82 did not 
affect the basal phosphorylation levels of ErbB3. Our data demonstrate that 
both control and CD82-overexpressing cells had similar levels of activated 
ErbB3 at basal level. However, differences were observed between the cell 
lines in the kinetic pattern of ErbB3 phosphorylation upon stimulation with 
heregulin. Specifically, the highest levels of phosphorylated ErbB3 were 
observed at 5 minutes following heregulin stimulation in the control cells 
compared to 2 minutes in the CD82-overexpressing cells. These data suggest 
that CD82 could have a role in modulating the formation of heregulin-induced 
ErbB3 heterodimers leading to receptor activation. It should be noted that 
ErbB3 has a defective kinase domain, whereby its activation occurs as a result 
of heterodimerisation with other ErbB receptors, induced by ligand binding 
(Olayioye et al. 2000;Roskoski, Jr. 2004). Since SKBR3 cells also express 
EGFR and ErbB2, it is possible that ectopic expression of CD82 facilitates rapid 
heterodimerisation of ErbB3 with either EGFR and/or ErbB2 upon ligand 
stimulation. However, in view of the fact that ErbB2 is reported to be the 
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preferred heterodimerisation partner for members of the EGFR family (Hynes 
and Lane 2005), it is thus possible that the ligand-induced phosphorylation of 
ErbB3 is due to ErbB2/ErbB3 heterodimers under these experimental 
conditions.  
 
The observation, that CD82 appears to have a modulatory role in facilitating 
heregulin-induced ErbB3 phosphorylation and thus its heterodimerisation in our 
model system of breast cancer cells is an interesting observation. An earlier 
report by Odintsova and colleagues using another model system of breast 
cancer cell lines (MCF-7) in which CD82 was overexpressed, it was 
demonstrated that CD82 did not affect ErbB2/ErbB3 heterodimerisation in cells 
stimulated with heregulin (Odintsova et al. 2003). It should be noted that MCF-7 
cells express low levels of ErbB2 (Kao et al. 2009), whilst we have 
demonstrated herein that SKBR3 cells overexpress the ErbB2 receptor. 
Therefore, our findings herein and in conjunction with the observations by 
Odintsova and colleagues thus imply that CD82 modulates ErbB receptor 
dimerisation based on the expression status of ErbB2, whereby it facilitates 
ligand-induced ErbB2/ErbB3 heterodimerisation in cells overexpressing ErbB2. 
Interestingly, in the same study by Odintsova and colleagues, the authors also 
demonstrated that CD82 negatively affected ligand-induced EGFR/ErbB2 
heterodimerisation in cells expressing comparable levels of EGFR, ErbB2 and 
ErbB3 (Odintsova et al. 2003).  
 
The C-terminal tail of activated ErbB3 contains six docking sites for p85 
regulatory subunit of PI3K, thereby making it a potent receptor for recruiting p85 
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and thus activation of the PI3K signalling pathway; ultimately leading to 
phosphorylation of Akt. In this regard, we assessed the phosphorylation pattern 
of Akt in both control and CD82-overexpressing cells. We found that 
phosphorylated Akt followed the same kinetic pattern as that described of 
activated ErbB3 upon heregulin stimulation. Similarly, CD82 expression did not 
affect Akt phosphorylation at basal level, as both control and CD82-
overexpressing cells had comparable baseline levels of phosphorylated Akt.  
 
On the other hand, assessment of the impact of CD82 expression and heregulin 
stimulation on ErbB2 activity not only revealed that this receptor is highly 
constitutively active in SKBR3 and BT474 cells, but also revealed some novel 
findings that implicate CD82 in the regulation of ErbB2. We found that ectopic 
expression of CD82 resulted in enhanced ErbB2 phosphorylation at Y877 and 
Y1221/1222 sites. Stimulation with heregulin resulted in a gradual 
dephosphorylation of ErbB2. However, we observed that the rate of ErbB2 
dephosphorylation was slower in the CD82-overexpressing cells when 
compared to control cells, thus suggesting implications on downstream 
signalling.  
 
Y877 is localised in the kinase domain of ErbB2 and is homologous to Y416 of 
Src. Phosphorylation of ErbB2 at this site couples the receptor to Src and its 
downstream targets including focal adhesion kinase (FAK) and the pro-
migratory p130CAS-CrkII complex (Cabodi et al. 2010;Muthuswamy et al. 1999). 
Our data demonstrate high Src activity correlating with ErbB2 (Y877) 
phosphorylation, particularly in the CD82-overexpressing cells when compared 
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to control cells. Furthermore, analysis of tyrosine phosphorylation supported the 
CD82-mediated effect on ErbB2 phosphorylation. These data also revealed two 
additional protein mobility masses (130kDa and 60kDa) whereby differences 
between control and CD82-overexpressing cells were observed. A 
phosphotyrosine mobility mass of 60kDa could correspond to Src family 
kinases; whilst a mobility mass of 130kDa could correspond to several proteins 
including FAK and p130CAS. These observations indicate that ectopic 
expression of CD82 not only modulates ErbB2 phosphorylation, but also key 
downstream signalling molecules such as Src, with ultimate implications on cell 
migration. Hence, these observations imply a higher migratory potential of 
CD82-overexpressing cells compared to control cells. However, work by others 
and our previously described data herein demonstrated that CD82 strongly 
suppressed cell migration and invasion in the CD82-overexpressing cells when 
compared to controls. In fact, it has been previously proposed that CD82 
suppresses migration by downregulating the expression levels of p130CAS, 
consequently inhibiting the formation of the pro-migratory p130CAS-CrkII 
complex and thus inhibiting cell migration (Zhang et al. 2003a). At this stage, 
the mechanism by which CD82 suppresses migration and invasion in our model 
system of SKBR3 cells is unclear. The fact that ectopic expression of CD82 in 
these cells results in suppression of cell migration even though CD82 
overexpression also resulted in increased phosphorylation of various molecules 
implicated in cell motility, including Src, suggests an alternative mechanism(s). 
In addition to the adhesion-dependent signalling, Src can also modulate other 
signalling pathways including the MAPK pathway (Olayioye et al. 2001).  
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Phosphorylation of ErbB2 at Y1221/1222 autophosphorylation site couples the 
receptor to the MAPK signalling pathway through binding of Shc, a scaffolding 
protein which when phosphorylated leads to the recruitment of effector 
molecules such as Grb2 and SOS (Alroy and Yarden 1997;Muthuswamy et al. 
1999). Accordingly, we found that ErbB2 phosphorylation at Y1221/1222 
correlated with the phosphorylation of MAPK proteins, particularly at basal level. 
The CD82-mediated increase in ErbB2 phosphorylation at basal level was also 
observed for phosphorylated MAPK proteins.  
 
The fact that ectopic expression of CD82 specifically affected the basal 
phosphorylation levels of only the ErbB2 receptor and its downstream signalling 
pathways and that it was not also observed for the ErbB3 receptor or the PI3K 
pathway, implies that the proportion of ErbB2 modulated by CD82 is not in a 
heterodimer complex with ErbB3. Since SKBR3 and BT474 cells express EGFR 
in addition of ErbB2 and ErbB3, it is possible that the CD82-mediated effect on 
ErbB2 and its downstream signalling is a result of modulating homodimerisation 
or the formation of a heterodimer with EGFR. This notion is further supported by 
our observations that control cells and CD82-overexpressing cells responded 
differently to heregulin stimulation. Specifically, control cells responded 
positively to heregulin stimulation as represented by an increase in protein 
phosphorylation. However in the CD82-overexpressing cells, the 
phosphorylation levels of MAPK proteins remained similar to the baseline levels 
even in the presence of heregulin stimulation. This was particularly observed for 
the MAPK proteins affected by the ectopic expression of CD82, namely MEK, 
Erk and p38. These data imply that the compartmentalisation and possibly the 
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dimers from which MAPK signalling is emanating are different between control 
cells and CD82-overexpressing cells. It is feasible that CD82-enriched 
microdomains facilitate various associations of the ErbB receptors, thereby 
modulating downstream signalling pathways. Indeed, our data presented herein 
and reports from others (Danglot et al. 2010;Odintsova et al. 2003;Odintsova et 
al. 2006) have demonstrated the importance of the membrane 
compartmentalisation of ErbB receptors for the CD82-mediated regulation of 
their activity. We have also demonstrated that the proportion of ErbB2 
distributed within these microdomains is increased by Herceptin treatment. 
Together, these findings suggest that ectopic expression of CD82 (and to some 
extent Herceptin treatment) induces clustering of ErbB receptors, particularly 
ErbB2 and possibly EGFR, thereby facilitating the activation of alternative 
signalling pathways, such as Src and MAPK signalling.  
 
Since the CD82-mediated effect on ErbB2 signalling at basal level was more 
pronounced in lysates from serum-starved cells than from cells maintained in 
complete medium, it is conceivable that in non-stimulated CD82-overexpressing 
cells, the proportion of ErbB2 redistributed to the CD82-enriched microdomains 
is higher; and/or that the ErbB2/ErbB2 and ErbB2/EGFR associations are 
enhanced in serum-free conditions. Conversely, it is possible that stimulation or 
serum conditions decrease the proportion of ErbB2 in these microdomains 
and/or disperse the homo-associations and ErbB2/EGFR hetero-associations. 
This is supported by data in the literature demonstrating that ErbB2 and EGFR 
interact in non-stimulated and stimulated cells (Milani et al. 2007;Yang et al. 
2007); furthermore, that the proportion of EGFR distributed in lipid rafts is higher 
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in non-stimulated cells than in stimulated cells (Sottocornola et al. 2006). 
Moreover, our data herein with heregulin stimulation suggest a possible role of 
CD82 in facilitating ErbB2/ErbB3 heterodimerisation upon ligand stimulation.  
 
Based on the observation of an increase in phosphorylation of ErbB2 and 
MAPK proteins in our model system of CD82-overexpressing breast cancer 
cells, we next examined whether CD82 affected the activity of Ras, a small 
GTPase upstream of the MAPK pathway, but is downstream of the ErbB 
receptors. Ras activity was assessed in heregulin-stimulated and non-
stimulated cells. We found no evidence of ectopic CD82 expression affecting 
Ras activity in non-stimulated cells, since comparable levels of active Ras were 
detected in non-stimulated control and CD82-overexpressing cells. This 
observation implies that the point at which CD82 regulates MAPK signalling 
could be downstream of the Ras proteins. This was later investigated further as 
discussed below. From these experiments, we also observed that heregulin-
induced Ras activation was suppressed in the SKBR3/CD82High cells when 
compared to SKBR3/Zeo cells. In control experiments whereby cell lysates 
were loaded with a non-hydrolysable GTP analogue (GTPγS), comparable 
levels of active Ras were detected in both SKBR3/Zeo and SKBR3/CD82High 
cells (Figure 3.18A, lanes 3 and 8). However in samples stimulated with 
heregulin, the level of active Ras detected in SKBR3/CD82High cells was 
significantly lower when compared to that in SKBR3/Zeo cells (Figure 3.18A, 
compare lanes 6 and 11). These data imply a possibility that the GTPase 
activity of Ras proteins is elevated in the CD82-overexpressing cells than in 
control cells under these experimental conditions. The activation state of Ras is 
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tightly controlled partly by its intrinsic GTPase activity through the action of 
GTPase activating proteins (GAPs), which increase the catalytic activity of Ras 
to hydrolyse and thus revert from the GTP-bound active state to the inactive 
GDP-bound state (Ahearn et al. 2012;Fehrenbacher et al. 2009). It is possible 
that this process is enhanced in CD82-overexpressing cells after prolonged 
ligand stimulation, whereby ligand-induced GTP bound to Ras is more readily 
hydrolysed in these cells than in control cells. 
 
The effect of CD82 on the activation of small GTPase proteins has previously 
been demonstrated (Delaguillaumie et al. 2002;Takahashi et al. 2007). 
Specifically, a study by Takahashi and colleagues demonstrated that ectopic 
expression of CD82 in a non-small cell lung carcinoma cell line resulted in 
inhibition of ligand-induced Ras activation, which was specific for c-Met 
signalling following stimulation with hepatocyte growth factor (HGF) (Takahashi 
et al. 2007). Moreover, CD82 is not the only tetraspanin to be implicated in Ras 
activation. Indeed, a study by Sawada and colleagues previously demonstrated 
that expression of tetraspanin CD151 specifically attenuated the adhesion-
dependent activation of Ras and diminished the activation of downstream 
signalling molecules, namely Erk1/2 and Akt (Sawada et al. 2003). Furthermore, 
the authors in that study proposed that the CD151-mediated negative effect on 
Ras activation was indicative of low levels of GTP-bound active Ras (Sawada et 
al. 2003). Based on the data presented herein and the reports described above, 
it is clear that tetraspanins are capable of influencing signalling pathways at 
various stages of a signalling cascade including regulation of the receptors and 
downstream signalling molecules.  
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Scaffold proteins regulate MAPK signalling by mediating the structural and 
functional organisation of the three-tier MAPK module (Dhanasekaran et al. 
2007;Sacks 2006). Kinase suppressor of Ras 1 (KSR1) is one of the scaffold 
proteins that regulate Erk signalling. It binds all three-tier MAPK proteins (Raf-
MEK-Erk) of the Erk signalling pathway, downstream of Ras. Since the above 
described data implied that the CD82-mediated effect on MAPK signalling is 
likely to be downstream of the Ras proteins, we next assessed whether CD82 
affected MAPK signalling by modulating KSR1. Specifically, we examined 
whether CD82 associated with KSR1 by use of immunoprecipitation. From 
these experiments however, we were unable to detect any possible 
CD82/KSR1 interaction in our experimental conditions. However, these findings 
do not rule out the possibility of CD82 modulating KSR1 or indeed other scaffold 
proteins. It is possible that although CD82 and KSR1 do not interact directly, 
they could still be localised within the same complex or compartment. Moreover, 
we have demonstrated herein that CD82 associates with ErbB2. Although the 
association of ErbB2 and KSR1 has not yet been reported in literature to date, it 
is feasible that these two molecules could interact or colocalise; and in such a 
case, CD82 could then modulate MAPK signalling via this interaction. Indeed, 
the association of ErbB2 and another MAPK scaffold has previously been 
demonstrated, resulting in modulation of MAPK signalling. A recent study by 
White and colleagues demonstrated that scaffold protein IQGAP1 is 
overexpressed in ErbB2-positive breast cancer tissue and Herceptin-resistant 
breast cancer cells. These authors further demonstrated that IQGAP1 directly 
associated with ErbB2 thereby regulating its expression, phosphorylation and 
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signalling. They showed that knocking down of IQGAP1 resulted in decreased 
expression and phosphorylation of ErbB2 in addition to decreased 
phosphorylation of downstream signalling molecules, including Akt and Erk 
(White et al. 2011). It would thus be interesting to determine whether ErbB2 
associated with KSR1, particularly in the CD82-overexpressing cells. 
 
In an effort to determine the point at which signalling from the growth factor 
receptors converges with the MAPK signalling cascade, downstream of Ras, we 
proceeded by assessing the effect of targeting MEK, the MAPKK which is 
downstream of Ras, but upstream of Erk. A previously described (Favata et al. 
1998) selective and potent MEK inhibitor, U0126 was used in these assays. 
This compound has previously been shown to be selective at inhibiting the 
kinase activity of MEK without affecting the kinase activity of other kinases 
(Favata et al. 1998). From these experiments, we found that U0126 completely 
inhibited Erk phosphorylation in both control and CD82-overexpressing cells. 
The inhibitory effect of U0126 was evident as early as 30 minutes of treatment 
and was maintained by up to 6h of treatment with the inhibitor in both cell lines. 
The fact that U0126 was effective at abolishing Erk phosphorylation in both 
control and CD82-overexpressing cells is indicative that our previous 
observations of increased Erk phosphorylation in the CD82-overexpressing 
cells are not a result of direct modulation of Erk, but rather of upstream targets, 
possibly MEK. These findings thus suggest that the CD82-mediated point of 
regulation in the MAPK signalling cascade in this model system is localised in 
the region between the receptor level and MEK, but downstream or 
independent of the Ras proteins.  
  Results and Discussion 
 
228 
 
 
Interestingly, we also observed that Erk inhibition with U0126 resulted in a time-
dependent activation of p38 MAPK in both control and CD82-overexpressing 
cells. Treatment with U0126 for 30 minutes resulted in elevated levels of p38 
followed by dephosphorylation at 1h and subsequently returning back to 
baseline levels by 6h of treatment (Figure 3.20A). A similar effect was observed 
with JNK phosphorylation following 30 minutes of treatment with U0126 in both 
control and CD82-overexpressing cells. The p38 and JNK signalling pathways 
can be activated by cellular stress (Roberts and Der 2007). Thus these data 
suggest that treatment with U0126 for short incubations such as 30 minutes 
could induce cellular stress, which in turn would lead to activation of p38 and 
JNK signalling pathways. This could ultimately lead to cell death. Indeed, a 
previous study by Monick and colleagues demonstrated that inhibition of 
constitutive Erk activity with U0126 resulted in a rapid loss of mitochondrial 
membrane potential and a decrease in ATP levels. These authors also found 
that prolonged inhibition of Erk subsequently led to cell death (Monick et al. 
2008). It would thus be interesting to determine whether treatment with U0126 
induces apoptosis in our model system. 
 
Whilst the data presented herein are intriguing, we were not able to identify the 
point at which the signal converges with the MAPK signalling cascade. At this 
point, it is not yet clear whether MEK is the point of regulation or indeed Raf, 
which is upstream of MEK, but downstream of Ras. A detailed assessment into 
the effects of targeting Raf is required in order to identify the key players in the 
CD82-mediated effect on MAPK signalling. This could be approached by the 
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use of Raf inhibitors such as vemurafanib (a B-Raf inhibitor), sorafenib (a C-Raf 
inhibitor) or RAF265 (a pan-Raf inhibitor) followed by analysis of effects on 
downstream signalling in both control and CD82-overexpressing cells. Such 
studies would not only determine whether CD82 overexpression affects Raf, but 
would also identify which Raf isoform(s) (if any) is affected. 
 
It is possible that the point of convergence is at the level of Raf, whereby Src 
family kinases serve as a link between the activated receptors and the MAPK 
signalling cascade, possibly at the level of Raf. Indeed, Src has previously been 
implicated in MAPK signalling. A study by Olayioye and colleagues using two 
breast cancer cell lines, including SKBR3 cells demonstrated the sensitivity of 
Erk activation to Src inhibition; whereby treatment of cells with the c-Src 
tyrosine kinase inhibitor (CPG77675) resulted in complete inhibition of Erk 
activation (Olayioye et al. 2001). In addition to observing a constitutive 
association of Src and Shc, these authors also demonstrated that in the 
presence of the Src inhibitor, ligand-induced Shc phosphorylation and the Shc-
Grb2 interaction was reduced. Interestingly, these authors found that in cells 
stimulated with high levels of ligand, Erk activation was not sensitive to Src 
inhibition (Olayioye et al. 2001). This study demonstrates that Src is able to 
influence MAPK signalling at the receptor level and their findings suggest that 
Src could play an important role in activating this signalling cascade under low 
levels of ligand. Moreover, the ability of Src to influence MAPK signalling 
through other downstream targets has also previously been demonstrated by 
several studies. Specifically, earlier studies demonstrated the involvement of 
Src in Raf phosphorylation; whereby it was shown that both Ras and Src activity 
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were required for the maximal activation of Raf-1 and A-Raf, whilst the 
activation of B-Raf required only Ras (Fabian et al. 1993;Marais et al. 
1995;Marais et al. 1997;Mason et al. 1999;Tran and Frost 2003).  
 
In addition to Src directly phosphorylating Raf, it can also indirectly influence 
MAPK signalling via protein kinase C (PKC), a family of serine/threonine 
kinases. A study by Tan and colleagues demonstrated that Src kinase activity 
played a critical role in the ErbB2-mediated upregulation and activation of PKCα 
(Tan et al. 2006). Moreover, an isotype of PKC (PKCδ) has previously been 
shown to activate the MAPK pathway in a manner that was independent of the 
Ras protein, but dependent on Raf (Ueda et al. 1996). Furthermore, the classic 
isoforms of PKC (α, β and γ) have previously been implicated in the induction of 
CD82 transcription in a manner that was independent of Ras, but required the 
activation of MEK1/2 and Erk1/2 (Rowe et al. 2008). These pathways are 
summarised in Figure 3.21. It would thus be interesting to determine whether 
Src and/or PKC family kinases are involved in the CD82-mediated effect on 
MAPK signalling in our model system and to identify which isoforms are 
involved. 
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Figure 3.21: Summary of the proposed CD82-mediated influence on MAPK 
signalling. 
 
Ectopic expression of CD82 results in an increase in basal levels of 
phosphorylated ErbB2, Src and MAPK proteins. Under conditions of low ligand 
levels, the MAPK pathway is likely to be activated independently of the Ras 
proteins but involving Src family kinases and/or protein kinase C. Under 
conditions of excess ligand, MAPK signalling is likely to be dependent of the 
Ras proteins. Data presented herein implies a possible dual modulatory role of 
CD82 on MAPK signalling that is dependent on the conditions: a stimulatory 
role during conditions of low ligand levels; and an inhibitory role in conditions of 
excess ligand. 
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The notion that a Src family kinase(s) could be the link between the receptors 
and Raf, is supported by our own observations presented herein showing a 
basal increase in pan-Src phosphorylation (Y416) in the CD82-overexpressing 
cells when compared to controls, similar to that observed for phosphorylated 
ErbB2 and MAPK proteins (Figure 3.14). This is an interesting observation 
since Src activation has recently been implicated in Herceptin resistance 
(Zhang et al. 2011). By using a model system of ErbB2-positive breast cancer 
cells that had developed resistance to Herceptin, Zhang and colleagues 
demonstrated a resistant phenotype that differed from the parental cells, 
whereby the resistant cell lines prominently expressed high levels of EGFR, 
ErbB3 and IGF-1R which correlated with increased Src phosphorylation at Y416 
(Zhang et al. 2011). In addition, these authors demonstrated that increased Src 
activity was sufficient to confer Herceptin resistance; and that inhibition of Src 
activity effectively blocked receptor activation and downstream signalling. 
Furthermore, these authors demonstrated that Src inhibition sensitised 
Herceptin-resistant cells to Herceptin (Zhang et al. 2011). This study by Zhang 
highlights the key role played by Src in modulating Herceptin response. Indeed, 
identifying Src as one of the central modulators of Herceptin response can offer 
some explanation to some of our observations presented herein. It is possible 
that the poor response to Herceptin observed in the CD82-overexpressing cells 
is due to increased Src activity in these cells. Thus response to Herceptin in 
these cells could be improved by the use of Src inhibitors. Moreover, we have 
demonstrated herein that Erk activation in both control and particularly in CD82-
overexpressing cells was sensitive to MEK inhibition. This is indicative that 
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targeting other signalling molecules within key pathways in conjunction with 
Herceptin could be an effective approach to improve the cellular response to 
Herceptin. Indeed, this approach has recently been demonstrated in the 
literature (Ferguson et al. 2012;Lu et al. 2007;Zhang et al. 2011;Zhang and Yu 
2012). 
 
Collectively, the data presented here demonstrate that CD82 modulates ErbB2 
phosphorylation leading to activation of downstream signalling, particularly the 
MAPK signalling pathway. Additionally, the point at which CD82 modulates 
MAPK signalling is likely to be independent of Ras proteins.  
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4 GENERAL DISCUSSION AND FUTURE WORK 
 
In this study we have endeavoured to determine the role of tetraspanin CD82 in 
Herceptin-mediated cellular responses. Our findings have identified several 
avenues in need of further investigation in order to fully understand the 
contribution of CD82 in the efficacy of Herceptin in ErbB2-overexpressing cells. 
Firstly, our data demonstrate that ectopic expression of CD82 resulted in a poor 
response to Herceptin treatment. Specifically, the antiproliferative effect of 
Herceptin was observed in control cells when cultured in various 3D 
extracellular matrices, whilst the CD82-overexpressing cells, in particular the 
BT474/CD82High cells showed resistance to Herceptin in these culture 
conditions. Thus these data suggest that CD82 and components of the 
extracellular matrix (ECM) may indeed cooperate in regulating sensitivity of 
cells to Herceptin treatment. Integrins are important receptors for specific 
components of ECM used in 3D culturing experiments; for example integrins 
α2β1 (collagen I) and α6β1/α6β4 for laminin-1, a component of Matrigel. BT474 
cells express higher levels of these integrins compared to SKBR3 cells. The fact 
that a higher level of resistance to Herceptin was observed in the 
BT474/CD82High cells suggests a functional relationship between CD82 and 
these integrin receptors in mediating the response to Herceptin. Thus, 
functional studies involving cells cultured on various ECM matrices and 
knockdown experiments would be valuable in verifying the roles of these 
proteins and CD82 in the cellular response to Herceptin. In this respect, a 
recent study by Yang and colleagues demonstrated the involvement of 
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tetraspanin CD151 and ECM proteins in regulating sensitivity of cells to 
Herceptin. In this study, the authors demonstrated that ErbB2-positive breast 
cancer cells were resistant to Herceptin when cultured on laminin-5 and that 
knockdown of CD151 and the laminin-binding integrins restored Herceptin 
sensitivity (Yang et al. 2010). Similar studies could be applied to our CD82 
model system in order to identify the ECM molecules involved in the CD82-
mediated effect on Herceptin sensitivity. 
 
Secondly, we show here that expression of CD82 results in changes in the 
compartmentalisation of ErbB2 whereby the receptor is redistributed to light 
gradient fractions; and that treatment with Herceptin increased the amount of 
ErbB2 redistributed in these fractions. This effect of Herceptin was obvious in 
CD82-overexpressing cells but not in control cells; however the significance of 
CD82-mediated redistribution of ErbB2 to these microdomains and thus 
implications on the efficacy of Herceptin remains to be elucidated. Several 
studies have previously demonstrated the importance of gangliosides in the 
function of CD82 (Odintsova et al. 2003;Odintsova et al. 2006;Todeschini et al. 
2007). For example, the report by Odintsova and colleagues demonstrated a 
correlation of CD82 expression levels and gangliosides, whereby they found 
that ectopic expression of CD82 resulted in an increase in surface expression of 
gangliosides GD1a and GM1 which correlated with the redistribution of EGFR 
and ErbB2 on the plasma membrane (Odintsova et al. 2003;Odintsova et al. 
2006). The same group also reported the importance of gangliosides in 
regulating the stability and organisation of CD82-enriched microdomains by 
demonstrating that depletion of gangliosides led to a decrease in CD82 protein-
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protein interactions and also caused a redistribution of CD82-associated 
proteins (Odintsova et al. 2006). Moreover, a study by Sottocornola and 
colleagues investigated the role of gangliosides in the association of ErbB2 with 
lipid rafts; specifically, they demonstrated that ErbB2 co-localised with 
ganglioside GM3 and that depletion of gangliosides led to redistribution of 
ErbB2 into detergent-soluble high density sucrose gradient fractions. These 
authors also found that although GM3 was important for the localisation of 
ErbB2 into lipid rafts in their model system, it did not affect the phosphorylation 
of the receptor (Sottocornola et al. 2006). In regard to all these reports and our 
current data, it is clear that CD82 plays a role in the distribution of ErbB2 into 
light gradient fractions and also that gangliosides are important for the 
localisation of ErbB2 into these microdomains. However, it remains to be 
verified as to which ganglioside(s) is (are) important for the CD82-mediated 
compartmentalisation of ErbB2 to these microdomains and also the effects of 
this distribution on the efficacy of Herceptin. Thus, further studies are required 
to clarify these issues, using the current knowledge in the literature as a starting 
point. 
 
Thirdly, our data demonstrate for the first time that ectopic expression of CD82 
results in an increase in ErbB2-mediated MAPK signalling without affecting the 
PI3K pathway. As an initial step towards elucidating the mechanism(s) by which 
CD82 exerts this effect, we investigated whether the expression of CD82 
affected Ras activity, a small GTPase upstream of the MAPK pathway; and 
whether CD82 affected the assembly of the three-tier MAPK proteins, by 
assessing its possible interaction with KSR1, a scaffold protein that binds all 
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three MAPK proteins (Raf-MEK-Erk). However, we found that expression of 
CD82 did not affect Ras activity; and no interaction was observed between 
CD82 and KSR1 under our experimental conditions, thus implying that the point 
at which CD82 modulates MAPK signalling could be independent of Ras. 
Further studies are therefore required in order to determine whether expression 
of CD82 affects the recruitment of signalling molecules to the activated receptor 
that can couple the receptor to the MAPK signalling cascade. Since we 
observed CD82-mediated changes to the phosphorylation of ErbB2 in particular 
at Y1221/1222 phosphorylation site that couples the receptor to the MAPK 
pathway, we propose that the recruitment of adaptor proteins Shc and Grb2 to 
this site should be investigated, as a starting point. 
 
In addition, we found that expression of CD82 affected phosphorylation of 
ErbB2 at another site, Y877 which couples the receptor to Src-mediated 
signalling. As we have discussed in the previous section, Src family kinases 
influence several signalling pathways including the MAPK signalling pathway; 
and they have been reported to play a critical role in modulating resistance to 
Herceptin. In view of the facts that we observed an increase in Src 
phosphorylation (using a pan-Src antibody) in the CD82-overexpressing cells 
and that we consistently observed a poor response to Herceptin in CD82-
overexpressing cells, it would be interesting to investigate the impact of 
targeting the activity of members of the Src family kinases on downstream 
signalling and also how this would affect the response of CD82-overexpressing 
cells to Herceptin treatment. This could be approached by the use of inhibitors 
such as saracatinib (a c-Src inhibitor); dasatinib (a pan-Src kinase inhibitor) or 
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indeed by the use of siRNA targeted against specific members of the Src family 
kinases. This would be useful to identify the family member(s) influenced by 
CD82 expression. 
 
Finally, in view of the fact that ectopic expression of CD82 correlated with 
enhanced ErbB2 phosphorylation and MAPK activation, it would be interesting 
to investigate the biological significance of this by determining whether ectopic 
expression of CD82 sensitises ErbB2-positive breast cancer cells to other 
ErbB2-targeted therapies such as Lapatinib, a tyrosine kinase inhibitor that 
targets the kinase activity of both EGFR and ErbB2. Results from such 
experiments, together with our current findings could be the building blocks in 
verifying whether tetraspanin CD82 could be a possible biomarker in identifying 
breast cancer patients with ErbB2-positive disease that could benefit or respond 
better to ErbB2-targeted therapies including Herceptin. 
 
In conclusion, the data presented here demonstrate that CD82 modulates the 
cellular response of ErbB2-positive breast cancer cells to Herceptin treatment 
by regulating not only the distribution of the ErbB2 receptor, but also its 
phosphorylation and activation of downstream signalling pathways, particularly 
the MAPK pathway. 
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5 APPENDICES 
 
5.1 Appendix I: Cell culture media and supplements 
 
 
BT474 
 
RPMI 1640 
10% HI FBS 
10µg/ml Insulin 
50 units Penicillin/ 50µg/ml Streptomycin 
± 1µg/ml Puromycin 
 
 
 
SKBR3 
 
DMEM 
10% HI FBS 
50 units Penicillin/ 50µg/ml Streptomycin 
± 100µg/ml Zeocin 
 
 
 
ZR75-30 
 
RPMI 1640 
10% HI FBS 
50 units Penicillin/ 50µg/ml Streptomycin 
 
 
 
Freeze mix 
 
10% DMSO 
90% HI FBS 
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5.2 Appendix II: Materials 
 
 
Product Supplier Catalogue number 
10X Tris/Glycine Geneflow EC-880 
10X Trypsin-EDTA Invitrogen 15400-054 
2-Mercaptoethanol Sigma M7522 
6.5mm Transwell
®
 with 8.0µm pore 
polycarbonate membrane insert 
Corning 3422 
Amersham Hyperfilm™ MP GE Healthcare 28-9068-46 
Ammonium persulfate Sigma A6761 
Anti-Mouse IgG (whole molecule)-
Agarose 
Sigma A6531 
Aprotinin Sigma A1153 
BD Matrigel™ BD Biosciences 354230 
Bio-Rad Dc protein assay Reagent A Bio-Rad Laboratories 500-0113 
Bio-Rad Dc protein assay Reagent B Bio-Rad Laboratories 500-0114 
Bio-Rad Dc protein assay Reagent S Bio-Rad Laboratories 500-0115 
BioTrace™ pure nitrocellulose blotting 
membrane 
PALL Life Sciences P/N 66485 
BM-Cyclin Roche 10799050001 
Bromophenol blue Fisher Scientific B/4630/44 
Calcium chloride (dihydrate) Sigma C5080 
Cell dissociation buffer Invitrogen 13151-014 
CellTrics
®
 disposable filters PARTEC 04-004-2327 
Collagen, Type I Sigma C7661 
Dimethyl sulphoxide Sigma D2650 
DMEM without Phenol Red Biological Industries 01-053-1A 
Dulbecco’s Modified Eagle’s Medium Sigma D6429 
Ethanol Fisher Scientific E/0650DF/P17 
Fetal bovine serum PAA Laboratories A15-101 
Fibronectin form bovine plasma Sigma F1141 
Fluorescent mounting medium Dako S3023 
FuGene
®
 6  Roche 11814 443001 
GeneJammer  Agilent Technologies 204130 
Glycerol Fisher Scientific G/0650/08 
Glycine Sigma G8898 
Haemocytometer Fisher Scientific MNK-420-010N 
HEPES solution Sigma H0887 
Hoechst 33342 Invitrogen H3570 
Insulin Sigma I6634 
Lab-Tek™ chambered coverglass (4-
wells) 
Nunc 155383 
Leupeptin Sigma L2023 
Magnesium chloride Fisher Scientific M/0600/53 
Methanol Sigma 24229 
MycoAlert
®
 mycoplasma detection kit Lonza LT07-418 
Paraformaldehyde powder Park Scientific 30525-89-4 
Penicillin/Streptomycin Invitrogen 15070-063 
Phenylmethanesulfonyl fluoride Sigma P7626 
Plasmid pLVTHM Addgene 12247 
Plasmid pMD2.G Addgene 12259 
Plasmid psPAX2 Addgene 12260 
Polybrene
®
 Sigma AL-118 
Precision red advanced protein assay 
reagent 
Cytoskeleton ADV02A 
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Pre-stained protein markers New England Biolabs P7708L 
ProLong
®
 gold antifade reagent Invitrogen P36934 
Protein A agarose Sigma P9269 
Protein-G Agarose Sigma P4691 
ProtoGel
®
 Acrylamide Geneflow EC-890 
Puromycin dihydrochloride Sigma P8833 
Ras activation assay kit Cytoskeleton BK008 
RPMI-1640 Sigma R8758 
Sodium acetate trihydrate Sigma S7670 
Sodium azide Fisher Scientific S/2380/48 
Sodium chloride BDH 10241AP 
Sodium citrate tribasic dihydrate Sigma C3434 
Sodium dodecyl sulphate BDH 444464T 
Sodium hydroxide Sigma S8045 
Sodium orthovanadate Sigma S6508 
Sucrose Sigma S0389 
Tetramethylethylenediamine Sigma T2,250-0 
Tris(hydroxymethyl)methylamine BDH 271195Y 
Triton
®
 X-100 Sigma T9284 
Trypan blue solution Sigma T8154 
Tween
®
 80 Sigma P1754 
U0126 Calbiochem 662005 
Zeocin™ Invitrogen P/N 46-0509 
β-Morpholino-ethansulfonsaeure Janssen Chimica 17-259-90 
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5.3 Appendix III: Components of reagents used in this study 
 
1% Triton X-100 
 
495ml  1X PBS 
5ml  Triton X-100 
1mM  MgCl2 
0.5mM CaCl2 
 
 
 
1% Brij-98 
 
495ml  1X PBS 
5ml  Brij-98 
1mM  MgCl2 
0.5mM CaCl2 
 
 
 
1M Tris-HCl at pH 6.8 and pH 8.8 
 
121.14g  Tris-HCl (mw: 121.14g/mol) 
800ml  dH2O 
 
 Adjust pH to pH 6.8 or pH 8.8 
 Make up to 1L with dH2O 
 
 
 
2% Paraformaldehyde (PFA) 
 
18ml  dH2O 
10µl  10M NaOH 
0.4g  PFA 
2ml  10X PBS 
8.5µl  Concentrated HCl 
1mM  MgCl2 
0.5mM CaCl2 
0.6g  Sucrose 
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Blocking solution for immunofluorescence 
 
For 20ml: 
 
4ml  HINGS (goat serum) 
16ml  PBS 
40µl  10% sodium azide (NaN3) 
 
 
 
4X Laemmli buffer 
 
8ml  20% SDS 
8ml   Glycerol 
6.5ml  Tris-HCl pH 6.8 
3.1ml   dH2O 
 
 A small amount of Bromophenol blue was added to the sample buffer 
 
 
 
10% ammonium persulfate (APS) 
 
10ml  dH2O 
1g   APS 
 
 
 
10X Running buffer for electrophoresis 
 
700ml  dH2O 
144.3g Glycine 
30.3g  Tris 
10g  SDS 
 
 Make up to 1L with dH2O 
 
 
 
10X TBS-T 
 
800ml  dH2O 
12.11g  Tris 
87.66g NaCl 
5ml  Tween-80 
 
 Adjust pH to pH 7.5 with concentrated HCl (+/- NaOH) 
 Make up to 1L with dH2O 
  Appendices 
 
244 
 
 
PBS-T 
 
1L  dH2O 
10   PBS tablets 
1ml  Tween-80 
 
 
 
Transfer buffer 
 
700ml  dH2O 
200ml  Methanol 
100ml  10X Tris/Glycine 
 
 
 
MES buffer  
 
1L  dH2O 
4.88g  MES hydrate 
8.77g  NaCl 
1.02g  MgCl2 
 
 Adjust pH to pH 6.5 with concentrated HCl (+/- NaOH) 
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5.4 Appendix IV: Supplementary figures 
 
 
Supplementary Figure 1: Expression levels of integrins in a breast cancer 
model system of CD82-overexpressing cells. 
 
The expression levels of integrins were analysed by western blotting. Lysates of 
equal protein concentration were resolved by 10% SDS-PAGE under reducing 
conditions and blotted for the indicated molecules. Shown are representative 
blots from at least two independent experiments. 
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Supplementary Figure 2: The association of CD82 with ErbB2 in 
SKBR3/CD82High cells following lysis with other detergents. 
 
SKBR3/CD82High cells were prepared for the immunoprecipitation assay as 
described in the Materials and Methods under section 2.3.4. Cells were lysed 
using either 1% Brij-98 or a mixture of 0.5% Brij-98 + 0.5% Triton X-100 lysis 
buffer for 4h at 4oC with rotation. Immune complexes were precipitated using 
mouse IgG agarose beads conjugated with M104 anti-CD82 mouse mAb 
followed by western blot analysis using anti-ErbB2 (Ab-17) and anti-CD82 (KAI1 
C-16) antibodies. 
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Supplementary Figure 3: The effect of Herceptin treatment on the 
distribution of ErbB2 and CD82 following detergent-free lysis. 
 
SKBR3/Zeo and SKBR3/CD82High cells were treated with Herceptin (10µg/ml) 
for the indicated time intervals prior to lysis. Not-treated and treated cells were 
mechanically lysed without any detergent followed by fractionation as described 
in the Materials and Methods under section 2.4. The resulting homogenate of 
equal protein concentration was centrifuged in a discontinuous sucrose density 
gradient composed of 90%, 35% and 5% (w/v) sucrose. 10 fractions were 
collected from the meniscus of the gradient and the pellet was resuspended in 
Laemmli buffer supplemented with protease and phosphatase inhibitors. Equal 
amounts of each fraction were mixed with loading buffer and the protein 
distribution was analysed by SDS-PAGE under reducing and non-reducing 
conditions followed by western blot analysis using antibodies against (A) ErbB2 
(Ab-17); and (B) CD82 (TS82b). 
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Supplementary Figure 4: The effects of CD82 expression and short 
incubations of Herceptin treatment on the PI3K and MAPK signalling 
pathways in BT474 cells. 
 
BT474/Puro and BT474/CD82High cells in log phase were serum-starved 
overnight prior to treatment with Herceptin (10µg/ml) for the indicated time 
intervals. Lysates were collected at the end of each time-point and 
subsequently blotted for the indicated molecules of the PI3K and MAPK 
signalling pathways. Shown are representative blots from three independent 
experiments. 
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Supplementary Figure 5: The effects of CD82 expression and long 
incubations of Herceptin on the PI3K and MAPK signalling pathways in 
BT474 cells. 
 
BT474/Puro and BT474/CD82High cells in log phase were serum-starved 
overnight prior to treatment with Herceptin (10µg/ml) for the indicated time 
intervals. Lysates were collected at the end of each time-point and 
subsequently blotted for the indicated molecules of the PI3K and MAPK 
signalling pathways. Shown are representative blots from three independent 
experiments. 
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